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ABSTRACT
Haematological malignancies arise from the transformation
of cells at various stages of development during
haematopoiesis . Current treatment using standard
chemotherapy or high dose chemotherapy and stem cell
rescue leads to cure in a proportion of patients. However
residual tumour may persist after treatment and in some
patients relapse may result from growth of the original
tumour. Detection of minimal residual disease was
restricted by the low sensitivities of the techniques
available. Detection of minimal residual disease in
remission would have clinical application in monitoring
an individual patients response to therapy and provide an
early indication of relapse. Enzymatic amplification of
DNA by polymerase chain reaction (PCR) can be used to
identify minimal tumour. The aims of this study are i) to
screen tumour from patients with leukaemia and lymphoma
and determine the incidence of tumour markers, t(14;18)
translocation, T-cell receptor 5 (TcR6) chain and
immunoglobulin heavy chain (IgH) gene rearrangements ii)
to develop sensitive PCR based techniques using these
tumour markers and iii) to analyse serial remission
samples and peripheral blood stem cells (PBSC) for
residual tumour.
Southern blot analysis showed that 55% of patients with
pre-B acute lymphoblastic leukaemia (ALL) had TcR V52-D63
rearrangements and that 85% of patients with B-lineage
xviii
disease had IgH rearrangements. PCR analysis showed a
TcR6 marker in 53% of pre B ALL and a CDRIII marker in
77% of B-lineage disorders therefore these patients were
available for further study of minimal disease. Direct
sequence analysis of PCR products from TcR V62-D63 and
the third complementarity-determining region (CDRIII) of
IgH demonstrated sufficient junctional diversity to
permit unique clone specific probes of 20 nucleotides to
be designed. Junctional diversity was generated by random
N-nucleotide insertion, gene segment deletion and
addition of other D segments. In serial titration
experiments, clone specific probes could detect one
tumour cell in 10,000 to 100,000 normal cells. Clone
specific probes were able to detect residual tumour in
blood and marrow obtained during clinical remission.
Serial analyses of remission samples showed residual
tumour may either persist for up to 2 years before the
onset of relapse or patients may become PCR negative at
varying times during treatment and these patients
continued to be in remission at 2 years. PCR analysis of
PBSC demonstrated tumour in all of those collected from
patients with pre-B ALL and in one third of patients with
lymphoma. Concurrent bone marrow samples from NHL
patients showed a higher frequency of PCR positivity than
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Haematological malignancies encompass a spectrum of
diseases which affect various developmental stages within
the haematopoietic compartment (Figure 1.1). The
transformation of cells during haematopoiesis leads to a
neoplastic proliferation of developmentally arrested
clones. The development of cytotoxic chemotherapeutic
agents in the treatment of disease has provided an
improvement in prognosis and recent advances in the
fields of immunology and molecular biology have enhanced
our understanding of tumour biology. These disorders can
broadly be divided into leukaemias which affect
progenitor cells and lymphomas which have a more mature
phenotype (Table 1.1).
1.1.1 Classification of leukaemia
Leukaemia results from the accumulation of myeloid or
lymphoid precursors in the stroma of the bone marrow
which then enter the peripheral circulation. Diagnosis is
made on the presence of greater than 30% lymphoid blast
cells in the bone marrow.
1.1.1.1 Acute lymphoblastic leukaemia
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Figure 1.1 Differentiation pathway of haemopoietic cells.
Disorders associated with particular compartments are














































Myeloma 7-20 (increases >50 IgH
with age)
Table 1.1 Summary of age of onset and incidence of
haematological malignancies (Harman 1991, Rosenthal 1991,
Churchill 1991) . Associated gene rearrangements and the
most common chromosomal translocations are also shown
(Rubin and Rowley 1993, Greisser 1989, Felix and Poplack
1991).
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and is a common disease of childhood (up to 16 years)
accounting for 80% of acute leukaemias, though is less
frequent in adults, seen in only 20%. Subtypes are
classified by morphological and immunological criteria.
B-lineage cell surface determinants and/or IgH chain
rearrangements are found in 80% of cases, the remainder
bear T-lineage markers. Expression of a coordinated
series of cell surface determinants allows
characterisation of the differential stage; the majority
of B-lineage ALL express CD19 and CD10 and are classified
as group III ALL (Foon and Todd 1986), whereas expression
of CD19 without CD10 defines pro-B or null ALL. Group IV
disease is associated with CD19, CD10 and CD20
expression, and together with group III constitutes
common ALL. Cell surface immunoglobulin is found in
mature B-cell ALL although this is relatively rare.
A range of cytogenetic abnormalities have been
characterised which are of prognostic significance,
including the t(9;22) Philadelphia chromosome which has
been reported in up to 50% of adult and 5% of childhood
cases (Maurer et al 1991); the t(4;ll), frequent in ALL
of infants (up to 1 year old) ; t(ll;14) and t(l;9)
(Rubin and Rowley 1993). Mature B-ALL is associated with
the t(8;14) also found in Burkitt's lymphoma which
results in the juxtaposition of the mvc oncogene on
chromosome 8 to the IgH locus on chromosome 14 (Shiramizu
et al 1990). Although translocations usually indicate a
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poor prognosis, polyploidy (greater than 50 chromosomes)
is associated with a low risk group.
1.1.1.2 Acute myeloid leukaemia
AML results from the expansion of myeloid progenitor
cells accounting for 80% of adult acute leukaemias though
is less common in children. Differential stage is
determined by morphological criteria although progressive
expression of myeloid markers analogous to those in acute
leukaemia can be detected by immunophenotypic analysis.
Specific chromosomal abnormalities have been reported in
particular subtypes, such as the t(15;17) found in most
cases of acute promyelocytic leukaemia (Larson et al
1984).
1.1.2 Classification of lymphoma
Lymphomas are characterised by the proliferation of more
mature lymphocytes which have migrated from the marrow to
the lymph nodes, although neoplastic cells can be
disseminated to both the marrow and the bloodstream.
Subtypes are determined by morphological analysis of
tumour biopsies.
1.1.2.1 Non-Hodgkin's lymphoma
NHL of both the T- and B-lymphoid compartments is found
and can take an indolent (low grade) or aggressive (high
grade) course depending on the maturity of the neoplastic
cell (non-Hodgkin's lymphoma pathologic classification
project 1982). Low grade NHL is characterised by a late
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onset, whereas high grade disease is found in all age
groups. Several chromosomal translocations have been
described, the best conserved of which is the t(14;18)
associated with up to 80% of low grade NHL and perhaps 5%
of high grade disease (Weiss et al 1987). The t(8;14)
found in mature B-ALL is also commonly associated with
Burkitt's lymphoma, an aggressive high grade
lymphoblastic disease.
1.1.2.2 Hodgkin's lymphoma
Demonstration of cells of a committed lineage associated
with HD have not been consistently demonstrated although
proliferations within involved lymph nodes are associated
with an unusual binucleate cell, termed the Reed-
Sternberg cell.
1.1.3 Myeloma
Myeloma originates from the deregulated division of
activated B-lymphocytes, with a late onset increasing in
incidence from the age of 50. A more mature form
resulting in the expansion of terminal immunoglobulin
secreting plasma cells in the peripheral blood is termed
plasma cell leukaemia.
1.2 Treatment of haematoloqical malignancies
Cytoreduction of tumour load provided by chemotherapy is
dose dependent (Frei and Canellos 1980). Remission status
is achieved if light-microscopy detects the presence of
fewer than 5% leukaemic blasts (Bisel et al 1956), or if
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no obvious evidence of disease is present on CT scan
analysis in the case of lymphoma. Remissions are induced
by chemotherapeutic agents possibly with radiotherapy to
reduce bulk disease and are maintained by consolidation
therapy. However a proportion of patients will go on to
relapse due to the persistence of disease or resistance
of the neoplastic cells to the drugs administered.
Chemotherapy can induce remission in 90% of children with
ALL and 60 - 80% of these will remain in remission for 5
years or more (Champlin and Gale 1989). Over 70% of
adults enter remission of whom 20 - 35% continue in
remission at 3 to 5 years. Similar figures are reported
in AML (reviewed Craig 1990) with 76% of patients under
50 years of age achieving remission with a LFS of 25 to
40% at 3 years. Two thirds of patients with HD are cured
by a combination of radiotherapy and chemotherapy, though
50% of NHL patients achieving remission eventually
relapse and only 10% are cured. Few patients with myeloma
achieve remission and those who do frequently relapse
(Kyle, Greipp and Geitz 1986). Patients with refractory
disease are candidates for transplantation.
Although the response of malignant cells to myeloablative
therapy is dose dependent, the dose that can be
administered is limited by toxicity to the bone marrow.
In many cases sufficient therapy can be administered to
provide long term remission or cure, however in those
patients with refractory disease, bone marrow
transplantation enables a very large dose of chemotherapy
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to be given, followed by rescue of the bone marrow with
donor haematopoietic stem cells. These stem cells can be
derived from several sources, each with its own
particular application.
Marrow collected from a sibling is used in allogeneic
transplantation. The donor cells confer a graft versus
leukaemia effect which can reduce tumour burden, as can
the action of activated T- killer cells (Goldman et al
1988, Hamblin 1988). However a potentially lethal graft
versus host reaction with varying degrees of severity is
also observed.
An unrelated donor transplant is an option if an HLA
matched sibling is not available (Ash et al 1990). Marrow
is harvested from an HLA matched donor identified from a
database of tissue typed volunteers, although this
procedure is still in its infancy.
Another alternative is to use stem cells harvested from a
patients own marrow whilst in remission, though this
requires a relatively healthy and cellular marrow which
has recovered from chemotherapy. Such autografts may
still harbour neoplastic cells hence purging with
monoclonal antibodies has been performed in an attempt to
reduce this burden and minimise reinfusion of tumour
which may promote relapse (Negrin et al 1991). The
problems of hypocellular bone marrow and potential tumour
contamination have been addressed with the development of
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peripheral blood stem cell (PBSC) transplantation whereby
mononuclear cells from the peripheral circulation are
collected and stored (reviewed Craig, Turner and Parker
1992). PB does not normally contain significant numbers
of pluripotent stem cells, but during regeneration
following chemotherapy or in response to growth factors
such as G-CSF, there is a large increase of these cells
in circulation. Engraftment following transplantation is
also more rapid, possibly due to the increased presence
of mature leucocytes in the graft which reduce the period
of depressed neutrophil counts during which time the
patient is immunocompromised hence susceptible to
infection.
Allogeneic transplantation can provide up to 50% LFS in
ALL though this falls to 30% for autologous
transplantation (Champlin and Gale 1989). A LFS at 5
years of 48% has been reported for AML patients
undergoing allogeneic BMT compared to 36% at 7 years for
autologous transplants (Craig 1990). Autologous
transplantation in HD results in a 50% complete response
in patients with disease refractory to chemotherapy . BMT
in NHL shows survival at 3 years to be approximately 50%.
Autologous transplantation with PBSC has been
successfully used to reduce tumour load in myeloma and is
better tolerated by older patients (Fermand et al 1989).
Although a greater reduction in tumour load is provided
by transplantation, relapses still occur due to the
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expansion of endogenous disease or from reinfused disease
(in autologous transplantation) therefore the study of
MRD in patients undergoing both chemotherapy and
transplantation will enable the response of disease to be
closely followed and perhaps provide an early indication
of relapse. In these patients, treatment regimes may be
ultimately tailored to their individual requirements.
1.3 Minimal residual disease
At presentation, a patient with ALL may have a tumour
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burden of 10 neoplastxc cells (van Bekkum 1984). After
induction therapy, 90% of patients with ALL achieve
remission, defined by the detection of less than 5%
lymphoid blasts in a bone marrow sample analysed by light
microscopy. However, this still represents a large tumour
burden of up to 10"^® neoplastic cells. This persisting
tumour is termed MRD although its definition has been
refined as increasingly more sensitive tumour detection
techniques become available. Like morphological analysis
of BM smears, the sensitivity of cytogenetic analysis is
limited at the 5% level. Dual colour immunofluorescence
analysis is applicable to a subgroup of patients with
leukaemia and skilled investigators can optimally detect
one neoplastic cell in a population of 100000 normal
cells in specific instances (Campana et al 1990a),
however changes in the expression of cell surface markers
can lead to false negative results.
Likewise, patients with lymphoma or myeloma may have
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persisting tumour cells in circulation when the patient
has achieved clinical remission, the detection of which
may have prognostic significance.
1.3.1 Molecular analysis
The application of recombinant DNA technology to the
analysis of haematological malignancy has provided a
great deal of insight into the biology of the disease as
well as providing sensitive tools for the study of
disease kinetics.
PCR facilitates the amplification of discrete regions of
DNA many million times, hence is invaluable in the
detection of very rare DNA or RNA species (Saiki et al
1985, 1988). The amplification of tumour specific
translocations permits the sensitive detection of
neoplastic cells, even when masked by large populations
of normal cells.
The exploitation of immune receptor gene rearrangements
and the diversity therein provide more widely applicable
markers and enable the study of both T- and B-lymphoid
disease, though are of less value in the analysis of
myeloid disorders. The TcR6 locus is frequently
rearranged on both T- and B-lineage leukaemia and has
been applied to the detection of residual disease (Yokota
et al 1991a), as has the TcR y locus (Maclntyre et al
1990). Virtually all disorders of the B-lineage bear IgH
rearrangements, hence this locus provides a widely
11
applicable marker for neoplastic cells (Yamada et al
1989, Trainor et al 1990).
1.4 Aims
I sought to investigate the use of Southern blot analysis
with IgH and TcR6 chain genomic probes to characterise
the frequency gene rearrangements in a group of patients
with leukaemia, lymphoma and myeloma. These patients
would then be screened by PCR analysis using primers
specific for the t(14;18) in low grade NHL, IgH
rearrangements in B-lineage disease and TCR6 chain
rearrangements in both T- and B- lineage disorders. I
then wished to refine these PCR systems to facilitate the
sensitive analysis of disease persistence in patients
undergoing either standard chemotherapy or
transplantation. Tumour contamination in PBSC harvests
would also be compared to that in autologous BM harvests
to investigate if they provide a purer source of
progenitor cells. Finally the prognostic value of PCR
status would be evaluated.
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CHAPTER 2
THE t (14;18) TRANSLOCATION
2.1 INTRODUCTION
2.1.1 Characterisation of the lesion
The t(14;18)(q32;q21) karyotypic abnormality is closely
associated with low grade follicular NHL (Fukuhara et al
1978) though the reported incidence varies from 30 to 90%
(Amakawa et al 1989, Weiss et al 1987). The translocation
results in the juxtaposition of the bcl-2 oncogene on
chromosome 18 next to one of the 6 IgHJ segments on
chromosome 14 (Tsujimoto et al 1984). Although the
neoplastic cell has a mature B-lymphocyte phenotype, the
translocation is thought to occur at an early stage of
pre-B cell development, possibly as the result of
imprecise V-D-J recombination (Tsujimoto et al 1985). The
signal sequences which would mediate this event have not
been clearly demonstrated however, hence the precise
mechanism has yet to be determined.
The majority of the breakpoints are found within a 2. 8kb
locus in the bcl-2 gene known as the major mbr which
accounts for 30 to 70% of translocations studied
(Pezzella et al 1990, Bakhshi et al 1987). This is
located within the 3' untranslated region and does not
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interrupt the coding sequence of the gene. A second group
of breakpoints have been mapped to a site 20kb downstream
of the mbr accounting for 25% of translocations and is
known as the mcr (Cleary et al 1986).
2.1.2 Role Of Bcl-2
Transcription of the rearranged locus produces chimeric
bcl-2/JH mRNA species which are translated into
structurally normal bcl-2 protein molecules although the
level of expression is elevated (Weiss et al 1987). Bcl-2
has been postulated to encode a low molecular weight G
(GTP binding) protein involved in signal transduction
(Haldar et al 1989) although homology with other G
proteins such as Ras is weak (Reed et al 1988). The bcl-2
product has been localised on the inner surface of the
mitochondrial membrane (Hockenberry et al 1990) and two
species have been characterised, bcl-2a and 2)3, 26 and
22kD respectively. They differ in their carboxyl termini
due to differential splicing and have short membrane
spanning domains but both lack leader or kinase domains
(Reed et al 1988). Elevated levels of bcl-2 are normally
found in early B-cell development but expression
disappears with maturation (Tsujimoto et al 1989).
Mitogen induction was shown to increase bcl-2 mRNA levels
in normal peripheral blood lymphocytes due to an increase
in both transcription and stability of the message
indicating the presence of both positive and negative
regulatory elements in a complex mechanism (Reed et al
14
1987). Bcl-2 protein was shown to cooperate with c-myc in
cellular transformation demonstrating oncogenic potential
(Vaux et al 1988). As all t(14;18) lymphomas with
rearranged bcl-2 show elevated transcription, gene
transfer experiments to investigate the effect of
overexpressed bcl-2 have been devised. Mice transfected
with bcl-2/JH fusion genes develop a population of mature
B-cells with a growth advantage (McDonnell et al 1989)
but a murine fusion gene introduced into various factor-
dependent cell lines will not confer long term survival
in the absence of factor (Nunez et al 1990). High bcl-2
expression does, however, prolong short term survival of
IL-3 and IL-4 as well as GMCSF dependent haemopoietic
lines.
IL-3 deprived cells die via a highly regulated mechanism
termed "apoptosis" hence bcl-2 may have a role in this
programmed cell death pathway. This concept was supported
by the finding that overexpressed bcl-2 resulted in the
maintenance of an IL-3 dependent pro-lymphocytic B-cell
line in GO stage after IL-3 deprivation. Restoration of
IL-3 allowed the cells to re-enter the cell cycle
(Hockenberry et al 1990). Blockage of de novo protein
synthesis with cyclohexamide also prevents death in the
absence of growth factor supporting the existence of an
active cell death mechanism. High levels of bcl-2 seem to
interfere with the "programmed cell death pathway"
prolonging lymphocyte survival which allows the
accumulation of further genetic changes eventually
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leading to neoplastic transformation.
A role was also demonstrated in maintenance of memory B-
lymphocytes which maintain immune responses to specific
antigens long after the initial exposure (Nunez et al
1991) and also postulated in Ig class switching (Amakawa
et al 1991). The action of bcl-2 protein is not B-
lymphocyte specific, immature thymocytes susceptible to
apoptosis during positive selection in the thymus can be
rescued by deregulated bcl-2 expression. Negative
selection of self-recognising T-lymphocytes appears to be
mediated by a bcl-2 independent pathway (Hockenberry et
al 1990) .
2.1.3 Southern Blot Analysis
The majority of low grade lymphomas with translocations
can be detected by Southern blotting using a combination
of mbr and mcr probes, with the advantage over
cytogenetic analysis that viable tissue to provide
metaphase spreads is not required (Zelenetz et al 1991).
Southern blotting also allows other leukaemia or lymphoma
subtypes to be assessed for t(14;18) translocations.
Aisenberg et al (1988) reported that 19% of diffuse B-
cell lymphomas had mbr bcl-2 rearrangements, whereas none
could be detected in cases of small lymphocytic lymphoma
or T-cell leukaemia or lymphoma suggesting that bcl-2
rearrangements are rare outwith NHL of follicle centre
cell lineage. PFGE exploits electric field reversal and
rare cutting restriction enzymes such as Not I to map
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larger DNA fragments than are permitted by conventional
electrophoresis. Even though the mbr and mcr of bcl-2 are
20kb apart they co-migrate on a 630kb DNA fragment, along
with other breaks which could be even more distal, after
Not I digestion (Zelenetz et al 1991). This means that a
single digestion and single hybridisation with a bcl-2
probe will detect breaks in the bcl-2 gene more
effectively than regular Southern analysis. The rare
cases of low grade NHL negative by PFGE may indicate an
alternative mechanism of bcl-2 activation or the
existence of rare 5' breakpoints.
2.1.4 Polymerase chain reaction analysis
In addition to the methods described above, PCR of mbr
and mcr loci can be performed to detect bcl-2/JH
junctions. PCR will not detect as many translocations as
PFGE but is of great value due to the vastly enhanced
sensitivity it provides over all other techniques, which
are limited by detection limits at the 1-10% level.
Further to this archival material such as paraffin
sections or stored BM slides can be assayed (Wright &
Manos 1990, Fey et al 1987). The conserved nature of the
majority of the translocation breakpoints provides an
ideal locus for PCR analysis. Lee et al (1987) were the
first to exploit the bcl-2/JH mbr junction sequence
information and design bcl-2 and consensus JH amplimers.
Using 12mer oligonucleotides, the Klenow fragment of DNA
polymerase I and 30 cycles of amplification they reported
a detection limit at the level of 1 tumour cell in 105
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normal cells. Crescenzi et al (1988) used the
thermostable Tag DNA polymerase to amplify the mbr region
and demonstrated sensitivity at the level of 1 tumour
cell in 10® normal cells after 45 cycles of
amplification. Stetler-Stevenson et al (1988) used an
mbr primer in conjunction with 3 JH primers; primer 1 was
complementary to Jl, 2, 4 and 5; primer 2 to J3 and
, C
primer 3 to J6. Sensitivity at the level of 1 in 2x10
was reported. The mcr is also amenable to amplification
(Ngan et al 1989) hence approximately 90% of patients
with a t(14;18) can be assayed with these techniques.
2.1.5 Sequence Analysis
To enhance the specificity of the technique and
investigate possible mechanisms mediating the
rearrangement sequence analysis of the translocated
region was performed. Sequencing of the mbr locus showed
clustering breakpoints to within a few nucleotides.
Random "N" nucleotide insertions characteristic of
rearranged immune genes were also seen along with
evidence for the occasional presence of D segments
(Creszenczi et al 1988).
Eick et al (1990) sequenced mbr PCR products to generate
patient specific amplimers derived from the unique N
regions. They attempted to sequence the products either
directly (using 2-5pg of DNA) or following a subcloning
step. The former was more satisfactory as the high
nucleotide misincorporation rate associated with Tag
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polymerase was averaged out by sequencing the products of
many reactions simultaneously. Asymmetric PCR which
generates a single stranded product proved the most
convenient as less target DNA was required per sequencing
reaction.
To investigate the origin of N nucleotides observed at
the translocation junctions, Cotter et al (1990)
sequenced both the translocation and the reciprocal
translocation junction. This was made possible by the
observation that the 18q- reciprocal join showed evidence
for the presence of D segments. To amplify this region
they used a primer derived from the conserved DH
recombination signal sequence and mbr or mcr bcl-2
primers. The 14q+ strand on the translocated chromosome
was amplified as usual with a consensus JH primer again
with mbr or mcr primers. It was possible in 2 patients to
amplify both the join and reciprocal join, one with the
mbr and one with the mcr primers. Comparing both
sequences showed the N insertions in the 14q+ strand only
and that they truly were non-template encoded
nucleotides, with no bcl-2 deletion as previously
reported (Bakhshi et al 1987). This indicated a similar
mechanism of rearrangement for both the mbr and mcr loci.
Sequence analysis of a series of follicular lymphomas
with N insertions at the 14q+ locus demonstrated homology
with a known DH segment in one patient, suggesting that
in some cases long runs of N insertions may correspond to
uncharacterised DH segments.
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Booster PCR (Ruano et al 1989) involves performing two
sets of amplification cycles initially with a low primer
concentration, followed by a higher concentration to
maximise yields. Price et al (1991a) used this technique
in conjunction with nested PCR to amplify translocations
from remission material to provide sufficient DNA to
sequence. When compared to presentation tissue, 29% of
patients demonstrated additional translocations which
sequence analysis proved were novel and not due to carry
over. These could represent secondary translocations by
the initial clone, true biclonality or sporadic
translocations occurring in normal B-lymphocytes. The
final suggestion is supported by the evidence that
t(14;18) translocations have been reported in reactive
tissues which do not progress to neoplasia (Grace et al
1989) and in normal PB lymphocytes (Limpens et al 1992).
This phenomenon may also explain the discovery of the
t(14;18) in 30% of Hodgkin's lymphoma patients (Stetler-
Stevenson et al 1990) which may derive from normal B-
lymphocytes rather than Reed-Sternberg cells.
A possible mechanism mediating the translocation event
was proposed by Wyatt et al (1992) after more extensive
sequence information was collated. They observed the
tight clustering of bcl-2 breakpoints in 3 regions within
a 150bp region of the mbr associated with short elements
resembling prokaryotic chi recombination initiation
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signals. The frequent observation of DXP sequences in
excised signal joints lead them to suggest that the
initial event in a translocation was a chi mediated
be 1-2 -DXP recombination followed by a DXP-JH
recombination resolved by the regular V-D-J recombinase
complex.
2.1.6 Aims
We wished to study and evaluate the t(14;18) as a
potential tumour marker which could be used to monitor
minimal residual disease during remission in patients
with low grade NHL and Hodgkin's lymphoma. Initially, to
determine gross tumour infiltration, tumour samples were
screened by Southern blot analysis with an IgHJ probe.
PCR techniques to amplify the t(14;18) were evaluated and
modified to improve their specificity in detecting the
presence of minimal tumour. This modified PCR technique
was then used to analyse our patients for the presence of
this clonal marker. To confirm the involvement of bcl-2
and JH sequences in our PCR amplification products and to
determine the position of the breakpoint within the mbr
region PCR products were sequenced directly. From the
sequence information the clustering of breakpoints and JH
segment usage was analysed. On the basis of these studies
we intended to monitor tumour contamination in patients





A total of 23 low grade NHL patients (15 male, 8 female)
with a mean age of 54 years (range 32 to 7 9 years) were
available for analysis. In addition 8 patients with
Hodgkin's lymphoma (7 male, 1 female) with a mean age of
35 years (range 15 to 48 years) were studied.
2.2.2 Cytogenetic analysis
Cytogenetic analysis was carried out on the NHL patients
by standard G-banding techniques on tumour samples of
lymph node. Cytogenetic information was available on 14
patients indicating the presence of the t(14;18)(q32;q21)
chromosome in 11, a further 2 with a t(8;14)
translocation and one with a complex karyotype.
2.2.3 Cell lines
The SU DH L6 line (Epstein 1978) was provided by Dr. J.
Cossman. It was derived from a peritoneal effusion from a
43 year-old male patient with a diffuse histiocytic
lymphoma and carries the t(14;18)(q32;q21) translocation.
The line was received as pellets frozen in DMSO and was
cultured in IMDM with 10% FCS before DNA was extracted.
The promyelocy tic HL60 cell line was obtained
commercially from ATCC and used as a source of control




























Tris HC1 pH7.6 0.01M
EDTA pH8.0 0.001M
RNase A (Sigma, Poole, Dorset, U.K.) 5mg/ml, boiled
lOmin
Proteinase K (Sigma) lOmg/ml
Tris buffered phenol (Camlab, Cambridge, U.K.)
Equilibrated to pH8.0 (aqueous phase) in buffer
supplied
Gel electrophoresis loading buffer




Tris acetate buffer (TAE)
Stock solution 20x concentrated
Tris-acetate 0.04M
EDTA 0.001M
Tris borate buffer (TBE)





38% acrylamide 2% bisacrylamide (NBL, Cramlington, U.K.)
SeaKem LE agarose (Flowgen, Sittingbourne, Kent, U.K.)
Electrophoresis grade
SeaKem GTG agarose (Flowgen)
Genetic technology grade, low melting point
NuSieve 3:1 agarose (Flowgen)
Electrophoresis grade
NuSieve GTG agarose (Flowgen)
Genetic technology grade, low melting point












Stock Solution 2Ox concentrated
NaCl 0.15M









Adjust to pH7.5 with Na2HP04
Random primed DNA labelling kit (Boehringer Mannheim,
Germany)
Klenow polymerase buffer
















GBX developer 20 %
Fix (Sigma)
GBX fixer and replenisher 20%
Stop (Sigma)
Indicator stop bath 4%
3 9 .
X-ray film Hyperfilm MP ( P emission), hyperfilm /3max
3 5
( S emission) Amersham International, Amersham,
Buckinghamshire, U.K.






Polymerase chain reaction buffer
Stock solution lOx concentrated

















Recovery of DNA fragments from agarose gels
Gene-Clean II kit (Stratech Scientific, Luton U.K.)
MERmaid kit (Stratech)
DNA sequencing
Sequenase DNA sequencing kit (USB, Cambridge, U.K.)
Repel Silane (Pharmacia)
Bind Silane (Pharmacia)
dATPa^S specific activity >1000 Ci/mmol (DuPont)
Synthetic oligonucleotides (Oswell DNA Services,
Edinburgh U.K.)
Obtained in dl^O, after gel filtration.
All chemicals were of Analar grade and supplied by BDH
(Poole, Dorset, U.K.) unless otherwise stated.
Restriction endonucleases supplied by Promega limited
(Southampton, U.K).
2.4 METHODS
All methods are based on Sambrook, Fritsch and Maniatis
(1989) unless otherwise stated.
2.4.1 DNA extraction
2.4.1.1 Peripheral blood and bone marrow
PB or BM collected at presentation or in the course of
therapy was layered onto Ficoll-Paque and centrifuged at
29
400g for 20min. MNC were suspended in high TE and lysed
with an equal volume of lysis solution. RNase A was added
to a final concentration of 50pg/ml before incubation at
37 °C for 30min. Proteinase K was added to a final
concentration of 100/jg/ml before incubation at 40°C for
16h. Lysates were then mixed on ice with an equal volume
of tris- buffered phenol and the aqueous phase collected
by centrifugation at 1600g for lOmin. This was repeated
until the aqueous phase appeared clear at which stage
extraction with an equal volume of chloroform/isoamyl
alcohol was performed.
DNA was precipitated by the addition of 0.5 volumes of
7.5M ammonium acetate and 2 volumes of absolute ethanol
before washing with 66.7% ethanol. After drying for 5min
the DNA was resuspended in 500pl of TE and left to
dissolve at 4°C for several days. If no precipitate
formed, the sample was transferred to -40°C overnight and
the DNA collected by centrifugation at 1600g for 30min at
4°C. The pellet was resuspended in 1ml 70% ethanol,
further centrifuged at 16000g for lOmin at 4°C and dried
under vacuum. Finally, the DNA was resuspended in lOOpl
TE.
When dissolved, an aliquot of the sample was diluted
1:100 in dE^O to enable the concentration and purity to
be measured by UV spectroscopy. Absorbance readings were
taken at 260 and 280nm, 1.0 OD unit at 260nm being
equivalent to 50ng of DNA. An OD2gQ:OD280 rati° in the
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1.8-2.0 range indicated sufficient purity.
2.4.1.2 Mononuclear cells
MNC were isolated from PBSC harvests by Ficoll-hypaque
density gradient centrifugation (400g for 30 min) and
collected in culture medium. Cells were pelleted at 700g
for 5min, suspended in an equal volume of TE and lysed
with an equal volume of lysis solution. The lysates were
processed as detailed above.
2.4.1.3 Biopsy material
Such material, collected at presentation or relapse
consisted of lymph node, skin or spleen and was obtained
as fresh tissue. Following maceration with a razor blade,
the biopsy specimen was suspended in high TE and an equal
volume of lysis solution added before the DNA was
extracted as above.
2.4.1.4 Frozen sections
Fresh frozen cryostat sections 10pm thick were lysed
according to the method of Cotter et al (1988).
Approximately 20 sections were suspended in 10ml lysis
solution at 4°C then centrifuged at 700g for 20min. The
pelleted nuclei were resuspended in 2.5ml nuclear lysis
solution with 125pl 10% SDS and 50pl proteinase K and
incubated overnight at 37°C. Phenol/chloroform extraction
and ethanol precipitation were performed as above before
dissolving the DNA in lOOpl TE.
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2.4.2 Restriction endonuclease digestion
To detect the alteration in restriction enzyme sites
caused by translocation or rearrangement events, 7pg of
genomic DNA was mixed with digestion buffer to a final
concentration of lx and dl^O to a volume of 68^/1. Samples
were mixed on ice for several hours before the addition
of 35U of Hindlll or BamHI. After gentle mixing the
reactions were transfered to 37°C for 30min followed by
the addition of a further 35U of enzyme. Digests were
performed for a further 16h.
2.4.3 Southern blotting
2.4.3.1 Gel electrophoresis
For size fractionation of restriction enzyme digests,
0.8% SeaKem LE agarose gels were cast in lx TAE. Gels
were submerged in lx TAE buffer and samples loaded in lx
loading buffer. Electrophoresis was performed for 16h at
2V/cm. Bacteriophage lambda DNA, digested with Hindlll
was included as a size marker. Staining was performed in
lx TAE with ethidium bromide at 0.5pg/ml and viewed under
UV light.
2.4.3.2 Transfer of DNA to nylon membranes
DNA was transfered to nylon membranes by the method of
Southern (1975). Gels were acid hydrolysed, denatured
then neutralised in the relevant solutions for 30min each
step. The gel was placed on a wick of Whatman N°6 3mm
filter paper and immersed in lOx SSC. A sheet of nylon
membrane previously soaked in lOx SSC was laid on top of
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the gel, followed by 3 sheets of filter paper, also pre-
soaked in lOx SSC. A layer of paper towels approximately
10cm thick was placed on top of the filter paper
followed by a glass plate and weight. Capillary transfer
was allowed to occur for 16h before the membranes were
removed, rinsed in 2x SSC before air drying.
2.4.3.3 Probe
To detect the presence of IgHJ rearrangements, a joining
region probe (Flannagan and Rabbitts 1982) consisting of
a 2.5kb fragment maintained in the SacI site of a pAT
plasmid (Figure 2.1) was used. The probe was prepared by
digestion of the plasmid with SacI followed by
electrophoresis through 0.8% SeaKem GTG agarose (section
2.4.3.1). The relevant band was excised with a new razor
blade and purified by extraction with glass beads
(section 2.4.6.1).
Labelling was performed according to the method of
Feinberg and Vogelstein (1983) to a specific activity of
>10^cpm/pg DNA. To 25/jg probe was added buffer/
hexanucleotide mix to a final concentration of lx, 0.5M
nucleotide mix (dATP, dGTP, dTTP), 2U Klenow fragment DNA
polymerase I and 30pCi a P dCTP. The reaction was
incubated overnight at room temperature before
incorporation was calculated by the precipitation of
incorporated nucleotides on to Whatman DE81 filters with
0.5M phosphate buffer pH7.0. Unincorporated nucleotides
specific activity of the eluted fraction determined by
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FIGURE 2.1 Diagram of IgH locus showing location of J
segments. The location of IgHJ probe used in Southern
blotting is indicated.
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counting an aliquot in a /3-scintillation counter.
2.4.3.4 Hybridisation
Incubation steps were performed in a dedicated
hybridisation oven (Robbins Scientific) in the tubes
supplied. Membranes were rolled, placed inside the
hybridisation tubes and sufficient hybridisation fluid
added to allow even wetting. A further 3ml of fluid was
added and the tubes placed in the oven at 65°C. The probe
was denatured by boiling and plunging on ice before
sufficient probe solution to give 4.5x10® dpm total
(1.5xl0®dpm/ml) was injected into the tube, taking care
not to touch the membrane with neat probe. Membranes were
returned to the oven and allowed to rotate overnight.
2.4.3.5 Washing
The excess fluid was poured off, 20ml of wash 1 added and
the tube rotated at room temperature for 30min before the
solution was replaced with wash 2. Washing was continued
at 65°C for 30min before the addition of wash 3 and
incubation at room temperature for a further 30min.
Radioactivity was monitored with a hand held counter,
when a reading of 2-5cps was obtained the membrane was
removed and wrapped in cling film otherwise wash 3 was
repeated at 65°C until the radioactivity was reduced
sufficiently.
2.4.3.6 Autoradiography
Membranes were placed in an X-ray cassette next to
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preflashed X-ray film and exposure performed at -70°C for
one to 14d. The film was developed by immersion in
developer solution for 5min, stop solution for 30s and
finally fixer for 2min before rinsing in running water
for 5min and drying.
2.4.4 Polymerase chain reaction analysis
The initial PCR protocol followed was that described by
Stetler-Stevenson et al (1988) with some modification.
Amplification was performed with the bcl-2(25mer) and
Jl,2,4,5; J3 and J6 primers (Table 2.1) which delineate a
product of 150-300bp. The number of cycles was reduced as
it had been suggested that yields decrease if more than
30 cycles were performed (Sambrook et al 1989) and a
final elongated extension step was included to increase
yields. Various optimisation steps were performed to
improve specific product yield and sensitivity.
2.4.4.1 Reaction conditions
Each lOOpl reaction contained lx PCR reaction buffer,
200pM each dNTP, 1.5mM MgC^, 500ng each primer and 2.5U
Taq polymerase. Cycles were as described in Table 2.2 and
carried out in a thermal cycler (Hybaid Limited,
Teddington, Middlesex U.K.). In order to optimise the
yield of the specific product, several parameters were
tested. Initially the annealing and extension conditions
were altered to improve the specificity, followed by
primer and magnesium ion concentration titrations using
lpg SU DH L6 DNA as the template in each instance.
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Oligo Sequence Tm(°C)
bcl-2 (25mer) 5'-TTA GAG AGT TGC TTT ACG TGG CCT G-3' 74
IgHJ 1,2,4,5 5'-GGA CTC ACC TGA GGA GAC GGT GAC C-3' 82
IgHJ 3 5'-CAT CTT ACC TGA AGA GAC GGT GAC C-31 76
IgHJ 6 5'-AAA CAA AGG CCC TAG AGT GGC CAT T-3' 74
bcl-2 (20mer) 5'-TTG ACC TTT AGA GAG TTG CT-3• 56
IgH 1-6 5'-ACC TGA GGA GAC GGT GAC C-3• 62
Internal bcl-2 5'-CAA CAC AGA CCC CAG AGC CCT CCT GCC
probe CTC CTT CCG CGG GGG C-3■
Labelling Hexamer 5'-GCC CCC-3'















Table 2.2 Initial PCR cycling conditions, bcl-2(25mer),
Jl,2,4,5; J3; J6 amplimers.
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2.4.4.2 Extension time
Two extension times (180s and 120s) were analysed (Figure
2.2, lanes 2 and 3 respectively) and an extension time of
120s resulted in a reduction of non-specific product
bands and was used in all further amplifications.
2.4.4.3 Annealing time
Two annealing times (120s and 90s) were analysed (Figure
2.2, lanes 3 and 4). A 60s annealing time further reduced
the presence of non-specific PCR bands and was used in
all subsequent amplifications.
2.4.4.4 Primer concentration
The effect of primer concentrations of 500, 250 and 125ng
per reaction are shown in Figure 2.2 (lanes 4, 5 and 6).
Analysis of the PCR product demonstrated maximum yields
using 125ng (Figure 2.2 lane 2) of each amplimer and this
concentration was used in subsequent amplifications.
2.4.4.5 Magnesium concentration
The concentration of magnesium ions was increase from 1.0
to 3.5mM in 0.5mM increments (Figure 2.2, lanes 7 to 12)
with 1.5mM generating the maximum target band and minimal
non-specific banding. However 2 bands were still
consistantly obtained and titration using 0.25mM
increments from 0.5 to 1.5 mM was performed (Figure 2.3,
lanes 2 to 6). Two bands were consistantly observed in
each lane due to mispriming, possibly mediated by the
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Figure 2.2 Ethidium bromide stained 5% PAGE of PCR
amplification products of SUDHL6 DNA. Lane one contains
0X174 DNA digested with Hinfl (band sizes 726, 713 553,
500, 427, 417, 413, 311, 249, 200, 151, 140, 118, 82, 66,
48, 42, 40, 24bp). Amplification was carried out using
cycle conditions in Table 2.2 with the following
modifications to optimise specificity. Lanes 2 and 3
compare extension times of 180s and 120s. Using 120s
extension time, lanes 3 and 4 compare annealing times of
120s and 60s. Using 120s extension and 60s annealing,
lanes 4, 5 and 6 compare 500, 250 and 125ng primer
concentrations. Using 125ng of primer, lanes 7 to 12 show
the effects of increasing magnesium concentrations from
1.0 to 3.5mM in 0.5mM increments.
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Figure 2.3 Ethidium bromide stained 5%PAGE of PCR
amplification products of SUDHL6 DNA. Lane 1 contains
0X174 DNA digested with Hin.fi. Lanes 2 to 6 show the
effects of increasing magnesium concentration of 0.5 to
1.5mM in 0.5mM increments. Using 1.5mM magnesium
concentrations lanes 7-9 show the amplification products
of each individual 3' amplimer used in conjunction with
the 5' bcl-2 amplimer. Amplificaton in lane 7 was carried
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2.4). The cell line SU DH L6 must have J6 juxtaposed to
Bcl-2 and J6 has two possible amplimer binding sites as
shown in Figure 2.4, explaining the consistent appearance
of two bands. To test this a reaction using each
individual 3'- primer in conjunction with the 5' bcl-2
amplimer was performed (Figure 2.3 lanes 7 to 9)
resulting in a single band in each lane, with a heavier
band apparent in the J6 amplimer lane corresponding to
the more 3' binding region. A further magnesium titration
is shown in Figure 2.5 with concentrations in lanes 2 to
10 of 0.6, 0.8, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.OmM MgCl2
performed with the bcl-2 and Jl,2,4,5 amplimer. A single
discrete band can be seen in the 2.OmM lane.
2.4.4.6 Cycle number
As amplification of the template is exponential only for
part of the PCR process, a cycle number titration was
performed to maximise yields of specific product. Figure
2.6 shows duplicate reactions removed from the heat block
between 25 and 34 cycles (lanes 1-10). Analysis of the
PCR product on PAGE demonstrates optimal yields with 31
cycles of amplification.
2.4.5 Analysis of PCR products
2.4.5.1 Polyacrylamide gel electrophoresis
For fine resolution of PCR products, 5% vertical PAGE
gels were cast in lx TBE buffer and samples loaded in lx
loading buffer. Electrophoresis was carried out at lOV/cm
for 90min with Hinfl digested X174 DNA, or occasionally
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Figure 2.5 Ethidium bromide stained 5%PAGE of PCR
amplification products of SUDHL6 DNA. Lane 1 contains
bacteriophage lambda DNA digested with EcoRI and BamHI.
Amplification was performed with the amplimers bcl-2 and
Jl,2,4,5. Lanes 2-10 show the effects of increasing
magnesium concentrations of 0.6, 0.8, 1.0, 1.5, 2.0, 2.5,
3.0, 4.0 and 6.0 mM.
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Figure 2.6 Ethidium bromide stained 5%PAGE of PCR
amplification products of SUDHL6 DNA. Lane 12 contains
bacteriophage lambda DNA digested with EcoRI and BamHI.
Lanes 1 to 10 show the effects of increasing the number
of amplification cycles from 25 (lane 1) to 34 (lane 10)
in 1 cycle increments.
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bacteriophage lambda DNA digested with Hindlll and BamHI,
as molecular weight size markers. Gels were stained for
15min in lx TBE with ethidium bromide at O.lpg/ml, rinsed
in di^O then viewed under UV.
2.4.5.2 Agarose gel electrophoresis
This was performed as described in section 2.4.4.1 using
4% NuSieve 3:1 agarose and Hinfl digested 0X174 DNA size
markers.
2.4.5.3 Slot blotting
To 2pl of PCR product was added 98pl denaturing solution
before boiling for 3min. After incubation on wet ice for
2min samples were slotted onto a nylon membrane pre-
soaked in 20x SSC using a slotblot manifold (BRL
Hybrislot). Vacuum was applied until the wells had
drained, the vacuum shut off and 50ml of 2x SSC added and
the vacuum replaced until all the fluid had drained. The
membrane was then removed and immersed in 2x SSC before
drying. Membranes were stored in cling film.
2.4.5.4 Southern blotting
Following agarose gel electrophoresis as described in
section 2.4.5.2, capillary transfer was performed as
described in section 2.4.3.2 with the acid hydrolysis
step omitted and denaturation and neutralisation steps
reduced to 15min each.
2.4.5.5 Probes
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The IgHJ probe was as described in section 2.4.3.3. In
addition, a bcl-2 oligonucleotide probe derived from a
region 5* of the mbr (Stetler-Stevenson et al 1988)
(Table 2.1) was used. The bcl-2 probe was labelled as
described for the JH probe above except the buffer/
hexanucleotide mix primer solution was substituted with
Klenow polymerase buffer and lOOpM of a specific
hexanucleotide complementary to the 3' end of the probe
replaced the random hexanucleotides (Table 2.1)
2.4.5.6 Hybridisation
Hybridisation steps were performed as 2.4.3.4 for lh
only.
2.4.5.7 Washing
Membranes were rinsed in wash 1 at room temperature for
15min before stringent washing in wash 3 at 65°C for
30min.
2.4.5.8 Autoradiography
With the exception of shorter exposure times of 2 to 16h,
this was carried out as detailed in section 2.4.3.6.
2.4.6 Direct sequencing
2.4.6.1 DNA purification
Mineral oil was removed from PCR reactions with 3 volumes
of chloroform, followed by the addition of 3 volumes of
sodium iodide and by 5jj1 of vortexed glass beads. After
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incubation at room temperature for 5min, the sample was
pulse spun at 16000g, the supernatant discarded and the
pellet washed 3 times in ethanol wash. Purified DNA was
eluted into lOpl of dl^O by incubating for 5min at 55°C
followed by a pulse spin. The elution step was repeated
and the eluates pooled.
2.4.6.2 Sequencing reaction
Sequencing was based on the dideoxy chain termination
method (Sanger et al 1977) with the modifications of
Winship (1989). PCR products were sequenced in both
directions using the PCR amplimers as sequencing primers.
The annealing reaction contained 40mM Tris HC1 pH7.5,
25mM MgCl2, 50mM NaCl, >50pmol primer, 10% DMSO and
approximately lOOng template DNA in a volume of 10/j1.
This reaction was boiled for 3min, plunged into methanol
at -70°C for 10s before transfer to wet ice. This was
mixed with the labelling reaction which contained 0.025M
DTT, 0.5pM dCTP, 0.5pM dGTP, 0.5pM dTTP, 5pCi a35S dATP
and 2U sequenase enzyme in a total volume of 6pl.
Immediately 3.5pl of the resulting mix was added to 2pl
of each termination reaction preheated to 50°C. These
consisted of 80pM dATP, 80pM dCTP, 80pM dGTP, 80pM dTTP
and 10% DMSO. The "A" reaction also contained 8pM ddATP,
the "C" reaction 8pM ddCTP, the "G" reaction 8pM ddGTP
and the "T" reaction 8pM ddTTP. The termination reaction
was allowed to continue for 3min before the addition of
4pl stop solution containing 95% formamide, 20mM EDTA,
0.05% bromophenol blue and 0.05% xylene cyanol. Completed
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reactions were stable for several days at -20°C before
electrophoresis.
2.4.6.3 Electrophoresis
Samples were heated to 80°C for 3min prior to
electrophoresis through 0.2mm thick, 5% PAGE gels cast
in lx TBE with 8M urea. A Pharmacia LKB sequencing rig
was employed and gels run at a constant temperature of
55°C at 30V/cm for 2h. At the end of electrophoresis, the
gel was washed twice in 10% acetic acid for lOmin and
dried onto the glass sequencing plate.
2.4.6.4 Autoradiography
Dried gels were exposed to Hyperfilm /3max X-ray film (not
pre-flashed) at room temperature for one to 7d before
developing as described in section 2.4.3.6 with the fix
step extended to 5min.
2.4.6.5 Data analysis
Mbr junction nucleotide sequences were aligned with
published bcl-2. JH and DH segments (Ravetch et al
1991, Ichihara et al 1988) using the University Of
Wisconsin Genetic Computer Group (UWGCG) software
package.
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2.4.7 Design of alternative amplimers
Due to the non-specific nature of the 3" JH amplimers, a
single consensus 3' amplimer was designed. Using the GAP
program through UWGCG, a 19bp consensus region was
identified (Figure 2.4). In addition a new 5' mbr bcl-2
amplimer was selected to ensure a matched annealing
temperature. This was chosen from a region immediately 5'
to the existing primer to generate a product of a similar
size to the previous amplimer set. The 5' amplimer was
designed according to the following criteria (Innis and
Gelfand 1990):-
a) No 3' end complementarity between the amplimers in
order to avoid primer-dimer artifacts.
b) Select a region with average GC content.
c) Avoid extensive runs of G or C nucleotides.
With these constraints taken into consideration, a 20bp
primer was synthesised (Table 2.1).
2.4.7.1 Reaction conditions
The reaction conditions were as described in section
2.4.4.1 except that 250pmol of each primer was used. The
cycling conditions are shown in Table 2.3.
2.4.7.2 Optimisation
A magnesium titration was performed using 0.5 to 3. OmM
MgCl2 in 0.5mM increments (Figure 2.7, lanes 2-7) with
the optimal result seen in lane 4, 2.5mM.
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Figure 2.7 Ethidium bromide stained 5%PAGE of PCR
amplification products of SUDHL6 DNA. Lane 1 contains
0X174 DNA digested with HinfI. Using the Bcl-2 (20mer)
amplimer and the IgHJl-6 consensus amplimer (Table 2.1)
and cycling conditions shown in table 2.3. Lanes 2 to 7
show the effects of increasing magnesium concentration of
0.5 to 3.OmM in 0.5mM increments.
2.4.7.3 Prevention of false positivity
The extreme sensitivity provided by PCR can also lead to
the amplification of products from previous reactions
giving false positive results. The effect of
contamination can be minimised by the careful separation
of pre amplification reagents and post amplification
products. The steps recommended by Kwok and Higuchi
(1989) were taken and consisted of the use of separate
laboratories for preparation and analysis of PCR
reactions, storage of reagents in small single use
aliquots, the use of aerosol resistant pipette tips and
negative control reactions which contained no template
DNA to monitor "carry-over".
2.4.7.3 Conclusion
The use of multiple 3'- primers does produce specific
amplification but the use of a single consensus amplimer
results in a single PCR product making interpretation of
results less ambiguous. Resolution of two closely spaced
bands in agarose is difficult, making sequencing from the
3'- amplimer difficult if J6 was involved. This problem
is obviated by the use of a single amplimer. In addition
the use of several 25mer amplimers is expensive compared
to the use of a single pair of shorter oligonucleotides




The sensitivity of Southern blotting in detecting clonal
populations of neoplastic cells varies depending on the
hybridisation characteristics of the probe used and the
quality of the DNA studied, but is generally at the one
to 5% level (van Dongen and Wolvers-Tettero 1991).
The JH probe is derived from the 3'region of the IgHJ
locus and will generate a band of 9.5kb when hybridised
against Hindlll or BamHI digested genomic DNA with the
IgHJ region genes in germline, or non-rearranged
configuration. If a significant population of neoplastic
cells are present (i.e. >5%) then a band of a different
size will be apparent due to the alteration in pattern of
restriction enzyme sites generated by a rearrangement.
When a monoallelic rearrangement is involved, a single
new band will be seen along with the germline band
derived from the non-rearranged chromosome and any non¬
neoplastic cells in the sample. In cases where a
biallelic rearrangement has occurred, two new bands will
be seen in addition to any germline band contributed by
normal cells.
A group of 19 patients with low grade NHL were studied.
DNA from involved tumour tissue, lymph node in each case
with the exception of bone marrow in patients JW and HG,
was digested with the restriction enzymes Hindlll or
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BamHI, blotted and hybridised against the JH probe
(Figure 2.8). Rearrangements were apparent in all 19
patients, with a biallelic pattern evident in 11. In
addition lymph node DNA from all 8 patients with HD were
digested and hybridised as described above, however only
germline bands were observed.
All low grade patients studied therefore had appreciable
degrees of tumour as demonstrated by Southern blotting
(i.e. greater then 5%) but no clonal populations could be
detected in the group with Hodgkin's lymphoma.
2.5.2 PCR initial primers
2.5.2.1 Sensitivity
The optimal PCR conditions were as follows: l]jg genomic
DNA, 200jjM each dNTP, 250ng each primer, 50mM KC1, lOmM
Tris pH8.3 and 2.5mM MgCl2. The cycling conditions are
detailed in Table 2.3.
Tenfold dilutions of the t(14;18) cell line were made in
the HL60 cell line, ranging from 10-"'" (one tumour cell in
_ n
a background of 10 HL60 cells) to 10 (one tumour cell
in 10000000 HL60 cells) and the DNA extracted. PCR
amplification was performed using the bcl-2 and J6
primers on l^g of the mixed DNA along with a 100% SU DH
L6 positive control and the products analysed by PAGE
(Figure 2.9). Bands of the expected 237bp size can be
seen in lanes 2 to 6, with no band evident in lane 7
— R ...
(the 10 lane) indicating the limit of detection at
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Figure 2.8 Autoradiograph of Hindlll digested DNA from 10
patients with low grade NHL (lanes 2 to 12) hybridised
against the JH probe. Lane 2 contains normal PB DNA and
lane 13 no DNA. Hindlll digested bacteriophage lambda DNA
was run in lanes 1 and 14 (band sizes 23.1, 9.4, 6.6,
4.4, 2.3, 2.0 and 0.56kb). The location of the germline
band is indicated with a G and rearranged bands rangeing
in size from 4 to 9kb can be seen. The bands which appear
















Figure 2.9 Ethidium bromide stained 5%PAGE of PCR
amplification products of SUDHL6 DNA diluted in HL60 DNA.
Lane 1 contains 0X174 DNA digested with HinfI. Lanes 3 to
9 show tenfold dilutions of SUDHL6 amplified with the
Bcl-2 (25mer) and Jl,2,4,5 primers. Dilutions range from
10 to 10 with undiluted SUDHL6 DNA in lane 2. Lane 10
shows a negative control with no DNA template. The faint
band observed in lane 8 did not subsequently hybridise to
the bcl-2 probe.
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one tumour cell in a background of 10000 normal cells.
These products were slot blotted and hybridised against
the bcl-2 probe (Figure 2.10) which facilitated a tenfold
increase in sensitivity. Bands were evident in lanes 1 to
6 (the 10-5 lane) i.e. sensitivity at the one tumour cell
in 100000 level. As one microgram of DNA was used as
substrate, this represents the detection of a single copy
of the bcl-2-JH sequence.
2.5.2.2 Substrate dependence
With only limited amounts of tissue available for
analysis in some patients, the minimum PCR requirement
for substrate DNA was investigated. To 4 reactions were
added 10, 100 and 1000 whole cells which were be
amplified directly without prior DNA extraction (Higuchi
1989) as well as purified DNA equivalent to 10000 cells
(lOOng). PAGE analysis was performed on the products
(Figure 2.11) with no bands visible in lane 1, the
control reaction with no DNA. Bands could be visualised
in lanes 2 to 5 therefore DNA from 10 intact cells was
sufficient to generate a detectable PCR product.
2.5.2.3 Screening
DNA prepared from presentation lymph nodes of 5 patients
was amplified with the bcl-2 primer in conjunction with
each 3'- JH primer in individual reactions. A PAGE gel
was run (Figure 2.12) and distinct bands were visible in
patients SP (lanes 2 to 4), LW (lanes 5 to 7), JI (lanes
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Figure 2.10 Autoradiograph of PCR amplification products
of SUDHL6 DNA diluted in HL60 DNA and hybridised to the
Bcl-2 probe. Slots 2 to 8 show tenfold dilutions of
SUDHL6 amplified with the bcl-2 (25merl and .11,2,4,5
primers. Dilutions range from 10 to 10" with undiluted
SUDHL6 DNA in lane 1. Lane 8 shows a negative control
with no DNA template.
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Figure 2.11 Ethidium bromide stained 5%PAGE of PCR
amplification products of small number of whole SUDHL6
cells amplified with be1-2 (25mer) and Jl,2,4,5
amplimers. Lane 1 contains no template DNA, lanes 2 to 4
shows the amplification of 10, 100 and 1000 whole cells
without prior DNA extraction. Lane 5 shows the
amplification of lOOng of SUDHL6 DNA equivalent to 10 000
whole cells.
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Figure 2.12 PCR amplification products of presentation
lymph node DNA from 5 patients amplified with the bcl-2
(25mer) and each of the 3 individual IgHJ amplimers
(Table 2.1). Lane 1 shows $X174 DNA digested with
Hinfl. Lanes 2-4 is amplified DNA from patient SP, lanes
5-7 patient LW, lanes 8-10 patient JI, lanes 11-13
patient JC and lanes 14-16 patient JK. The first lane
from each patient is the amplificaton product using
amplimer Jl,2,4,,5; the second lane J3 and the third lane
J6. The upper figure shows an ethidium bromide stained
5%PAGE, the middle and lower figure show autoradiographs
of Southern blots of the amplification products probed
with the IgHJ and bcl-2 probes respectively.
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8 to 10) and JC (lanes 11 to 13) although no bands could
be seen in patient JK (lanes 14 to 16). The band sizes
are summarised in Table 2.4. The PCR products were
resolved by agarose gel electrophoresis, Southern blotted
and hybridised with JH and bcl-2 probes to confirm their
origin in the translocated sequences. Therefore 4 of the
initial group of 5 patients had a t(14;18) translocation
with an mbr breakpoint. The patient without a
demonstrable mbr translocation event did have tumour
detectable by Southern blotting, therefore the negative
result was not due to the integrity of the material under
study or degree of tumour infiltration.
To confirm the origin of the 3 bands obtained when the
different JH amplimers were used, the PCR products from
patient SP were sequenced (Figure 2.13). All 3 sequences
were identical, except at the 3' end, which varied
depending on which amplimer was employed. The size
difference of 23bp was due to the binding of the J6
amplimer 23bp downstream of the Jl,2,4,5 and J3
amplimers. The presence of all three bands indicates the
selection of IgHJ segment 6, as the binding site for J6
is not present on J segments 1 to 5. Sequence analysis
was carried out on the remaining three patients to
confirm this. The nucleotide sequence data from the
junctional regions are shown in Table 2.5 indicating that
J6 was involved.
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Table 2.4 Size (bp) of PCR amplification products of
patients with low grade NHL amplified with bcl-2(25mer)











TA CTA CTACTA CTACATGGACGTCTGGGGGCAAGGGACCACGGTCACCGTCTCCTCAGGT
TA CTA CTACTA CTACATGGACGTCTGGGGGCAAGGGACCACGGTCACCGTCTCCTCAGGT




Figure 2.13 Sequence analysis of PCR products from a
patient with a t(14;18) translocation. Each PCR product
from separate amplifications using the 5' bcl-2 primer
with individual 3' JH primers (Jl,2,4,5; J3 and J6)(Table
2.1) was directly sequenced using the amplimers as
sequencing primers. The bcl-2 and JH amplimers are boxed














































































































































































































































Table 2.5 Sequence analysis of PCR products from 8
patients (IM, SP, JI, JC LW, AM, CM and WG) with a
t(14;18) translocation. DNA was amplified using the bcl-2
(20mer) and IgHJl-6 consensus primers and the products
directly sequenced.
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2.5.3 PCR consensus amplimers
2.5.3.1 Sensitivity
The sensitivity of the second primer system using the
bcl-2 (20mer) and JH consensus amplimers was tested as
above. The PAGE gel of the amplified dilution products is
shown in Figure 2.14 and the same products slot blotted
and hybridised against the bcl-2 probe in Figure 2.15.
Again sensitivity demonstrated by PAGE analysis is at the
level of one tumour cell in 10000 HL60 cells, with a
tenfold enhancement provided by slot blotting.
2.5.3.2 Screening
A total of 22 patients, on whom lymph node or involved
marrow was available were screened using this PCR system.
On amplification, marker bands were present in 8 patients
(36%) after PAGE analysis (Figure 2.16) with the band
sizes and cytogenetic data summarised in Table 2.6. The
origin of the bands was confirmed by Southern blotting
the products and hybridising against JH and bcl-2
probes (Figure 2.16).
The patients previously found to be positive with the
original PCR system were also positive when screened
with the consensus JH amplimer, one patient remained
consistently negative. Of the 14 patients found to be mbr
negative by PCR, 9 were previously shown to contain
significant tumour populations by Southern blotting
indicating that the samples studied were suitable
substrates for analysis therefore the negative results
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Figure 2.14 Ethidium bromide stained 5%PAGE of PCR
amplification products of SUDHL6 DNA diluted in HL60 DNA.
Lane 1 contains $X174 DNA digested with HinfI. Lanes 3 to
8 show tenfold dilutions of SUDHL6 amplified with the
bcl-2 (20mer) and IgHJl-6 consensus primers. Dilutions
range from 10 to 10 with undiluted SUDHL6 DNA in lane
2. Lane 9 contains no template DNA.
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Figure 2.15 Autoradiograph of PCR amplification products
of SUDHL6 DNA diluted in HL60 DNA and hybridised to the
bcl-2 probe. Slots 2 to 8 show tenfold dilutions of
SUDHL6 amplified with the bcl-2 (20mer) and Ig_HJl-6
consensus primers. Dilutions range from 10 to 10 with
undiluted SUDHL6 DNA in lane 1. Lane 8 shows a negative





Figure 2.16 PCR amplification products of presentation
lymph node DNA from 7 (lanes 2 to 8) patients amplified
with the bcl-2 (20mer) and IgHJl-6 consensus amplimers
(Table 2.1). Lane 1 shows 0X174 DNA digested with
Hinfl. Lane 9 contains normal DNA. The upper figure shows
an ethidium bromide stained 5%PAGE, the middle and lower
figure show autoradiographs of Southern blots of the
amplification products probed with the IgHJ and bcl-2
probes respectively.
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Patient Southern Cytogenetics t(14; 18)
SP RR 14 18 195
LW RR 14 18 234
JC RR 14 18 295
JI RR 14 18 234
IT GR 14 18 -
WGr GR 14 18 219
EB RR 14 18 -
JS GR 14 18 -
JK GR 14 18 -
CL RR 8;14 -
AMc RR 8;14 -
HG GR NA -
WG1 GR 14; 18 -
IM GR NA 141
AMa GR NA 126
GN RR NA -
AS RR ND -
EW RR NA -
JW RR NA -
CM ND 14; 18 188
JB ND Complex -
ML ND NA -
Table 2.6 Summary of Southern blot, cytogenetic and PCR
results from patients with low grade NHL amplified with
bcl-2(2Omer) and consensus JH primers. Band sizes are
indicated in bp.
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were not due to lack of tumour infiltration. Of the 10
patients known to bear t(14;18) translocations by
cytogenetic analysis, 6 showed mbr PCR positivity
suggesting that the remainder have mcr translocations or
more distal mbr breakpoints.
Following PCR amplification with the consensus primer
system and PAGE analysis, mbr translocations were not
detected in any of the 8 patients with HD at the 10~^
level or above.
2.5.4 Sequence analysis
All 8 PCR positive patients were sequenced in both
directions, using the PCR amplimers as sequencing
primers, in order to assess JH usage and to map the
breakpoints within the be 1- 2 gene. A typical
autoradiograph from a denaturing PAGE gel of such a
reaction is shown in Figure 2.17 and shows chain
extension from the bcl-2 and JH primers, with the
junctional sequence indicated. Sequence data obtained on
all 8 patients is shown in Table 2.5. Due to variation in
the bcl-2 mbr breakpoints over a 150bp region, there is
large variation in the amount of bcl-2 sequence involved
in the translocation, lllbp separates patients IM and LW.
The mbr breakpoint conversely varies by only 3
nucleotides between 4 patients (LW, JC, WG and JI), with
2 (JC and WG) occurring at the same base. No evidence
for the involvement of D segments was found therefore the
junctional nucleotides were classified as N nucleotides
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Figure 2.17 Autoradiograph of an 6% denaturing PAGE gel
for sequencing PCR products from a patient with a
t(14;18) translocation. Products were sequenced from the
bcl-2 (20mer) (left) and IgHJl-6 (right) consensus
primers. Termination reactions were loaded in the order
G, A, T and C.
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which showed a GC content of 50%. Insertions varied from
one (SP) to 59 (JC) nucleotides. Differing JH selection
was also observed with 6 patients displaying J6, one
patient (AM) using J4 and one (IM) using J5. Variable
degrees of exonucleolytic "trimming" was observed, with
only two patients showing intact J boundaries (SP and
IM) with up to 21 nucleotides being deleted (WG). Two
patients displaying J6 usage had a GGT triplet deleted
from the germline sequence. A summary of the bcl-2
breakpoints described here in addition to those
previously reported is presented in Figure 2.18.
In summary, clonal IgH rearrangements were detected in
all 19 patients studied. PCR analysis generated specific
products in 8 of 22 cases (36%), the nature of which were
confirmed by sequence analysis which demonstrated tight
clustering of breakpoints within a lOObp region.
2.6 DISCUSSION
Southern blotting with the IgHJ probe identified clonal
expansions of lymphocytes in tumour DNA from all 19
patients with low grade lymphoma, however no such
proliferations could be detected in 8 patients with HD.
The latter finding is in accord with the published
incidence of IgH rearrangements in HD, reported in
approximately 10% of patients (Daus et al 1989).
PCR based techniques provide more sensitive methods for




Figure 2.18 Map of nucleotides 50 to 177 of the mbr
region of the be1-2 gene. Open squares indicate
breakpoints previously published (reviewed Wyatt et al
1992). Solid squares indicate breakpoints identified in
our series of patients. Three breakpoint clusters are
indicated by underlining.
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taken in determining the optimal reaction conditions in
order to ensure consistency and simplify the
interpretation of results. Specific amplification was
improved by the careful selection of primer sequences and
by determination of optimum magnesium ion concentration.
Excessive numbers of cycles were found to increase non¬
specific banding without an increase in yield. The
amenability of PCR to the analysis archival material,
such as frozen sections, increased the number of patients
available for analysis to 22. Previous studies have
reported the incidence of mbr breakpoints in 30 to 70% of
low grade NHL patients with a t(14;18) (Amakawa et al
1989, Weiss et al 1987) and the overall frequency of mbr
translocations in this study, regardless of cytogenetic
status, was 36%. Among patients previously characterised
as bearing t(14;18) translocations, 6 out of 10 produced
a discrete amplification product. Pezzella et al (1990)
reviewed the overall incidence of mbr and mcr
translocations and reported these to be 35.3% and 5.9%
respectively. According to these figures, an mcr
translocation would occur in approximately 1 of 22
patients in this study, although this was not
investigated.
The initial primer system used (Stetler-Stevenson et al
1988) employed 3 JH specific primers, however due to lack
of specificity to the particular JH segments to which
they were designed, a single consensus JH primer was
designed. This contains a single bp mismatch with J3, but
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this did not lead to an under representation of this
sequence when used for CDRIII amplification (discussed in
Chapter IV). Dilutions of the t(14;18) SU DH L6 line in a
myeloid cell line demonstrated the sensitivity of the
technique, which was able to detect a single copy of a
translocated sequence in a background of 10^ normal
sequences. PAGE analysis of the amplification products of
only 10 cells yielded a clear signal, which has
implications for the study of archival or specimens on
which little material is available.
Sequence analysis using a simple direct sequencing
technique which avoided asymmetric PCR or sub-cloning was
confirmed the source of the bands demonstrated by
electrophoresis. Some of the features of normal IgH V-D-J
recombination events (Tonegawa 1983), such as N insertion
and exonucleolytic trimming of JH segments was evident.
Other groups have reported the involvement of D segments
(Eick et al 1990, Cotter et al 1990, Kneba et al 1991)
however no evidence for this was found in this series.
Clustering of mbr breakpoints was evident with lllbp
separating the most distal, but it is possible that
breaks 5' of the bcl-2 primer could occur. Wyatt et al
(1992) characterised one breakpoint one kb 3' of the
region designated cluster 3 but any occurring more 3' of
this may not amplify to be detected. Breakpoints outwith
the mbr are relatively rare but those proximal can be
detected by Southern analysis (Pezzella et al 1990) or
those more distal by PFGE (Zelenetz et al 1991). The
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application of FISH with chromosome 14 and 18 probes to
interphase cell preparations would also be effective in
the detection of translocation events, however this does
not permit the study of preserved material and the
sensitivity would be less than that of PCR.
Variation was seen by with the insertion of differing
lengths of N nucleotides though a high GC bias was not
apparent as in other immune gene junctions. This was also
observed by Kneba et al (1991). A bias towards J6
selection was also clear with varying exonucleolytic
trimming apparent at all JH termini. One patient had a
GGT triplet deleted 15 nucleotides from the 5' boundary
of J6. The N-J junctional sequences therefore resembles
the junctional regions produced by regular IgH
recombination events although more extensive N nucleotide
insertion was present in some cases. The signal sequences
which would mediate the bcl-2- (D)-JH recombination have
not been clearly demonstrated. Wyatt et al (1992) first
characterised the clustering of bcl-2 breakpoints in 3
distinct regions within a 150bp region of the mbr. Each
cluster region was associated with an 8 nucleotide
sequence homologous to the prokaryotic chi recombination
initiation signal which they suggested mediated an
initial bcl-2-DXP recombination. This was then followed
by a DXP-JH event before resolution by the regular IgH
recombinase mechanism. They also observed duplication of
mbr sequences and the presence of DXP signal sequences in
some junctions but these were not observed in the 8
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patients sequenced here. All the be1-2 breakpoints
studied fell within the 3 cluster regions described by
Wyatt, with one exception, which was located 4bp 5' of
cluster region 1. Interestingly a tight grouping of 4
breakpoints was observed in cluster region 3. Further
analysis of translocation signal and coding sequences
will be required in order to understand the mechanisms
underlying non-homologous recombination.
Eick et al 1990 exploited sequence data to generate clone
specific oligonucleotides to monitor disease, in order to
minimise the occurrence of false positives. Kneba et al
(1991) also designed clone specific oligonucleotides but
used these as primers for a clone specific PCR
amplification following an initial amplification with
regular bcl-2 and consensus JH primers. These techniques
do not provide an enhancement in sensitivity but do
ensure specificity and enable non-radioactive detection
of rare species however as different oligonucleotides do
not amplify uniformly and require varying reaction
conditions, this approach may be limited in certain
patients. Price et al (1991a) used "booster" and nested
PCR in order to generate sufficient material to allow
sequence analysis of very rare t(14;18) species from DNA
samples obtained in remission. Nested PCR reactions can
lead to carry over problems as separate equipment,
reagents and preparation areas are required for each
subsequent stage. The single step system described here
is straightforward and sufficiently sensitive to detect a
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single translocated sequence and is potentially less
prone to carry over than nested systems although it does
not facilitate the characterisation of rare species
generated in the course of therapy. However as these
species did not replace the initial clone at relapse,
this is not a necessary step in order to successfully
follow tumour progression. Also, these rare species may
be derived from translocation events occurring in normal
lymphocytes, as detected by Limpens et al (1992) in
enriched B-cell populations. This may explain the finding
by Stetler-Stevenson et al (1990) of t(14;18) events in
lymph nodes from patients with HD. These translocations
may have originated in reactive lymphocytes rather than
Reed-Sternberg cells.
In conclusion, t(14;18) translocations were detected in
36% of patients with low grade NHL, but not detected in 8
patients with HD. Optimisation of reaction conditions
provides a sensitive disease marker for the determination
of MRD in a proportion of low grade NHL patients
undergoing therapy. Sequence analysis confirmed the
origin of the markers and demonstrated features
associated with normal immune gene junctions and
clustering of mbr bcl-2 breakpoints. If residual disease
analysis is to provide meaningful results, carry-over
must be avoided by careful laboratory technique and
monitored by the rigorous use of control reactions.
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CHAPTER III
T-CELL RECEPTOR 6 CHAIN IMMUNOGENOTYPE ANALYSIS
3.1 INTRODUCTION
3.1.1 T-cell receptor a/3 complex
T-lymphocytes are conditioned in the thymus to recognise
foreign antigens presented in a "self" MHC context
mediated via a transmembrane glycoprotein heterodimer
non-covalently linked to the signal transducing CD3
complex on the cell surface (Saito et al 1987). The most
prevalent heterodimer is the TcR a/3 complex, found on the
majority of peripheral T-cells. It is associated with
either a CD4+, CD8- or CD4-, CD8+ single positive (SP)
phenotype corresponding to helper and killer cells
respectively (Lanier and Weiss 1986). A signal
transduction cascade is activated by the interaction of
the TcR complex with antigen which results in cell
proliferation and secretion of IL- 2 by mature T-cells.
The generation of immune diversity is mediated by a
recombinase system analogous to that involved in Ig gene
rearrangements whereby germline encoded segments are
recombined to produce a unique TcR gene (Saito et al
1984). This involves endonucleolytic cleavage and
ligation of random germline segments mediated by
heptamer/ nonamer RSS and a recombinase enzyme. This
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generates a chromosomal coding joint and a closed
circular extrachromosomal signal joint. A polyclonal
population of T-cells will therefore bear the diverse
repertoire of TcR genes necessary for antigen
recognition. The TcRa locus has >50 variable (V) segments
and approximately 55 joining (J) segments and the /3 locus
>70 V segments and 13 J segments as well as 2 diversity
(D) segments, providing extensive combinatorial diversity
(Davis and Bjorkman 1988). Further variability is
provided by random exonucleolytic digestion of these
germline encoded segments and insertion of non-template
encoded N nucleotides at the junctions mediated by the
enzyme TdT. During development in the thymus, T-cells
undergo positive selection for the ability to recognise
foreign antigens in the correct MHC context and negative
selection to remove autoreactive TcR's. These steps are
regulated by the a/3 complex in addition to its role in T-
cell activation (Finkel, Kubo and Cambier 1991).
3.1.2 Characterisation and structure of the T-cell
receptor 6- chain locus
After the predominant CD3 associated TcR complex was
characterised, a population of CD4-, CD8- thymic T-cells
expressing CD3 in conjunction with a novel protein,
designated TcR y (Saito et al 1984), was described
(Brenner et al 1986). A combination of FACS analysis and
immunoprecipitation with framework region monoclonal
antibodies followed by Northern blotting confirmed the
existence of this T-cell subset that lacked functional a
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or (3 chain expression. Two molecules of molecular weight
55kD and 40kD co-precipitated with the CD3 complex from
these cells, with the 55kD molecule corresponding to the
inferred weight of the fully glycosylated TcR gamma
protein. The second molecule was therefore designated the
TcR6 chain, which was not initially found to be
disulphide linked to the 7 chain.
The TcR6 locus was mapped to chromosome 14 and localised
within the TcRa locus (Chien et al 1987), nested between
the Va and Ja segments. The C6 locus mapped 85 kb
upstream of the Ca region and these genes were found to
be homologous (Takihara et al 1988) indicating a possible
duplication event in the divergence of the TcR loci.
Three J6 and 2 D6 segments were sequenced, displaying
recombination signal heptamer and nonamer sequences
consistent with those previously characterised in other
immune receptor genes. Further studies identified 6 V, 3
D and 3 J segments, hence the amount of germline encoded
diversity was extremely small compared to that of the a
and /3 loci (Takihara et al 1989). Sequence analysis of
rearranged TcR6 genes from thymic cell lines showed a
further restriction of germline variability due to the
restricted selection of V and J segments (Loh et al
1988). Frequent selection of V61 and J61 was apparent,
with the rarer selection of a second V6 segment but the
actual junctional diversity was found to be enormous due
to the selection of multiple D6 segments that could be
read in all 3 frames, extensive exonucleolytic trimming
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of germline sequences and the insertion of non-germline
encoded N nucleotides mediated by the enzyme TdT (Hata et
al 1988). Single sided or "anchored" PCR (A-PCR) of mRNA
which enabled amplification with a single specific primer
facilitated the characterisation of previously unknown V
segments recombined to J61 segments expressed in
peripheral T- cells (Loh et al 1989). All the sequences
obtained were distinct and in frame, and again restricted
V selection was apparent, with only 2 members of the V6
family observed, V61 and V62. This indicated a difference
in the repertoire of V selection between cells of thymic
(selecting primarily V61 and V63) and peripheral T-cell
origin (selecting V61 and V62). Further to this, the
previously described multiple D6 segment selection
observed in thymic cells was less frequent. The selection
of V6 segments proximal to the D6/J61 region appears to
explain such preferential selection (Greisinger et al
1991). This may be mediated by the inaccessibility of
more distal segments to a recombinase enzyme bound at a
particular site perhaps due to the local chromatin
structure (Tycko, Coyle and Sklar 1991).
The localisation of the TcR6 locus within the TcRa locus
indicated that the TcR6 chain would rearrange at an early
stage as recombination of the TcRa locus would remove the
TcR6 genes. Signal sequences flanking the TcR6 locus
mediating its deletion have been determined, the 5' 6rec
and 3' pseudo Ja regions (De Villartay et al 1988). When
the TcR6 locus was mapped to the TcRa locus, it was
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assumed that V segments could be shared between the 2
chains. However, the V segments characterised were
distinct although some V6 segments are interspersed
within the Ja cluster and some RSS are shared. Chimeric
TcRa6 rearrangements have been reported but these arise
via a mechanism that bypasses the 6rec signals and does
not involve the shared signal sequences. This results in
a V5D6-Ja molecule which may be an intermediate of a
mature TcR Va-Ja molecule (Yokota, Bartram and Hansen-
Hagge 1991b).
Another feature of TcR and other immune gene junctions is
the presence of P or palindromic nucleotides, previously
assumed to be TdT mediated N insertion but may actually
be germline encoded (Lafaille et al 1989). These
nucleotides are found at the intact boundaries of
germline segments, are of one to 2 nucleotides in length
and are palindromic with respect to the adjacent germline
sequence. They were postulated to arise during the
recombination process via the "nicking" of one strand 2
base pairs from the boundary of the segment selected,
followed by inversion of the 2 terminal nucleotides and
repair of the newly created 4 nucleotide single stranded
projection to generate a short palindrome. Exonucleolytic
digestion at the junction would remove one or more
nucleotides, hence these P nucleotides occur only at
intact germline segments.
Restricted combinatorial germline diversity has also been
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reported at the TcR Y locus on chromosome 7. Fifteen
V segments were described, of which 8 are functional
along with 5 J segments and 2 C regions, the selection of
which determines the disulphide linkage status of the
Y/6 complex. Mature TcR heterodimers involving
C Y 1 are disulphide linked whereas those involving
C Y 2 are not due to the lack of a cysteine residue in
the second exon (Krangel et al 1987). Although TcRY
bearing lymphocytes are rare, they are abundant in
epithelial tissues (Itohara et al 1990a) with subgroups
of these lymphocytes expressing TcR's which are highly
homogeneous, both at the junctional and combinatorial
level (Lafaille et al 1989).
3.1.3 T-cell ontogeny
The precursors of T-lymphocytes are thought to originate
in the bone marrow before migrating to the thymus (Ezine,
Weissman and Rouse 1984) where they develop, via an
ordered process involving TcR gene rearrangement to
mature thymocytes. Positive selection for MHC context and
negative selection for autoreactivity was identified for
TcRa/3 T-cells (Davis and Bjorkman 1988), but although
selection is involved in y6 T-cell development, an
extra thymic component may be involved (Dent et al 1990).
High levels of TdT is expressed in the nuclei of immature
lymphoid cells (Bollum 1979) suggesting the onset of
immune gene rearrangement, with persisting expression in
cortical thymocytes, but expression is not found in
85
mature T-cells (Foon and Todd 1986).
Studies of T-ALL suggest that it represents a clonal
expansion of cells arrested at different stages of T-
lymphocyte development in different patients, resulting
in a range of TcR gene rearrangements. Such cells are
mainly CD3 negative and do not express mature surface TcR
molecules. Many have both (3 and Y chain gene
rearrangements, though some show ' y chains only,
suggesting that y genes rearrange before /3 whereas a-
chain involvement is rare indicating a later
rearrangement (Felix et al 1987). The majority of T-ALL
have one or 2 6-chains rearranged or deleted, with the
gamma and (3 chain genes in germline configuration in some
cases (Foroni et al 1989) hence 6-chain rearrangement
would appear to occur first.
This pattern of rearrangements suggests an ordered
hierarchy of TcR gene rearrangements and some of the
regulatory elements mediating this process have been
described. An unusual 2.0kb TcRa mRNA species lacking a
Va region was found in early T-cells and was designated
T-earlya (TEA-Ca) (Hockett et al 1988). The gene coding
for this transcript is in the germline configuration in
immature T-cells and TcR y6 lymphocytes but deleted
in TcRa/3 T-cells. Such transcription may have a role in
rendering the Ja locus accessible for 6-chain gene
deletion via the 6rec/ pseudo Ja mechanism thus enabling
a-chain rearrangement.
86
Rearrangement events result in the excision of circular
extrachromosomal elements bearing the signal sequences
and these can be studied and intermediate structures
analysed (Fujimoto and Yamagishi 1987). Such studies have
indicated a progressive mechanism whereby germline or
non-functional 6-chain rearrangements can be deleted,
followed by a-chain rearrangements which in turn can
further recombine to form new genes using upstream Va and
downstream Ja segments (Takeshita et al 1989).
Tissue specific enhancer elements are involved in the
transcriptional activation of the TcR locus which are
silenced in non T-cells by cis acting "silencer" elements
(Winoto and Baltimore 1989). Two 6-chain enhancers
located between J63 and C6 have been described which are
T-cell specific and active in both J6 and a/3
lymphocytes. A cis-acting Y gene silencer which
prevents Y chain transcription in mice has also been
reported (Ishida et al 1990, Bonneville et al 1990).
Van Dongen et al (1990) proposed a coordinated model for
TcR gene rearrangement during T-lymphocyte maturation
involving a pivotal role for the TcRa/6 locus. The
earliest event is the activation of TcR6 enhancers
resulting in TcR6 rearrangement followed by concomitant
Y and /3-chain rearrangements. Ultimately " Y <5 T-
cells would result if activity of the a-silencer
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persisted repressing a-chain rearrangement. Inactivation
of the a-silencer would lead to transcription mediated
opening of the a locus via TEA-Ca and exposure of the
pseudo Ja element. The 6rec element would already be
accessible due to previous 5-chain gene activation,
leading to a-chain gene recombination and the subsequent
production of a/3 T-cells.
The process of thymic selection of a/3 T-cells for
restricted MHC recognition is thought to be mediated by
the CD4 and CD8 molecules, however few peripheral y6
T-cells bear either molecule. This suggests that y5
cells may mature via an extra thymic pathway, supported
by the fact that few TdT positive y <5 thymocytes have
been observed, most being TcRa/3 although the junctional
regions of the former are far more diverse. A study of
children with Di George's anomaly (DGA) in which varying
degrees of thymic aplasia are found enabled the
relationship of thymic mass and T-cell repertoire to be
studied (van Dongen et al 1990). In healthy children
mature T-lymphocytes are mainly TcRa/3 positive whereas in
DGA the levels of TcRa/3 are affected by reduction in
thymic mass while y 5 cells remain virtually constant.
Further to this, the number of peripheral T-cells in
healthy children falls until adolescence, mainly
affecting a/3 lymphocytes as the thymus involutes which
agrees closely with the relationship of thymic mass and
the level of a/3 T-cells in DGA patients. These findings
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indicate that at least part of the maturation process of
76 T-lymphocytes must occur at some as yet
uncharacterised extra-thymic location.
3.1.4 Involvement of the TcRa/6 locus in leukaemia
The analysis of various leukaemias by Southern blotting
with TcR probes has demonstrated the frequent association
of 6-chain rearrangements with different leukaemia sub¬
types (Felix and Poplack 1990). These can involve
complete or incomplete V(D)DJ rearrangements in addition
to translocations recombining the a/6 locus to other loci
including oncogenes which may have a direct role in
tumour aetiology.
Translocations associated with T-lineage ALL usually
involve the a/6 locus as opposed to either /3 or gamma
genes, perhaps due to the early rearrangements of the 6
locus in lymphocyte ontogeny (Rabbitts and Mengle-Gaw
1988). Translocations involving known oncogenes such as
the t(8; 14 ) (q24;ql1) which juxtapose the a/6 locus on
14qll next to c-myc on 8q24 probably have a direct role
in tumour aetiology. Some sporadic translocations, such
as inversions involving the a/6 and IgH loci are probably
not related to the tumour lesion and represent a rare
event in cells which have been rescued by a progression
to neoplasia.
Recombination of the Tal-1 locus on lq34 to the a/6 locus
is found in 3% of T-ALL although site specific deletions
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of the Tal-1 gene are associated with a further 26%
(Brown et al 1990, Chen 1990). This gene encodes a helix-
loop-helix protein and such genes have a DNA binding
affinity these are involved in developmental gene
regulation hence such a lesion probably has a direct role
in tumourigenesis in addition to being a useful marker of
disease.
Rearrangements of TcR genes are found in all cases of a/3
and gamma6 expressing T-ALL's as described above but in
addition, frequent rearrangements of /3, 7 and 6
genes were reported in B-lineage ALL (Felix et al 1990).
Restricted repertoires of TcR6 gene selection were
reported in both T- and B-ALL with the majority of T-ALL
selecting V61 or V62 with J61. Complete V-D-J 6-chain
rearrangements were not common in B lineage ALL but
deletions at the TcR6 locus are frequent and
recombinations involving V62 and D63 have been observed
in approximately 50% of patients (Biondi et al et al
1990). Further rearrangements to Ja genes creating
chimeric V62D63Ja molecules have been reported in 27% of
cases of B-lineage ALL (Yokota, Hansen-Hagge and Bartram
1991b).
3.1.5 Analysis of minimal residual disease
The enormous diversity at TcR junctions has the potential
to provide extremely specific markers for clonal
populations of neoplastic cells. The restricted
repertoire of germline flanking sequences associated with
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disease subtypes are suitable for the selection of PCR
amplimers. In addition, the relatively low reported
incidence of oligoclonality and clonal evolution at this
locus may provide a stable marker for disease (Beishuizen
et al 1992 ) .
V61-J61 rearrangements found in 25% of T-ALL were the
first TcR genes exploited as a tumour specific marker
(Hansen-Hagge, Yokota and Bartram 1989). A
"clonospecific" probe was generated by amplifying the
junctional sequence from tumour material at presentation
which appeared as a discrete band on resolution by
agarose gel electrophoresis. After therapy, the
diminished level of neoplastic cells would result in the
amplification of a polyclonal population and the tumour
band would be masked by sequences from normal
lymphocytes. The presence of neoplastic cells within a
background of normal cells could then be discerned by
hybridisation with the "clonospecific" probe. Dilution of
tumour cells in normal mononuclear cells demonstrated the
sensitivity of this technique at the 10-^ level i.e. if
the equivalent of 1000000 cells (lOpg of DNA) was
amplified, then one tumour cell could be discerned.
Neale et al (1991) extended this approach by designing
primers to V61, V62 and V63 and J61, J62 and J63 which
they used to screen T-ALL patients in pairwise
configurations. This detected TcR rearrangements in 76%
of patients, the majority being V61-J61 as expected. They
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sequenced the PCR product and used this information to
design anti-junctional oligonucleotide probes to monitor
remission populations of neoplastic cells. Dilution
experiments estimated the sensitivity of the system to be
at the level of one tumour cell in a background of 100
000 normal cells if lpg of DNA was examined.
These approaches were restricted to a subgroup of T-
lineage ALL patients to be analysed, but were extended by
exploiting the V62-D63 partial rearrangement frequently
found in B-lineage ALL (Yokota et al 1991a). However,
this is only a partial rearrangement and provides less
diversity. Probes raised against this junction may be
less sensitive in some cases than those against the V61-
J61 junction but can still be successfully applied to
detect residual disease.
3.1.6 Aims
1 wished to determine the incidence of TcR6-chain
rearrangements in a range of haematological disorders and
investigate the potential application of PCR analysis
to the detection of residual disease. Initially patients
were screened by Southern blotting before the development
of a PCR system to provide rapid screening and sensitive
disease detection. Sequence analysis was performed to
confirm the nature of the amplification products and
evaluate to the degree of diversity shown at this locus
and therefore the effectiveness of clone specific probes




A group of 8 patients with T-cell ALL (3 male, 5 female)
with a mean age of 27 years (range 5-71 years) were
studied.
3.2.2 B-lineage ALL
A total of 14 adults (8 male, 6 female) with a mean age
of 33 years (range 16-60 years) were available for
analysis along with 22 children (10 male, 12 female) with
a mean age of 6 years (range 2-14 years).
3.2.3 T-cell NHL
Ten patients (7 male, 3 female) with a mean age of 60
years (range 20 to 74) were screened.
3.2.4 AML
Sixteen patients with AML (9 male, 7 female) with an
average age of 41 years (range 30 to 75) were studied.
3.3 MATERIALS
The materials were as detailed in section 2.3 with the







T4 Polynucleotide kinase (Amersham)
dATP gamma ~^PdATP (DuPont)
TMAC1 (Camlabs, Cambridge, U.K.)
3.4 METHODS
The methods were as detailed in section 2.4 with the
following additions.
3.4.1 Restriction endonuclease digestion and Southern
blotting
This was performed as section 2.4.2 except genomic DNA
was digested with Hindlll or Bqlll.
3.4.2 Probes
TcR6 chain gene rearrangements involving J61 were
detected with a 1.2kb J61 SacI fragment designated J6S16
(Boehm et al 1988) and is illustrated in Figure 3.1.
3.4.3 PCR analysis of the V61-J61 rearrangement
This involved an approach essentially as described by
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Figure 3.1 Diagram of the TcR6 locus. The germline
configuration of the TcRd gene segments is shown in the
upper diagram with the location of the J6sl6 probe,
Hindlll and Bglll restriction enzyme recognition sites
indicated. The middle shows a V61-D-D61 recombination
with the amplimer binding sites indicated by boxes. The
lower diagram shows a V62-D-D63 partial recombination
event with the amplimer regions indicated.
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Hansen-Hagge et al (1989) which exploited the conserved
V61-J61 rearrangement associated with T-cell ALL. An
initial set of PCR cycles was performed using outer V61 L
(leader) and 3'-J61 amplimers followed by a second nested
step using 3'-V61 and 5'-J61 amplimers (Table 3.1). The
product of the second cycle was excised from an agarose
gel, digested with a restriction enzyme to remove 3'
germline sequences, radio1abe11ed and used as a
"clonospecific" probe to monitor disease progression in
patients undergoing therapy.
3.4.3.1 Polymerase chain reaction analysis
Each reaction contained lpg DNA, lx PCR buffer, 200/jM
each dNTP, 30pmol each primer, 1U Tag polymerase and
0.01% gelatin. Cycles were as detailed in Table 3.2. The
first round of amplification was performed with outer
primers V61 L (leader) and J61 3' (Table 3.1). An aliquot
of this first reaction (1%) was transferred to a second
reaction with fresh reagents and amplification performed
with primers V61 3' and J61 5'. A magnesium titration was
performed using presentation tumour DNA from a T-ALL
patient with a biallelic V61-J61 rearrangement as
template (Figure 3.2). Lane 2 contains the first round
product (approximately 700bp) and lanes 3-6 the second
round product amplified with 1-2.5 mM MgCl2 in 0.5 mM
















Table 3.1 Nucleotide sequence of PCR primers fo
amplification of the V61-J61 and V62-D63 loci. Th
artificial Fokl site is underlined within the J61 5
sequence, the altered nucleotide is in bold type
Hexanucleotide labelling primer sequences are also shown
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Table 3.2 Cycling conditions for V61-J61 and V62-D63
amplification. For the inner (nested) reaction the





Figure 3.2 Ethidium bromide stained 5%PAGE of nested PCR
amplification products of presentation marrow DNA from a
patient with (DL) T-ALL with a V61-D-J61 rearrangement.
Lane 1 contains 0X174 DNA digested with Hinfl. Lane 2
shows first round amplification product (approx. 700bp)f
lanes 3 to 6 show second round amplification products
using the first round product as substrate with
increasing magnesium concentration from ImM (lane 3) to
2.5mM (lane 6) in 0.5mM increments. The presence of two
amplification products indicates a biallelic
rearrangement.
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3.4.3.2 Generation and labelling of "clonospecific"
probes
After the second cycle of amplification, the PCR product
was subjected to digestion with the restriction enzyme
Fokl to separate the specific region of the probe from
germline DNA sequences. The PCR product was resolved in a
4% NuSieve 3:1 agarose gel and the probe band excised
with a clean razor blade. The fragment was purified by
adhesion to glass beads (MERmaid kit) and radiolabelled
by extension from a specific hexamer (Table 3.1) as
described for labelling of bcl-2 in section 2.4.3.3.
3.4.3.3 Sequence analysis
PCR products purified as described above were sequenced
as previously detailed (section 2.4.6.2) using the 3' V61
amplimer as the sequencing primer.
3.4.3.4 Detection of residual disease
Patients DNA samples were amplified using the system
detailed above, slot blotted onto nylon membranes as
described in section 2.4.5.3. Fokl digestion of PCR
products was not performed. Membranes were hybridised
against the patients particular "clonospecific" probe,
washed stringently and autoradiographed as described in
sections 2.4.5.6-8.
3.4.4 PCR Analysis of V62-D63 rearrangements in B-lineage
ALL- generation of "clonospecific" probes.
The technique outlined for the detection of residual
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disease in cALL (Yokota et al 1991a) is analogous to
that described above, with the exception that primers
derived from V62 and D63 regions are employed (Figure
3.1) as these segments are commonly recombined in B-
lineage ALL.
3.4.4.1 Polymerase chain reaction analysis
PCR was performed using the primers designed by Yokota et
al (1991a) listed in Table 3.1. Each reaction contained
the reagents described in section 3.4.3.1. The cycling
conditions are as detailed in Table 3.2.
The technique devised by Yokota also involved a nested
approach, with the V62 L (leader) and J61 amplimers in
the first set of cycles and either the V62 3', D63 5* or
V62 5', D63 3' configuration in the second set of cycles
for the generation of "clonospecific" probes or
monitoring of residual disease respectively (Figure 3.1).
A magnesium titration to determine the optimal value was
undertaken for each set of amplimers with DNA from a
patient previously characterised by Southern blot
analysis and 2mM MgCl2 found to be the optimal value in
each case. A typical titration is shown in Figure 3.3.
3.4.4.2 Generation and labelling of " clonospecific"
probes
This was as detailed above (section 3.4.3.2) using the




Figure 3.3 Ethidium bromide stained 5%PAGE of PCR
amplification products from a cALL patient with a V62-D63
rearrangement. Lane 1 contains 0X174 DNA digested with
HinfI. Lanes 2 to 7 show the effect on increasing
magnesium concentration from 0.OmM (lane 2) to 2.5mM
(lane 7) in 0.5mM increments.
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3.4.4.3 Detection of residual disease
This was as detailed above (section 3.4.3.4) with V62 L
and J61 primers employed for the first round and V62 5"
and D63 3' for the second.
3.4.5 PCR Analysis of V62-D63 rearrangements in B-lineage
ALL- design of oligonucleotide probes
Due to the problem of background signals associated with
probes produced directly from amplified tumour in
patients known to have a V62-D63 rearrangement by
Southern blotting ("clonospecific" probes), sequence
analysis of the junctional region was performed. Further
to this, a single step system was developed to minimise
the time required preparing reactions, reduce problems
associated with carry-over and reduce background signals.
PCR conditions were as described before, using only the
V62 5' and D63 3' primer pair in combination with the
cycle conditions described in Table 3.3.
3.4.5.1 Sequence analysis
After amplifying O.lpg tumour DNA, the product was
resolved by 4% agarose gel electrophoresis and purified
by adhesion to glass beads (GeneClean). Sequences were
extended from the V62 3' amplimer using the procedure
described in section 2.4.6.2
3.4.5.2 Design of anti-junctional oligonucleotides
Due to the restricted junctional variation at incomplete
V62-D63 rearrangements compared to that seen in V61-J61,
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56 60 - 1
72 600 -
Table 3.3 Cycling conditions for single step V52-D63
amplification.
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20 nucleotide synthetic probes were designed against the
junctional VN(DN)D region to maximise the specificity of
hybridisation and reduce non-specific signals.
Oligonucleotide probes were end labelled, the labelling
reaction consisted of lx end labelling buffer, lOpmol
probe DNA, 20/jCi gamma "^P dATP, 1U T4 polynucleotide
kinase in dl^O to 20pl. After incubation at 37°C for
20min, the reaction was diluted to 500pl with
hybridisation buffer and the incorporation and specific
activity determined from a 2/j1 aliquot by scintillation
counting (section 2.4.3.3). An appropriate amount of
probe to give 1.5x10^ dpm per ml prehybridisation fluid
was used without further purification.
3.4.5.3 Hybridisation with oligonucleotide probes
Calculation of melting temperature (Tm) for individual
probes was performed according to this formula (Sambrook
et al 1989) :
Tm=81.5+16.6(log1Q[Na+])+0.41(%G+C)-600/L
where [Na+] is the molarity of sodium ions (generally
0.5M), (%G+C) is the percentage G and C content and L the
length of the oligonucleotide (20 bases).
Optimal hybridisation and washing conditions were
determined empirically. PCR products were transferred to
nylon membranes as described in section 2.4.5.3 and
hybridised in glass tubes in 1.5ml of hybridisation
solution at 65°C, or 5°C below the Tm if the melting
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temperature of a particular oligonucleotide was below
70°C. Prehybridisation was performed for lhr before the
addition of labelled probe and further hybridisation for
lhr. Initially washing was performed for lOmin at room
temperature in wash 1 followed by 30min at the
hybridisation temperature in wash 3.
To minimise background signals and maximise the intensity
of specific binding, replicate membranes slotted with
amplified tumour DNA from patient BM consisting of a 0.1%
titration point and a normal DNA negative control were
hybridised with 1.5 xlO^ cpm/ml probe (Tm 72°C). The
efficiency of washing was determined by comparing
standard wash conditions to washing in tetramethyl
ammonium chloride (TMAC1) which removes the differential
binding characteristics of GC as compared to AT base
pairs, hence probes of the same length will have the same
Tm irrespective of base composition (Wood et al 1985).
Replicate blots as described above were hybridised rinsed
in wash 1 and washed for 30min in the same wash at room
temperature. Membranes were washed twice in TMAC1 wash at
60, 61, 62 and 63°C, 60°C gave the strongest signal and
the lowest background (Figure 3.4).
In order to determine if TMAC1 washing was more effective
than washing in SDS solutions, replica blots (as above)
were prepared and hybridised with the particular
oligonucleotide probe. TMAC1 washing at 60°C was compared
to washing in wash 3 at 45 , 55 and 65°C which
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Figure 3.4 Autoradiograph showing replicate V62-D63 PCR
amplification products from the bone marrow of a patient
with cALL. PCR products were slot blotted onto nylon
membranes and hybridised with a clone specific
oligonucleotide probe. The replicate blots were washed
using TMAC1 at the following temperatures 60°C, 61°C,
62°C and 63°C. Eachblot consisted of 3 PCR products,
undiluted tumour, 10 dilution of tumour and a pooled PB
control.
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demonstrated that TMAC1 washing resulted in the loss
of specific signal compared to the 55°C wash in solution
3 (Figure 3.5).
3.4.5.4 Detection of residual disease
Patients with V62-D63 rearrangements were sequenced and
probes designed against the VN(DN)D region. Presentation
and post chemotherapy samples were amplified and 2yl PCR
product slotted onto nylon membranes which were
hybridised with the individual patient specific probe,
washed and neoplastic cells visualised by
autoradiography. In order to monitor possible binding of
probes to sequences contributed by normal lymphocytes,
controls consisting of pooled normal peripheral blood or
bone marrow DNA were used. Applications of this technique
in the monitoring of MRD are discussed in Chapter 5.
3.5 RESULTS
3.5.1 Southern blotting
As described in section 2.5.1, Southern blotting and
hybridisation with DNA probes detects clonal populations
of cells only when they exceed 5% of the population under
study, generating bands which differ in size from the
normal germline band. Hybridisation with the J6S16 probe
to Hindlll or Bglll digested DNA results in a germline
band of 6.8 and 5.2kb respectively. A clonal population
bearing a V61-J61 rearrangement will give rise to lOkb
HindiII and 5.4kb Belli bands, whereas a 7.Okb HindiII







Figure 3.5 Autoradiograph showing replicate V62-D63 PCR
amplification products from the bone marrow of a patient
with cALL. PCR products were slot blotted onto nylon
membranes and hybridised with a clone specific
oligonucleotide probe. The replicate blots were washed
using 0.lx SSC, 0.1% SDS at the following temperatures
45°C, 55° and 65°C. Each blot consisted of 3 PCR
products, undiluted tumour, 10 dilution of tumour and a
pooled PB control.
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D63 rearrangement. A BqlII band of 8.5kb with no
additional Hindlll band is associated with a D62-D63
rearrangement and deletions can be detected by assessing
the relative intensities of bands observed.
A total of 3 T-ALL and 22 B-lineage ALL were probed and
the results summarised in Tables 3.4 and 3.5. TcR
rearrangements or deletions were detected in 2 of 3 T-ALL
(66%) of which one involved V61-J61 and in 15 B-lineage
ALL (68%) , of these 12 (55%) showed a V62-D63
configuration. Monoallelic deletions were apparent in 4
(18%) of B-lineage ALL and D62-D63 recombinations in 5
(23%). Of these, biallelic rearrangements (involving
deletions, V62-D63 or D62-D63 rearrangements) were
detected in 6 (27%). Figure 3.6 shows a group of 7 ALL
(B-lineage ALL with the exception of one T-ALL in lane 5)
and a normal peripheral blood DNA control digested with
Bqlll and hybridised against the J6S16 probe. Patient 1
has a V62-D63 on one chromosome and a D62-D63 on the
other, while patient 2 has a monoallelic deletion. Lanes
3 and 4 show a deletion on one chromosome, along with a
V62-D63 rearrangement on the other. Patient 5 exhibits a
biallelic V61-J61 configuration when digested by Bqlll
whereas an additional band was seen in the Hindlll lane,
the reason for this is described below. Patient 6 is in
germline configuration and patient 7 shows a monoallelic
rearrangement of V62-D63. Lane 8 contains the control











































Table 3.4 Comparison of J51 Southern blotting and V62-D63
PCR results in B-cell ALL patients. Germline
configuration is represented by G, rearranged by R and
deletion by D. The presence of a PCR marker is indicated












Table 3.5 Comparison of J51 Southern blotting and V61-J61
PCR results in T-cell ALL patients. Germline
configuration is represented by G, rearranged by R and
deletion by D. The presence of a PCR marker is indicated
by a + symbol.
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Figure 3.6 Autoradiograph of a Southern blot of
presentation marrows from 6 patients (lanes 1-4,6,7) with
cALL and one patient with T-ALL (lane 5). Control DNA
(pooled normal PBL) was run in lane 8. The DNA was
digested with Bglll and hybridised with probe J6S16. Lane
10 contains a bacteriophage lambda digested with Hindlll
size marker. Germline configuration is indicated with a
5.0kb band, V62-D63 rearrangement by a lO.Okb band (lanes
1,3,4,7), D62-D63 (lane 1) by a 9.0kb band and V61-J61 by
a 5.3kb band (lane 5).
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Ten patients with T-lineage NHL were screened with the
J6S16 probe and none demonstrated the presence of
rearrangements involving the J61 segment.
Of 16 AML patients analysed, 2 (12.5%) showed J61 segment
usage, although none showed bands indicative of either
V62-D63 or V61-J61 rearrangements hence were not amenable
to PCR analysis. This suggests that V63, V64, V65 or V66
had rearranged to D63 or J61.
3.5.2 PCR analysis of V61-J61 rearrangements
3.5.2.1 Generation of "clonospecific" probes
A total of 8 T-ALL patients were screened by PCR for the
presence of such a rearrangement, though only one
(patient DL) demonstrated amplification products in the
expected lOObp range. Bands were seen (Figure 3.7, lane
2) at 100 and 120bp indicating a biallelic rearrangement,
confirming the Southern blot result (patient 6 above).
Also shown in Figure 3.7 is the Fokl digest of these
products (lane 1), in which residual non- digested
material is apparent in addition to the newly generated
"clonospecific" probes. The piece of DNA digested from
each band will be of the same size and comigrate, forming
the lightest fragment observed. Serial dilutions of the
presentation DNA in pooled peripheral blood DNA were
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Figure 3.7 Ethidium bromide stained 5% PAGE gel of V61-
J61 PCR amplification product from a patient with T-ALL.
Lane 6 contains 0X174 digested with HinfI. Lanes 2-4
contain the second cycle product using 3' V61 and J61 5'
primers. A double band indicates a biallelic
rearrangement. Lane 1 contains the second cycle PCR
product digested with Fokl generating clonospecific
probes. The 2 upper bands contain undigested PCR
products, the 2 middle bands contain the clonospecific
probes and the lightest band contains the fragment
excised by Fokl digestion.
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Figure 3.8 Autoradiograph of V51-J61 amplification
products. Tenfold serial dilutions of DL DNA in normal
pooled PBL DNA (lanes 1-7) were hybridised against the
"clonospecific" probe. Lane 8 contains control PBL DNA.
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The 2 bands described above were sequenced, extending
from the V61 3' primer to determine the degree of
variability at this locus (Table 3.6). The junctional
regions were found to span 44 and 30 nucleotides, with
selection of multiple D segments, deletion of germline
information and extensive N nucleotide insertion
apparent. Probes derived from this region would be highly
clone specific. Interestingly, the additional Hindlll
band observed on Southern blot analysis is explained by
the creation of a Hindlll recognition site in the VND
region of one of the alleles resulting in a lighter band.
An in frame TAG stop codon was formed in one of the
junctional regions.
3.5.3 PCR analysis of V62-D63 rearrangements- generation
of "clonospecific" probes
A subgroup of 4 V62-D63 positive ALL patients identified
by Southern blotting were studied further by PCR. After 2
sets of amplification cycles, bands in the expected lOObp
size range were obtained although discrete bands were
also apparent in a pooled normal peripheral blood
control. However successful amplification was not
obtained in all patients. Figure 3.9 shows 2 patients and
a normal DNA control after nested (lanes 2-4)
amplification. Patient 1 (lane 2) demonstrates a PCR
product, however only an extremely faint band can be seen
in patient 2 (lane 3). A band is also visible in the
normal control DNA (lane 4). It is apparent using the
technique described by Yokota (1991a) that some patients
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V51 N DSl N D82 N D53 N JSl
DL1GGAACT AAGCTTA GAA GTG TCCT GCCTAG CTGGGGGAT TCCCAT ACAC
DL2 GGAACT AGATCATCTGG CTGGGGGATA T ACAC
Table 3.6 Nucleotide sequence of TcR V61-J61
rearrangements from a patient with T-ALL. A Hindlll
recognition site is underlined and palindromic
nucleotides are indicated in bold type. An in frame TAG
stop codon is shown in italic type.
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(j)X 1
4 1 3 >
3 1 1 >
82>
66>
Figure 3.9 Ethidium bromide stained 5%PAGE of TcR6 PCR
amplification products from 2 cALL patients. The first
lane contains 0X174 DNA digested with Hinfl. Lanes 1 and
2 show the second round amplification products using the
V62 3* and D63 5' amplimers (the first round was
performed with the V62 L and J61 amplimers) with a pooled
peripheral blood (PBL) control in lane 4. Lanes 4 and 5
shows amplified DNA from the same patients using a single
step PCR amplification with amplimers V62 5' and D63 3' .
A PBL control amplified with the same primers is shown in
lane 6.
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who should be amenable to PCR analysis from Southern blot
analysis data cannot be used for the generation of
"clonospecific" probes. Further to this, it was evident
that a total of 70 cycles of amplification increased the
intensity of background signals which may lead to false
positive results. This is confirmed by Figure 3.10 which
shows 3 patients and a negative control amplified by the
nested procedure and probed with the "clonospecific"
probe derived from the patient in lane 1. A strong
hybridisation signal is seen in all lanes, even after a
65°C O.lxSSC stringent wash, indicating a high degree of
non-specificity in the hybridisation of the probe to
tumour DNA.
3.5.4 PCR analysis of V62-D63 rearrangements- design of
oligonucleotide probes
3.5.4.1 Application of a single step amplification system
Of 36 B-lineage ALL patients amplified using a single
step system, 19 (53%) were PCR positive, including all of
those patients previously characterised as V62-D63 by
Southern blotting (Table 3.4). Two patients (6%)
demonstrated 2 distinct bands, in a biallelic
rearrangement. Figure 3.11 shows a sample of 5 patients
with the bands of varying size in the expected 340-380bp
range, along with a negative control DNA in which
discrete bands are not apparent. The patient described
above who did not amplify using the nested approach was
amplified using the single step system (Figure 3.9).
Whereas with the nested system no band could be seen
120
1 2 3 4 5 S 7 8 S 10 11 12
• I I I I i I I I I
Figure 3.10 Autoradiograph of V62-D63 nested
amplification products of 3 patients and normal PBL
hybridised with a clonospecific probe derived from
patient GG. Slots 1 and 2 contain products from patients
DP and WL, slots 3 and 4 contains PBL and marrow from
patient GG. Slots 5 to 10 contain products from DNA
samples obtained from patient GG during treatment. Lane
11 contains amplified pooled normal PBL with lane 12
containing a control with no template DNA. The membrane





Figure 3.11 Ethidium bromide stained 5% PAGE gel of V62-
D63 PCR amplification products from 5 patients with cALL.
Lane 1 contains a 0X174 digested with Hinfl size marker.
Lane 2 contains a pooled PB control. The size of the PCR
product varied from 340 to 380 bp.
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(Lane 3), with the single pair of more distal primers a
distinct band is present (Lane 6) suggesting that one of
the inner primer sites was deleted. Lanes 2 and 5 show a
patient who amplifies with both systems, with negative
control DNA in lanes 4 and 7, nested and single step
respectively.
3.5.4.2 Sequence analysis
The V62-D63 junctional sequence from 18 patients (11
children and 7 adults) was determined (Table 3.7) with a
typical autoradiograph shown in Figure 3.12. One of these
patients exhibited a biallelic pattern but only one
allele was sequenced. The junctional region varied in
size from 0-13 nucleotides, with an average length of 7.
Varying degrees of deletion from both the 3' terminus of
V62 and 5' of D63 germline sequences was apparent ranging
from 0 to 15 and 0 to 24 nucleotides respectively with
only one patient showing no deletion at either terminus.
N nucleotide insertion, ranging from 0 to 13 nucleotides
(average 5.5) was seen in 15 of 18 patients and were were
79% GC rich. D6 segment involvement was ascribed on the
basis of 3 consecutive nucleotides from either D61 or D52
germline segments and was apparent in 6 junctions. P
nucleotides were also observed at 5 intact germline
boundaries. Three patients had large deletions which
removed part of the sequence complementary to the D63
amplimer used by Yokota et al for the generation of
"clonospecific probes". This explains why "clonospecific"







WL CTGTGCCTGTG CCACAG GGGGGATACG CACAGTGCTACAAA
DP CTGTGCCTGTGACAC GCA GGATACG CACAGTGCTACAAA
GG CTGTGCCTGTGAC CCGACCCCCATGG TGGGGGATACG CACAGTGCTACAAA
BM C CGTCGCCGG GTGCTACAAA
DTP CTGTGCCTGTGACAC TCCCCATTGT* ACTGGGGGATACG CACAGTGCTACAAA
DTr CTGTGCCTG AGAAGG GGGGGATACG CACAGTGCTACAAA
DTr CTGTGCCTG AGAAGG GGGGGATACG CACAGTGCTACAAA
TM CTGTGCCT CCTTCGGAC CG CACAGTGCTACAAA
HS CTGTGCCTGTGACACC CCTT* ACTGGGGGATACG CACAGTGCTACAAA
RK CTGTGCCTGTGAC GTGTCTCCGTC GGGATACG CACAGTGCTACAAA
EC CTGTGCCTGTGACAC AAA
CA CTGTGCCTGTGAC CGA GGGATACG CACAGTGCTACAAA
CW CTGTGCCTGTGACACC *GGGGGG TGGGGGATACG CACAGTGCTACAAA
HM CTGTGCCTGTGACAC GGGG CTGGGGGATACG CACAGTGCTACAAA
MC CTGTGCCTGTGACAC *GGCCTT TACG CACAGTGCTACAAA
JM CTGTGCCTGTGA GACCCAC GGGGATACG CACAGTGCTACAAA
SM CTGTGCCTGTGACAC TCCCCTGGGGG TGGGGGATACG CACAGTGCTACAAA
LR CTGTGCCTGTG CCCCCCGGA ACAGTGCTACAAA
MK CTGTGCCTGTG GTCTGT* ACTGGGGGATACG CACAGTGCTACAAA
KM CTGTGCC CCCC GGGGGATACG CACAGTGCTACAAA
Table 3.7 TcR V62 to D63 gene rearrangements in ALL.
Germline V62, D61, D62 and D53 sequences are indicated at
the top. Homology with D63 sequences are underlined and
palindromic nucleotides are marked with an asterisk. The
D63 recombination heptamer is shown in bold. A 20 base
probe was designed for patient EC, although the 3*
component of the sequence is not shown on the table,
likewise the most 5' nucleotides from patient BM are not
shown. In patient CW, the probe was designed from a more
5' region to reduce a very high G bias. The sequence
shown in bold within the D63 germline sequence represents
the RSS. Elsewhere bold type indicates probe location.
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G AT C
Figure 3.12 Autoradiograph of a 6% denaturing PAGE gel
for sequencing PCR products from a CALL patient with a
V62-D63 rearrangement. Products were sequenced using an
internal sequencing primer. Termination reactions were
loaded in the order G, A, T and C.
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characterised as having a V62-D63 rearrangement by
Southern blotting. One patient (BM) had the V62 labelling
hexamer site deleted and another (KM) lost one nucleotide
from this site. These findings suggest that production of
"clonospecific" probes would either be difficult or
impossible in more than 10% of patients. The structure of
the junctions has implications for oligonucleotide probe
design as discussed below.
3.5.4.3 Probe design
To exploit the diversity contributed by D segment
involvement, N nucleotide insertion and germline
deletion, oligonucleotide probes of 20 nucleotides in
length were designed against the unique junctional
regions, flanked by germline V62 and D63 sequences.
Probes specific for 10 patients were synthesised in
total, indicated by bold type in Table 3.7. Replicate
slot blots consisting of the amplification products from
an initial group of 5 patients and one pooled normal
control DNA were probed in turn with oligonucleotide
probes derived from each patient (Figure 3.13). Specific
hybridisation of each probe was seen, with no signal
apparent in the negative control or cross hybridisation
between patients.
3.5.4.4 Probe sensitivity
Serial tenfold dilutions of presentation DNA from one
patient were made in control DNA were amplified in
triplicate and resolved by PAGE (Figure 3.14). PCR
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Patient
Probe 1 2 3 4 5 PBL
■ •
Figure 3.13 Autoradiograph of V52-D53 PCR amplification
products of tumour DNA from 5 patients and normal pooled
PBL. Replicate slot blots of PCR amplification products
were hybridsed with clone specific probes (probes A-E)
derived from each patient at presentation.
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Figure 3.14 Ethidium bromide stained 5% PAGE gel of V62-
D63 PCR amplification products from a patient with CALL.
Lane 11 contains a $X174 digested with Hinfl size marker.
Tenfold serial dilutions (10 to 10 ) of presentation
bone marrow DNA were amplified in duplicate (lanes 1-5,
6-10). A single band of 350bp indicates the presence of a
clonal V62-D63 rearrangement.
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products were slot blotted onto nylon membranes and
probed with the relevant probe (Figure 3.15). A decreased
signal intensity was seen with subsequent dilutions, lane
5 (10^ level) being the limit of sensitivity. However due
to the variation in junctional sequences, sensitivity
will be dependent on probe constitution. Further
titrations are discussed in Chapter V.
3.6 DISCUSSION
In order to determine the incidence of TcR6-chain
rearrangements in haematological disorders and the
potential application of this locus as a specific marker
for the detection of residual leukaemia, both Southern
blot and PCR based systems were investigated.
Southern blot analysis with a TcR6-chain joining region
probe was applied to a range of disorders to study the
association of TcR6 rearrangements with haematological
malignancies in samples collected at presentation.
Hybridisation with the J6S16 probe identified one of 3 T-
ALL patients (33%) with a V61-J61 rearrangement, compared
to a published incidence of 25% (Hansen-Hagge et al
1989). Approximately 10% of patients with AML have been
reported to show 6-chain rearrangements (Adriaansen et al
1991) and were found in 2 of 16 patients in this study
(12.5%). However, of these none demonstrated a
configuration amenable to further analysis, confirmed by
the report of Fontenay et al (1990) who detected no V61-
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Figure 3.15 Autoradiograph of V62-D63 PCR amplification
products of tumour DNA from a patient with cALL diluted
in pooled PBL DNA and hybridised to the jpatient's clone
specific probe. Dilutions range from 10 to 10" with
undiluted tumour DNA in lane 1. Lane 8 contains pooled
PBL DNA.
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J61 or V62-D63 rearrangements. One of 10 T-NHL also
displayed a TcR6 rearrangement, in concordance with the
published incidence, though again the gene segments
involved could not be analysed further by the V61 or V62
based PCR systems. The majority of T-NHL 6-chain
rearrangements are deletions (Kanavaros et al 1991) but
the quality of the lymph node biopsy specimens available
made accurate assessment of band intensity difficult, so
such events have not been recorded here. The group of
most interest however was that of B-lineage ALL, of the
22 probed 15 (68%) showed mono- or biallelic TcR6-chain
rearrangements, 80% of which were V62-D63 events. TcR
D62-D63 recombinations and monoallelic deletions were
also detected. The previously reported overall incidence
of rearrangements at this locus range from 70 to 81%, of
these the majority were reported to be V62-D63 events
(Hara et al 1988, Biondi et al 1990). A total of 255
patients were investigated in this and other studies,
with a 50% overall incidence of V62-D63 rearrangements
(Hara et al 1988, Yokota et al 1991a, Yano et al 1991,
Biondi et al 1990).
As the junctional diversity shown at the TcR6 locus is
extremely high, it provides an excellent target for PCR
analysis (Hansen-Hagge et al 1989). Generally screening
by PCR involves the use of a single TcR6 primer pair,
determined by the disorder under study, V61-J61 in T-ALL
and V62-D63 in B-lineage ALL. The diversity encoded at
the V61-J61 junction enables the production of sensitive
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"clonospecific" probes in 25% of patients with T-ALL.
However, only one of 8 patients (12.5%) in this study was
amenable to analysis by this technique. In this case,
probes were derived from two rearrangements and
sensitivity at the 10-5 level was achieved. As one
microgram of DNA was used as the substrate for the
reaction, this represents the detection of one copy.
Sequence analysis demonstrated the enormous diversity
providing this level of specificity with 2 junctions of
44 and 30bp characterised. Deletion of germline segments,
N insertion and multiple D segment selection result in
extremely diverse sequences, with P nucleotide
involvement seen at intact germline boundaries. One of
the sequences contained an in frame stop codon indicating
that it would not encode a functional allele whereas the
other allele may code for a functional gene but as the
leukaemic clone did not express a y6 TcR neither
allele would encode a cell surface molecule. Neale et al
(1991) screened a group of T-ALL with a series of V61,
V62 and V63 5' primers and J61, J62 and J63 3' primers,
enabling amplification in 76% of cases, hence this
approach can be extended to a larger group of patients
and may also be of value in the study of AML.
Of the 36 patients with B-lineage ALL amplified, V62-D63
associated bands were found in 19 (53%) and these
patients should therefore be amenable to analysis with
"clonospecific" probes (Yokota et al 1991a). However,
when this approach was undertaken, problems were
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encountered. Unlike the V61-J61 rearrangement, V62-D63
junctions arise from incomplete recombinations, hence are
less diverse (Breit et al 1991). "Clonospecific" probes
derived from these regions vary in sensitivity,
necessitating the study of dilution series on an
individual patient basis. The results obtained with these
probes were unsatisfactory, due to the relatively
nonspecific nature of the "clonospecific" probe resulting
from the inclusion of germline sequences. Probes derived
from tumour DNA amplified at presentation may also
contain sequences from normal polyclonal lymphocytes
which would also reduce specificity. In addition, one
patient shown by Southern blot analysis to have a V62-D63
rearrangement did not amplify with the inner primer pair.
In order to minimise these problems, several steps were
taken. Initially a single step amplification was
introduced, reducing the number of cycles from 70 to 35
in order to minimise artefacts introduced by excessive
cycling, reduce the signal contributed by polyclonal
lymphocytes and remove the possibility of cross-
contamination associated with nested PCR. Nested PCR
involves using the products of one reaction as substrate
for another, hence the preparation of the second set of
reactions requires a separate area and extreme care with
handling vessels and reagents as the introduction of even
a single copy of contaminating DNA may lead to a false
positive result. A single step approach is therefore less
prone to contamination, requires fewer handling areas and
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reduces preparation and running time. Further to this it
was decided to sequence the PCR products and design
shorter probes derived from the junctional region which
would contain less germline sequence, hence would be less
likely to match polyclonal sequences.
Sequence analysis showed a variety of junctional regions
ranging in length from 0 to 13bp. Diversity was
contributed by extensive germline deletion, N insertion
and D segment selection. The majority of the junctional
sequence was contributed by N nucleotides which
constituted 75% of this region, with 18% from D
selection. Probes derived from less diverse regions may
be more likely to match a polyclonal lymphocyte but
generally considerable diversity was apparent and
oligonucleotide probes were designed which flanked the
junctional sequence. The GC bias of terminal transferase
would result in extremely GC rich probes in some
instances which may reduce probe sensitivity.
Interestingly, sequence data from other groups (Yokota et
al 1991a, Greisinger 1992) showed a high frequency of
intact 5' D63 termini leading to the suggestion that such
a configuration could be a feature of ALL. However this
was not confirmed by this study, in which only 3 of 18
D63 segments were intact. This discrepancy may be due to
the selection of amplimers close to the D63 gene,
resulting in primer site deletion in a proportion of
cases, therefore underestimating the frequency of
patients with extensive deletions. Such deletion removed
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the 5' D63 primer site in 3 patients, explaining why one
patient (BM) was shown to have a V62-D63 rearrangement on
Southern analysis but would not amplify with the nested
primer set to generate a " c1onospecific" probe.
Relocating the D63 primer to a more 3' site could extend
the applicability of "clonospecific" probes however this
would increase the involvement of germline DNA in a
supposedly patient specific probe which could further
reduce sensitivity. Likewise the "clonospecific" probe
labelling hexamer had been partially or completely
deleted in 2 patients but a 5' relocation of this hexamer
would also reduce specificity.
Probes 20 nucleotides in length were designed to provide
specificity and facilitate hybridisation conditions in
the 65°C range, exploiting the diversity provided by
trimming, D usage and N insertion. The N(D)N region was
selected as the centre of the probe, with the remaining
nucleotides derived from equal amounts of 5' V62 and 31
D63 sequences. The use of oligonucleotide probes rather
than "clonospecific" probes of varying length facilitates
allele specific washing. Conditions were selected to
destabilise non-specific matches between the probe and
target, reducing background signals. Initially washing in
a tetra alkyl ammonium salt which weakens G-C bonds
therefore minimising the effect of base constitution on
hybridisation kinetics was investigated (Wood et al
1985). This would enable probes with different nucleotide
sequence to be washed with uniform conditions. However
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empirical studies showed that optimum wash temperature
remained probe specific, hence a standard SSC wash was
pursued, with a simple 55°C wash step adequate to remove
signal from negative control DNA lanes. This simplified
discrimination of rare leukaemic signals from background
populations.
The selection of representative control DNA was crucial,
polyclonal sequences representative of "normal"
background rearrangements was required to show that probe
binding was specific to sequences associated with
neoplastic cells. This was approximated by pooling
peripheral blood DNA from a series of individuals and
running these with each set of amplification reactions.
Controls containing no template DNA were run to monitor
possible contamination.
Sensitivity at the 10-5 level was achieved when serial
tenfold dilutions of tumour DNA (assumed to be 100%
malignant blasts) were made in polyclonal DNA derived
from pooled normal mononuclear cells. As one microgram of
DNA is derived from approximately 10^ cells this
indicates the detection of one TcR6 chain rearrangement,
the physical limit of sensitivity. However the intensity
of background signals contributed by normal lymphocytes
will depend on the degree of junctional variability
therefore sensitivity will vary on a sequence dependent
basis, explaining the 10-^ limit observed for some
probes.
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When compared to the relative ease of "clonospecific"
probe production, sequencing may appear to be both
laborious and expensive, however the gain in sensitivity,
ease of interpretation and number of patients amenable to
analysis renders it advantageous. All the patients found
by Southern analysis to have V62-D63 rearrangements
produced discrete PCR products which could be sequenced,
likewise the negatives yielded no discrete amplification.
Southern analysis is of value in the detailed analysis of
rearrangements as a single probe can investigate a
variety of recombination events which would require a
series of PCR amplimers. However, when a single event is
studied, PCR analysis can be performed rapidly and is
relatively inexpensive.
Biallelic rearrangements at this locus have been detected
frequently by Southern blotting (Yokota et al 1991a), in
this study 2 patients analysed by PCR showed 2 discrete
V62-D63 PCR products. If biallelic bands are closely
spaced, sequencing can be difficult. If they cannot be
resolved by electrophoresis the bands can be pooled and
sequenced from both directions and the sequences
subtracted though this is not possible if more than 2
sequences are obtained, in which cases cloning would be
required. Biallelism has implications for probe design as
one allele may be lost at relapse, hence for prospective
analysis, probes should be designed against each
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junctional sequence to reduce the risk of not detecting
persisting disease.
The frequent involvement of D63 sequences in the
junctional regions, combined with the occasional
detection of D62-D63 rearrangements on Southern blotting
suggests a hierarchy of rearrangements, with D62 to D63
recombination the initial event, followed by D62-D63 to
V62 joining. This partial complex could then join to a J6
segment to form a complete 6-chain rearrangement (Hara et
al 1991) or alternatively recombine to downstream Ja
elements before formation of an a-chain rearrangement
(Yokota et al 1991a). However any subsequent
rearrangement would be blocked by the frequently observed
deletion of the recombination heptamer located
immediately 3' to D63.
The amplification of immune receptor gene rearrangements
as markers of disease provides a simple method for
screening large numbers of patients. The extension of TcR
analysis to include the y-chain genes would increase
the number of patients amenable to analysis and provide
corroboration of results. However there are problems
associated with TcR y chain analysis as amplification
of the gamma-chain genes involves the use of 6 family
specific 5' V and 3 3' J amplimers (d'Auriol et al 1989)
as opposed to the single primer pairs required for TcR6
chain analysis. This requires a pre-screening step by
Southern blotting to identify which families are involved
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prior to amplification. Taylor et al (1991a) described a
simplified method whereby restriction enzyme digestion
was employed to determine V y usage after
amplification using a single pair of consensus
amplimers. Consensus primers were also used by Tycko et
al (1989) to generate a product which was subsequently
characterised for V family usage. Residual disease
was then assessed by amplification from a 5" Vgamma
family specific and 3' patient specific junctional
primer, though sensitivity was not reported. Velkeen et
al (1991) described an "RNase" protection assay whereby
amplified TcR y junctions were transcribed from a T7
promoter linked to one amplimer and the resulting RNA
used to probe remission amplification products.
Mismatches were removed by the action of RNase and
sensitivity at the 10"^ level was reported. This method
avoids sequencing, but may suffer from the problems
associated with "clonospecific" probes discussed above.
The location of the TcR6 locus within the TcRa-chain
implies that recombination of TcRa subunits will delete
any previous rearrangement, hence 6-chain rearrangements
occurring prior to that of the a-chains cannot be
studied. This may make TcR y a more prevalent marker
but Maclntyre et al (1989) suggested that the presence of
polyclonal T-lymphocytes in samples under study could
diminish the sensitivity of TcR y derived probes.
It is essential to the study or MRD that tumour specific
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markers do not change with disease progression, a
phenomenon termed clonal evolution as this could lead to
false negative assessment of disease persistence. It has
been suggested that both the TcR y and 6 loci provide
stable markers for study as alterations from presentation
to relapse in only 10 to 20% of patients (van Dongen
1992), which compares favourably to the rate of evolution
reported at the IgH locus (Beishuizen et al 1991a),
although this will be discussed in greater detail in
chapter IV.
Other techniques, such as the amplification of
chromosomal translocations have been used, and these
events may provide extremely stable markers of disease as
they occur at an early stage of tumourigenesis. However
as the incidence of any specific translocation is low, if
all the most frequently occurring lesions are pooled,
only 20% of patients could be studied, therefore pools of
many primers would be required to screen relatively few
patients. Further to this, many translocations have not
been characterised at the molecular level and in those
which have, the size of the translocation breakpoints
usually requires an RNA substrate for analysis. The
t(4;ll) is associated with as many as 50% of infant ALL,
but this drops to 5% in children and adults hence has
limited application (Rubin and Rowley 1993). The
Philadelphia chromosome has been detected in over 50% of
adult and 5% of childhood ALL by molecular probing
(Maurer et al 1991), however PCR analysis is an RNA based
140
technique (Lee et al 1988) and difficult to quantify.
Rearrangements of the Tall locus has also been used as a
marker of malignancy but is only applicable to a subgroup
of patients with T-ALL (Jonsson et al 1991). The low
frequency of TcR6-chain rearrangements in AML limit their
use in MRD analysis however the t(15;17) found in
virtually every case of acute promyelocytic leukaemia has
been amplified by PCR (Castaigne et al 1992).
Translocation breakpoints from (11;14) cell lines have
also been cloned (Meeker et al 1991) which may have
potential application in some ALL.
Of the methods which do not involve molecular techniques,
dual colour immunofluorescence has the highest reported
sensitivity (van Dongen et al 1992, Campana et al 1990a).
This can be applied to a subgroup of patients with B- and
T- lineage ALL expressing combinations of cell surface
molecules not associated with normal haemopoietic cells.
— 4, —RUnder these conditions, sensitivity at the 10 to 10
level has been reported, though such detection is
immunophenotype dependent and fresh material is required
for investigation. Campana et al (1990b) compared dual
colour immunophentoypic and TcR V61-J61 and V62-D63 PCR
analysis in 4 ALL and found that in 2 cases PCR detected
residual disease when immunophenotyping could not,
whereas immunologically detectable populations
accompanied PCR positivity in the other 2 patients.
Immunologic methods are also applicable to some AML
141
expressing cross-compartmental markers, but the presence
of such markers on normal cells reduces the sensitivity
— *3
to approximately 10 .
FISH has also been successfully applied to MRD analysis
in ALL (Anastasi et al 1991) but the sensitivity is not
comparable with that of PCR analysis. The predictive
value of culturing neoplastic lymphocytes has also been
investigated in ALL, although this does not allow the
sensitive analysis of disease progression (Estrov et al
1986).
3.6.4 Conclusion
Southern analysis with genomic probes can identify
clonally expanded populations of cells, but its relative
insensitivity renders it of little value in assessing
residual disease. PCR provides detection of low copy
number sequences hence can successfully be applied to MRD
detection in one of 8 T-ALL and 19 of 36 B-lineage ALL.
The junctional diversity displayed at V61-J61
rearrangements in T-ALL provides sensitivity at the level
of one cell in 10^ normal cells. V62-D63 junctional
diversity is relatively restricted but the use of
oligonucleotide probes can approach a similar level of
sensitivity when B-lineage ALL is studied.
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CHAPTER IV
IMMUNOGLOBULIN HEAVY CHAIN ANALYSIS
4.1 INTRODUCTION
4.1.1 Role of immunoglobulins
A diverse repertoire of immunoglobulin molecules are
synthesised by mature B-lymphocytes enabling the
recognition of foreign antigens. Hypervariable regions
bind determinants presented by foreign matter leading to
ingestion by macrophages or the formation of insoluble
aggregates. Recognition of bacterial surface proteins
signals the activation of the complement cascade
resulting in lysis of the invading cell.
Immunoglobulins consist of 2 heavy and 2 light chains
linked by disulphide bonds with the N terminal end
interacting with antigen and the C-terminal end
determining the class of molecule. The heavy chain is
composed of variable (V), diversity (D) and joining (J)
segments and the class of molecule is determined by the
selection of one of 5 a, 7 e , 6 or p constant
region genes. IgM molecules are the first to be produced
and use the ]j gene although subsequent class switching
occurs via the selection of alternative constant regions.
Two classes of light chain exist, K and X which
both have V and J regions, but no D segments. Assembled
immunoglobulin molecules use either 2 k or 2 X
chains, never one of each, a phenomenon termed isotypic
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exclusion (Alberts et al 1989).
4.1.2 Generation of antibody diversity
To provide the variation required to recognise foreign
particles, both heavy and light chains are assembled from
arrays of V, D (in the case of heavy chain) and J
segments which are selected at random and joined via a
recombinase system similar to that described for TcR
genes (Tonegawa 1983). A hierarchy of somatic
recombination events analogous to those in TcR genes have
been described, with the IgH genes rearranging first
followed by K then X light chains. The IgH locus
on chromosome 14 consists of the 2500kb VH locus
containing 6 families with 200 members, which is
interspersed with approximately 30 D segments, and the
3kb JH locus comprising 6 J segments. Random selection of
segments from these arrays facilitates a large degree of
combinatorial variability. Initially one D segment
recombines to one J segment mediated via the heptamer/
nonamer RSS before a complete rearrangement is formed by
the juxtaposition of a V region to the D-J complex.
Diversity is greatly enhanced by junctional variation
provided by exonuclease digestion of germline sequences
and TdT mediated N nucleotide insertion at the V-D and D-
J joins (Alt and Baltimore 1982, Desiderio et al 1984).
Affinity of immunoglobulin for antibody is enhanced by
somatic hypermutation (Kim et al 1981) via a process
called clonal selection. VH segments are divided into
hypervariable regions divided by conserved framework
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regions which are involved in the assembly of mature
molecules. The VNDNJ junction is delineated by framework
region 3A and the JH segment, forming the hypervariable
complementarity determining region III (CDRIII).
Kappa and lambda light chains undergo a similar
rearrangement process, although the germline repertoire
is restricted compared to that of the IgH locus. The
kappa locus on chromosome 2 consists of at least 100V and
4J segments whilst the lambda genes on chromosome 22 have
greater than 6V and 6J segments (Hieter et al 1981).
Heavy chains rearrange at an early stage of B-cell
differentiation but a productive, in frame rearrangement
may not result, in which case the genes on either
chromosome can continue to rearrange. A recombination
heptamer (TACTGTG) located at the 3' end of VH segments
resembles the signal sequence located immediately 5' to
DH segments and lies in the same orientation (Bird et al
1988). This mediates a process termed V-V replacement,
whereby one V segment can be replaced by another possibly
rescuing an out of frame rearrangement whilst maintaining
the DNJ sequence (Wasserman et al 1992a). Once a
productive allele is produced, allelic exclusion prevents
the second allele from rearranging further and the light
chains genes can rearrange, again non-functional genes
may result but once a mature gene is assembled a
functional antibody can be produced and presented on the
cell surface. The cell then undergoes selection in the
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bone marrow.
4.1.3 Southern blot analysis
Haematological neoplasms are thought to result from
clonal expansions of a single cell hence clonality can be
investigated by studying the status of immune receptor
genes. Lineage was initially determined using panels of
monoclonal antibodies for cell surface lymphoid and
myeloid antigens (Foon and Todd 1986). This enabled the
differential stage to be characterised, although this was
not possible in some immature disorders such as non T-
non B- ALL. Southern analysis with IgH probes was
employed in the assessment of lineage allowing non T- non
B- ALL to be characterised as an early B-cell disorder
due to the association of IgH rearrangements with 98% of
cases studied (Felix and Poplack 1991). Aisenburg et al
(1987) studied 100 cases of B-lineage chronic lymphocytic
leukaemia and non-Hodgkin's lymphoma and found that all
demonstrated clonal IgH rearrangements, 64% showing a
biallelic pattern. This suggests a good correlation
between IgH rearrangements and B-lineage but such
analysis cannot be used exclusively due to the phenomenon
termed "lineage promiscuity" (Greaves et al 1986). IgH
rearrangements have been reported in 15% of AML
(Adriaanson et al 1991), 10% of T-lineage leukaemia and
lymphoma (Kitchingman 1985) and 12% of T-ALL (Felix and
Poplack 1991) making unequivocal assignment of lineage
impossible on the basis of IgH rearrangements alone.
B-lineage ALL patients have been shown to demonstrate
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oligoclonality at the IgH locus in up to 45% of cases at
presentation (Beishuizen et al 1991b). This was defined
as the appearance of more than 2 rearranged bands in
patients shown not to be trisomic for chromosome 14.
4.1.4 PCR amplification of CDRIII sequences in B-lineage
disorders
PCR based techniques for the assessment of clonality have
several advantages over Southern analysis, in the
quantity and quality of material required and in the
relative simplicity of the technique.
Yamada et al (1989) first reported the application of PCR
to the analysis of IgH rearrangements in B-lineage ALL.
This exploited the region of consensus in the FR3A region
located at the 3' end of each VH segment and the region
of consensus shared by all JH segments, allowing a single
pair of primers to amplify 70% of patients. After cloning
and sequencing of the PCR products, the junctional
diversity was exploited to design clone specific
oligonucleotide probes which were hybridised against
amplified DNA from post therapy samples. Probing of
serial dilutions of tumour DNA indicated sensitivity at
the level of one neoplastic cell in 100 000 normal cells.
Trainor et al (1990) reported a PCR based technique for
the rapid detection of clonality in B-lineage leukaemia
and lymphoma using primers derived from the CDRIII region
described above, reporting successful amplification of
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junctional sequences in 70% of patients studied. This
technique was also appled to paraffin embedded material
(Wan et al 1991). Brisco et al (1990) reported a
sensitive method of tumour detection which was further
refined by the use of sense and anti-sense PCR amplimers
designed against unique VND and DNJ sequences
respectively from individual patients for the assessment
of persisting disease in childhood ALL (Brisco et al
1991).
Modification of PCR products derived from presentation
tumour DNA, circumventing the need to synthesise an
oligonucleotide probe have been described (Nizet et al
1991). Following CDRIII amplification of presentation DNA
using a modified JH primer containing a Sau9 61
restriction enzyme recognition site, the PCR product was
cleaved to excise JH sequences. Chromatography was
employed to remove contaminating CDRIII species of a
different size and the purified probe radio-labelled
extending from a hexamer derived from the 3' end of the
VH region to produce a highly patient specific probe.
A c
Sensitivity at the 10 to 10 level was achieved when
hybridised to amplified dilution series.
After sequencing CDRIII regions at presentation, Jonsson
et al (1990) designed patient specific VND amplimers and
used these in conjunction with the conserved JH amplimer.
Amplified products were then hybridised against a second
patient specific oligonucleotide probe to enhance
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specificity and sensitivity, which was reported at the
10^ level.
However, the use of immunoglobulin specific probes for
the assessment of residual disease was thought to be
limited by the observation of o1igoc1onality at
presentation and subsequent alteration of banding pattern
at relapse (Beishuizen et al 1991a). This could
potentially lead to false negative disease assessment if
the clonal rearrangement being followed became superseded
by a second and suggested that multiple probes may be
necessary to track certain patients. However, a number
of such bands detected by Southern blotting will derive
from incomplete D-J rearrangements (Carter, Neale &
Kitchingman 1991) which will not be detected by CDRIII
PCR and other changes may derive from V-V replacement or
independent V- DJ rearrangement events which will result
in the replacement of one V segment with another, yet
leaving the D-N-J region unchanged.
Wasserman et al (1992a) described a sensitive system for
monitoring oligoclonality at presentation by PCR.
Amplified CDRIII products were cloned and 20 independent
clones sequenced, sequences were defined as clonal if
they were frequently represented or were related to other
frequently occurring sequences. Analysis of amplified
normal populations indicated that the frequency of any
particular rearrangement was one per 20000 lymphocytes
hence the likelihood of 2 identical sequences appearing
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by chance was very small. Twelve patients were monitored
from presentation to relapse with those relapsing within
3 years displaying less clonal evolution i.e. complete
clonal change, V-V replacement or V-DJ rearrangements,
than those relapsing after 5 years.
Steward et al (1992) reported the use of anti D-N-J
probes which will recognise CDRIII sequences, even if a V
switch occurs, either by V-V replacement or progressive
V-DJ rearrangements. They indicated that complete clonal
change in the loss of conserved DNJ sequence was rare and
accounted for less than 10% of patients at relapse. This
suggested that anti DNJ oligonucleotides could be
successfully employed to track disease if care was taken
in their design.
The use of a consensus FR3A amplimer does have drawbacks.
As the amplimer is derived from a region at the extreme
3' end of the VH gene, exonucleolytic trimming can lead
to partial deletion of the binding site, rendering
amplification impossible or inefficient. In addition, the
degree of mismatch between the primer and particular VH
segments may result in poor amplification of some VH
family members.
These problems can be circumvented by using family
specific VH region FRl amplimers derived from the 5' end
of the gene. These have been used to characterise
malignant populations by a technique termed
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immunoglobulin "fingerprinting" (Deane and Norton 1991).
This involves the use of 6 VH family specific primers in
conjunction with a 3' JH primer. Although this technique
avoids sequence analysis, it is not as sensitive as those
described above but multiple evolving clones can be
monitored. Overall, more than 90% of patients with B-
lineage disorders can be studied with sensitivity
consistently at the 10 level. Amplification from FR2
sequences (Ramasamy, Brisco & Morley 1992) and VH family
specific leader region primers have also been performed
(Campbell et al 1992).
4.16 Aims
I set out to investigate the frequency of IgHJ
rearrangements in a range of B-lineage disorders using a
Southern blotting technique. A PCR based system was
refined and applied to the study of clonal IgH
rearrangements. Sequence analysis of a group of PCR
positive patients was performed to confirm the origin of
the amplified product and used as the basis for the
design of patient specific oligonucleotide probes for the





These were a described in section 3.2.2.
4.2.2 Low Grade non-Hodgkin's Lymphoma
These were as described in section 2.2.1.
4.2.3 High Grade non-Hodgkin's Lymphoma
Material from a total of 29 patients with B-lineage high
grade non-Hodgkin's lymphoma (18 male, 11 female) with a
mean age of 52 years (range 16 to 70 years) was available
for analysis.
4.2.4 Hodgkin1s lymphoma
Nine patients with HD (8 male, 1 female) with a mean age
of 35 years (range 15 to 48 years) were screened.
4.2.5 Myeloma
23 patients with myeloma were available for analysis, 13
male, 10 female, with a mean age of 68 years (range 54 to
84 years).
4.2.6 Cell Line
The Elijah Burkitt's lymphoma cell line was kindly
provided by the M.R.C. Human Genetics Unit, Edinburgh.
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4.3 MATERIALS
The materials were as detailed in section 3.3.
4.4 METHODS
4.4.1 Restriction endonuclease digestion
This was as detailed in section 2.4.2 except that genomic
DNA was digested with EcoRI, Hindlll or Bqlll prior to
Southern transfer.
4.4.2 Probe
The IgH joining region probe was as detailed in section
2.4.3.3.
4.4.3 PCR amplification of the IgH CDR III region
This was performed essentially according to Yamada et al
(1989). Primers without restriction enzyme sites
incorporate at the termini were employed as routine
subcloning of PCR amplified DNA was not performed. A
consensus FR3 primer (5'- ACACGGC C/T C/G TGTATTACTG -3')
was used in conjunction with the consensus JH amplimer
described in section 2.4.4. A diagram of the locus
showing primer locations is shown in Figure 4.1.
4.4.3.1 PCR conditions
Each reaction contained 0.ljjg DNA, lx PCR buffer, 200nM
each dNTP, 30pmol each primer and 1U Tag polymerase.
Cycles are detailed in Table 3.3.
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Figure 4.1 Diagram of the IgH CDRIII locus indicating the
location of the conserved variable region (VH) and
consensus joining region (JH) primers. Also shown are
random nucleotide (N) insertions and a Diversity (D)
segments. The primers delineate a region of approximately
80 to 120bp.
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A magnesium titration was performed using DNA prepared
from the Elijah Burkitt's lymphoma cell line in the 0.5
to 3.OmM range, in 0.5mM increments (Figure 4.2). The
optimal conditions are seen in lane 4, 1.5mM.
4.4.4 Sequence analysis
4.4.4.1 Purification of PCR products
CDRIII PCR products were excised from ethidium bromide
stained 5% PAGE gels with a clean razor blade under UV
illumination, crushed and eluted overnight at 37C in
200ml TE pH8.0. The eluates were purified by adhesion to
glass beads (MERmaid). Eluates were incubated 5min at RT
with 2 volumes of high salt binding solution and 8^/1
"glass fog". The beads were pelleted at 16000g for 30s
and washed twice in ethanol wash solution. Pellets were
dried and DNA eluted into 2x10^1 dl^O at 50°C for 5min.
4.4.4.2 Sequencing reaction
This was performed as described in section 2.4.6 with
chain extension initiated from either the VH or JH
amplimers.
4.4.4.3 Design of anti-junctional oligonucleotides
Probes of 20 nucleotides in length were designed against
the junctional region. Generally, these were derived from
the DNJ region in order to minimise the effect of VH
switching. If little variation was apparent at this site
was apparent, then a VND probe was designed. If short
junctional sequences were obtained then VN(DN)J probes
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1 2 3 4 5 6 7
118 bp >
82 bp >
Figure 4.2 Ethidium bromide stained 5%PAGE of PCR
amplification products from a Burkitts cell line (Elijah)
with a biallelic IgH rearrangement. Lane 1 contains
0X174 DNA digested with HinfI. Lanes 2 to 7 show the
effect on increasing magnesium concentration from 0.5mM
(lane 2) to 3mM (lane 7) in 0.5mM increments. The clonal




4.4.5 Determination of residual disease
This was performed according to the rationale and
conditions detailed in section 3.4.5.4. Briefly, one
microgram of DNA was amplified with the VH and JH primers
then 2ml of PCR product slot blotted onto a nylon
membrane before hybridisation with the relevant clone




Clonal IgH rearrangements were investigated with the
joining region probe described in Chapter 2.
4.5.1.1 Low grade NHL
These were described in section 2.5.1 Of 19 patient
samples blotted, all demonstrated rearrangements. Of
these 8 were monoallelic and 11 biallelic, results are
summarised in Table 4.1.
4.5.1.2 High grade NHL
Of the 12 patients studied by Southern blotting, 10 had
detectable rearrangements (83%) with 5 of these (50%)
showing a biallelic pattern (Table 4.2).
4.5.1.3 Hodgkin's lymphoma
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Patient Southern PCR IgH t(
SP RR + +
LW RR + +
JC RR + +
JI RR ND +
IT GR - -
WGr GR + +
EB RR + -
JS GR + -
JK GR - -
CL RR + _
AMc RR + _
HG GR - _
WG1 GR + _
IM GR + +
AMa GR + +
GN RR + -
AS RR ND -
EW RR + .
JW RR - -
CM ND + +
ML ND + _
Table 4.1 Summary of Southern blot and CDRIII PCR
analysis in low grade NHL. G refers to germline
configuration and R to rearranged. PCR positivity is
indicated by a + symbol, ND indicates not done. t(14;18)






























Table 4.2 Summary of Southern blot and PCR analysis in
high grade NHL. G refers to germline configuration and R
to rearranged. PCR positivity is indicated by a + symbol.
ND indicates not done.
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These were as described in section 2.3. Each of 8 patient
samples blotted showed germline configuration.
4.5.1.4 Myeloma
Seven of 8 patients tested (75%) had IgH rearrangements
(Table 4.3). Of these 6 showed a monoallelic pattern
(87.5%) and one 3 non-germline bands.
4.5.1.5 ALL
Twenty two patients with ALL were blotted and of these 18
(82%) had IgH rearrangements (Table 4.4). Seven patients
(39%) showed a monoallelic pattern and 7 a biallelic
pattern. A further 4 (22%) showed more than 2 rearranged
bands. A typical autoradiograph from a blot consisting of
a panel of ALL patients is shown in Figure 4.3.
4.5.1.6 Summary
A total of 62 patients with B-lineage disease (this
excludes the HD patients) were examined with IgH
rearrangements detectable by Southern blot analysis in 53
(85%). Thirty patients had a monoallelic pattern (48%)
and 19 had a biallelic pattern (31%) while 5 had 3 or
more non-germline bands (8%).
4.5.2 PCR amplification of the IgH CDRIII region
4.5.2.1 Low grade NHL
Fifteen of the 19 patients assayed by PCR displayed a


























Table 4.3 Summary of Southern blot and PCR analysis in
Myeloma.G refers to germline configuration and R to






























































































Table 4.4 Summary of Southern blot and PCR analysis in B-
cell ALL. G refers to germline configuration and R to
rearranged. PCR positivity is indicated by a + symbol. ND
indicates not done. For comparative purposes, the TcR6-






































23.1kb> 9.4kb> 6.6kb> 4.4kb> 2.3kb>
Figure 4.3 Autoradiograph of a Southern blot of 9
patients with ALL. Lanes 1 and 23 contain bacteriophage
lambda DNA digested with HindiII. Lanes 2-10 were
digested with Hindlll and lanes 12-21 with Bqlll. The
blot was hybridised with the IgHJ probe. Germline bands
are 9.8kb (Hindlll) and 4.5kb (Bqlll). Lanes 6, 7, 17
and 18 contain DNA from patients with T-ALL with the
remainder DNA from patients with cALL.
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pattern (Table 4.1). A typical page gel showing the
amplification products of a group of B-lineage patients
is shown in Figure 4.4.
4.5.2.2 High grade NHL
Of the 24 patients studied, 15 had detectable
rearrangements (63%) with 9 of these (60%) showing a
monoallelic pattern, 5 a biallelic pattern (33%) and one
patient displayed 3 bands (7%) (Table 4.2).
4.5.2.3 Hodgkin's lymphoma
Nine patients with HD were assayed, of these one (11%)
displayed an amplification product.
4.5.2.4 Myeloma
Twenty two patients were tested, with 15 showing
rearrangements (68%), 11 demonstrating a monoallelic
pattern (73%), 2 a biallelic pattern (13%) and one the
presence of 3 bands (7%) (Table 4.3).
4.5.2.5 ALL
DNA from 26 patients with ALL was amplified and of these
21 (81%) had IgH rearrangements (Table 4.4). Sixteen
patients (76%) showed a monoallelic pattern, 4 a




Figure 4.4 Ethidium bromide stained 5% PAGE gel of IgHCDRIII PCR amplification products from 7 patients with B-
lineage lymphoma (lanes 2-8) and a normal pooled PBL
control. Lane 1 contains 0X174 digested with Hinfl size




Of 91 patients with B-lineage disease examined by PCR,
IgH rearrangements were detected in 70 (77%). Fifty six
patients had a monoallelic pattern (80%) and 11 had a
biallelic pattern (16%) while 3 had 3 bands (4%).
In total 56 patients were studied with both Southern
blotting and PCR with concordance in 40 cases (71.5%). Of
these 37 were double positive (66%) and 3 (7%) were
double negative. Twelve cases were positive by Southern
analysis only (21.5%) and 3 by PCR alone (5.5%). A
combination of both techniques with therefore detect
clonality in 93% of patients with B-lineage disease
(Table 4.5).
Nineteen patients were found to have more than one
rearrangement when the data for Southern analysis and PCR
was pooled. This excludes the data for the low grade NHL
patients as one allele is involved in a translocation
event. Only in 2 cases was biclonality detected by PCR
when by Southern blotting monoclonality was observed and
in one case 3 bands were seen by PCR when only one band
was apparent on Southern analysis. In a further one
instance biclonality was seen by both techniques. A
greater number of rearrangements were observed by
Southern blotting than PCR in 15 cases, of these 9 showed
one more band by Southern blotting and in the remaining 6
cases at least 2 further rearrangements were detected.


























Table 4.5 Comparison of PCR and Southern blotting
results. A + symbol indicates detection of a clonal
rearrangement whereas a - symbol indicates a failure to
do so.
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rearrangements than Southern blotting and is relatively
poor at detecting biallelism and oligoclonality.
4.5.3 Sequence analysis
In order to confirm the origin of bands resolved on PAGE,
direct sequencing was performed on a group of patients. A
typical autoradiograph of a sequencing gel is shown in
Figure 4.5. Table 4.6 summarises sequence data collected
on 13 samples, showing the VH, DH and JH germline
sequences along with random N nucleotide insertions.
A diverse range of junctional sequences varying from 12
to 53 nucleotides was obtained. However selective usage
of 5' JH segments is found, with J1 and J2 not
represented. Biased DH selection can be seen, almost half
of the D segments involve either DLR4 or DXP4. Extensive
N insertion is common, ranging from 0 to 15 bases,
however 4 D-J joins with no random nucleotides are
apparent. Further diversity is provided by the selection
of multiple DH segments, although in some cases the
involvement of no DH segments is found. Deletion of 0 to
12 nucleotides was apparent at the JH terminus, however
such extensive deletion at the VH terminus would remove
the 5' primer site, hence not be detected.
4.5.4 Analysis of residual disease
4.5.4.1 Design of oligonucleotide probes
Twenty nucleotide probes were synthesised for 7 patients








Figure 4.5 Autoradiograph of a 6% denaturing PAGE gel for
sequencing PCR products from a high grade NHL patient
with an IgH rearrangement. Products were sequenced in
both directions using the VH amplimer (left) and JH
amplimer (right). Termination reactions were loaded in



















































Table 4.6 CDRIII sequence data. D segments are underlined
and named. Probe sequences are indicated in bold and J
segment usage indicated in parentheses. Two patients show
sequences obtained at presentation (p) and relapse (r) .
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variation provided by the combinatorial diversity of
subunit selection, germline deletion and random
nucleotide insertion (indicated in bold, Table 4.6). If
sufficient diversity was exhibited at the D-N-J junction,
then probes from this region were preferentially selected
to minimise the effect of VH switching. However in
patients JH and CL a V-N-D probe was designed to the
enormous variation within this region, compared to the D-
N-J junction. A V-N-J probe was synthesised in the case
of AM and JM due to the size of the junctional regions.
D-N-J probes were used to analyse MM, SM and RB. Both a
V-N-D and a D-N-J oligonucleotide probe was designed
against the Elijah junction to compare sensitivity.
4.5.4.2 Sensitivity
Ten fold dilutions of the Elijah Burkitt's lymphoma cell
line were made in HL 60 cells, before extraction and
amplification of the DNA. The resulting amplification
products were slot blotted and probed with either a V-N-D
or D-N-J oligonucleotide washed and sensitivity assessed
by autoradiography. PAGE resolution of the amplification
products is illustrated in Figure 4.6. An autoradiograph
of slot blots of the same products hybridised with the
VND probe is shown in Figure 4.7. Specific hybridisation
can be seen diminishing from the lO"^ (lane 1) to 10"^
level (lane 5) when probed with the VND sequence, however
the DNJ region probe was tenfold less sensitive.
171




Figure 4.6 Ethidium bromide stained 5% PAGE gel of IgH
CDRIII PCR amplification products from a Burkitts cell
line (Elijah). Lane 1 contains a 0X174 digested with
Hinfl size marker. Tenfold serial dilutions (10" to 10"
6, lanes 3-8) of cell line DNA were amplified. Bands of
lOObp indicate the presence of clonal rearrangements.
Lane 2 contains undiluted cell line DNA and lane 9 no
DNA. Lanes 10 and 11 contain normal PBL DNA.
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10-1 10-2 10-3 10-4 10-5 10-6 pb No DNA
• • •
• i i
Figure 4.7 Autoradiograph of IgH CDRIII amplification
products of serial tenfold dilutions of Elijah DNA in
normal PBL DNA (lanes 1-6) hybridised with the VND region
probe. Lane one contains the initial dilution point, 10"
, lane 7 contains control PBL DNA and lane 8 contains a




Southern blot analysis was used to assess the incidence
of clonal IgHJ rearrangements in tumour DNA isolated from
patients with a range of B-lineage disorders.
Rearrangements were detected in only 83% of patients with
high grade NHL, lower than the expected incidence of 100%
(Williams et al 1987). Mature lymphoid cells will have
undergone rearrangement of one or both heavy chain genes
hence the discrepancy may reflect the nature of the
biopsy specimens available for analysis, which were not
subject to histological examination prior to DNA
extraction. The 2 samples found to be in germline
configuration may not therefore have been uniformly
infiltrated with neoplastic lymphocytes. B-lineage ALL is
a disorder of immature lymphocytes therefore a proportion
of patients with B-lineage ALL will have IgH genes in
germline configuration, thought the incidence here of 82%
compared to the previously reported figure of 98% (Felix
and Poplack 1991) may reflect the sample size. One
patient with myeloma in whom no rearrangement was found
may represent a marrow sample heavily contaminated with
peripheral blood. Not surprisingly, no IgH rearrangements
were found in the group of 8 HD patients as the reported
incidence of rearrangements in this group of patients is
approximately 10% (reviewed by Daus et al 1989). Overall,
the majority of patients with rearranged IgH genes showed
a monoallelic configuration (48%) and slightly fewer
biallelic rearrangements (31%). Biclonality was
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relatively rare, seen in 8% overall and in 22% of B-
lineage ALL, though rates as high as 45% have been
reported (Beishuizen et al 1991b). This higher rate
probably reflects the ability of Beishuizen's technique
to consistently detect small populations of subclones
which may exist at the 1-5% level and the use of an
alternative probe (van Dongen pers. comm.). Biclonality
i.e. the presence of three or more non-germline bands may
be a poor prognostic indicator (Kitchingman et al 1986),
although this has not been confirmed by other studies
(Katz et al 1989). A proportion of apparently biclonal
patients in this study may be trisomic for chromosome 14,
hence not truly biclonal, however cytogenetic information
was not available.
Southern blotting is a laborious process which takes
approximately 2 weeks to perform and requires upwards of
5-10pg of high molecular weight DNA. It is not therefore
an ideal system for the routine analysis of specimens,
especially if only archival material, such as frozen
lymph node sections or dried bone marrow slides are
available. Fortunately, amplification of the IgH CDRIII
locus by PCR can be performed rapidly on both fresh and
preserved tissue, however the efficiency of clonal
rearrangement detection is reduced compared to Southern
blotting.
PCR analysis permitted the study of both archival and
fresh material so a larger group of patients than those
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amenable to Southern analysis could be investigated and
overall clonality was detected in 77% of 91 patients with
B-lineage disease, compared to 75% of 21 patients
reported by Trainor et al (1991) whereas Southern
blotting detected clonal rearrangements in 85% of 62
patients. PCR was also consistently poorer at detecting
biallelism and biclonality than Southern analysis. These
discrepancies can be explained by several reasons,
firstly exonucleolytic trimming of the 3' end of the VH
segment can delete all or part of the FR3A primer site,
secondly the VH amplimer is a consensus amplimer which
may match certain VH segments less well than others
resulting in inefficient amplification. Hakim et al
(1991) aligned the consensus VH amplimer with 40 VH
segments and found that 9 had more than one mismatch,
though the conserved 3' sequence should ensure reasonably
uniform amplification (Rovera et al 1991). Thirdly CDRIII
PCR will not amplify partial D-JH rearrangements which
will be detected by Southern analysis (Carter et al
1991). Southern blot and PCR analysis concur in 73% of
cases, but PCR could not detect clonality in 21.5% of
cases which had rearrangements demonstrable by Southern
blotting. Therefore PCR is a useful first line assay for
clonality although Southern blotting will enable the
detection of clonality in a proportion of PCR negative
samples. A combination of techniques demonstrated one or
more clonal rearrangements in 93% of patient samples at
presentation.
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Once it was established that PCR generated CDRIII markers
were widely applicable in B-lineage disorders and in one
patient with HD, the specificity of these markers for
possible MRD analysis was investigated. Sequence analysis
of 13 bands from 8 patients and one cell line
demonstrated large junctional regions which were greater
in size than those observed at the V62-D63 locus, due to
the formation of complete IgH VDJ rearrangements. This
would suggest that probes derived from the CDRIII locus
would be more specific than those derived from the V62-
D63 region, however there are several considerations. The
large pool of circulating polyclonal lymphocytes may
contain populations with IgH rearrangements which
resemble the patient specific junctional sequence. Such
sequences will contribute to non-specific "background"
signals when PCR based MRD detection systems using allele
specific probes are used. As circulating lymphocytes with
V62-D63 rearrangements are less frequent than those with
IgH rearrangements (Hara et al 1991), the former may be a
better marker even though the sequence variability is
restricted. Another consideration is stability of the
marker being analysed and the effect of clonal evolution
in disease progression, most notably V-V replacement
which substitutes VH segments leaving D-JH junctions
intact (Wassermann et al 1992a, Potter et al 1992a).
Clonal evolution will be discussed in detail in Chapter
V. The single bp mismatch between the JH amplimer and J3
does not apparently lead to the under representation of
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rearrangements involving this region as they constitute 3
out of 13 CDRIII regions detected, compared to 3 out of
50 of the series of Steward et al (1992). Jonsson et al
(1991) investigated the sensitivity of probes derived
from either CDR III sequence in patients with biallelic
rearrangements and found them to be equally sensitive,
though in some cases one VH segment may match the
consensus primer better than the other, resulting in
differing sensitivities.
The IgH locus provides a specific and sensitive marker
for the detection of residual disease, demonstrated by
experiments with a cell line indicating sensitivity at
the 10~4 to 10-5 level. The approach outlined here has
advantages over other published systems as the routine
use of direct sequencing obviates a subcloning stage.
Yamada et al (1989) discussed a quantification system
based on subcloning and transformation of PCR products
into a bacterial host. The degree of tumour infiltration
was assessed by comparing colonies positive for JH
sequences to those positive for clone specific sequences.
This does provide an absolute number, but is an extremely
time consuming procedure and assumes that all sequences
amplify equally well as the standard sensitivity
titration was performed on a cell line and not on an
individual patient basis. However an advantage of this
technique is that positive colonies can be sequenced to
confirm their relation to the original leukaemic clone.
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Brisco (1991) described the use of VND and DNJ patient
specific PCR primers, however this is expensive
especially if more than one rearrangement is studied and
does not take the influence of V-V replacement into
account. A nested approach was also taken, which is time
consuming and prone to contamination (discussed in
Chapter III). Jonsson et al (1991) used a similar
approach to that above, with the exception that allele
specific PCR was performed with a patient specific primer
followed by hybridisation with a second patient specific
oligonucleotide. This is provides great specificity but
is also shares the disadvantages of the Brisco method.
Billadeau (1992) also performed an allele specific PCR
to investigate PB contamination of plasma cells in
patients with myeloma. PCR reactions were performed with
on
the incorporation of P and resolved on PAGE gels before
densitometric analysis. This permitted accurate
quantification of tumour load but was not used to follow
residual disease, hence did not take the influence of
evolution into account.
Other groups have avoided sequence analysis, Nizet et al
(1991) used an approach similar to that detailed in
Chapter III described by Hansen-Hagge et al for the TcR6
locus. CDRIII amplification products obtained at
presentation were subjected to high power liquid
chromatography to remove contaminating species from
polyclonal B-lymphocytes after restriction enzyme
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digestion to remove some germline JH sequence. These were
then radiolabelled and used as clone specific probes.
Sensitivity at the 10"^ level was reported, however the
sensitivity of this technique cannot be as high as that
demonstrated by oligonucleotide probes due to the
representation of germline sequence within the probe.
Deane and Norton's "fingerprinting" technique (1991) is
useful for monitoring subclone progression and was
reported to detect clonality in over 90% of patients.
Amplification is performed from a 5' FRl and 3' consensus
primer, removing the problem of FR3A primer site deletion
and mismatch. However, 6 VH FRl primers are required to
screen patients at presentation for VH family usage. If
subclones using a different family emerge then they will
not be detected. This technique also requires the running
of sequencxng gels with P labelled PCR products and
sensitivity is maximally at the 10 level, insufficient
for the detection of low level disease. As no sequencing
is involved, potential subclones may be confused with
reactive non-neoplastic proliferations which may lead to
an overestimation of the incidence of clonal populations.
The considerations associated with FRl and FR3 PCR
analysis were addressed by Ramasamy, Brisco and Morley
(1992) who discussed amplification with FR2 and JH
specific amplimers. This was successful in 80% of
patients but was not evaluated as a sensitive marker for
MRD detection. A significant increase in patients
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amenable to analysis compared to FR3 amplification was
not demonstrated as although deletion of the primer will
no longer occur, mismatches with VH family members and
the consensus primer persist.
In conclusion, Southern analysis with an IgH probe is
more effective at detecting clonal rearrangements than
CDRIII PCR amplification, though the rapidity and low
cost of the latter technique make it a useful first line
assay. It also provides a unique marker applicable in
over 70% of patients with B-lineage disease, capable of
sensitive disease detection although care has to be taken
with probe design to maximise sensitivity and reduce the
influence of clonal evolution.
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CHAPTER V
PCR ASSESSMENT OF MINIMAL RESIDUAL DISEASE
5.1 INTRODUCTION
5.1.1 Lymphoma
Disease persistence in patients with low grade NHL has
been determined by amplification of the t(14;18)
translocation. Circulating tumour cells were investigated
in patients undergoing therapy to monitor disease
progression. Due to the indolent nature of this disease,
aggressive treatment regimes may not significantly reduce
tumour load and early reports (Crescenzi et al 1988)
confirmed the persistence of PCR detectable disease but
these studies were derived from relatively few patients.
Studies of larger patient cohorts have not involved
extensive longitudinal studies but have confirmed the
earlier reports of prolonged PCR positivity. A series of
152 patients with low or intermediate grade disease were
screened by Gribben et al (1991a) who detected mbr or mcr
rearrangements in 102, of whom all had disease detectable
by PCR following aggressive therapy. A larger study by
the same group reported mbr or mcr translocations in 125
of 205 patients (Gribben et al 1991b) and contamination
was revealed in all 114 marrow harvests collected in
remission for autologous transplantation. However,
following ex vivo purging with anti B-cell determinant
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monoclonal antibodies, 57 (50%) of these harvests became
PCR negative. Further to this, relapse following re-
engraftment occurred in only 4 patients from the PCR
negative group, compared to 26 from those receiving PCR
positive harvests, suggesting that reinfused tumour
contributed to relapse.
Price et al (1991b) reported the persistence of
circulating tumour cells in 6 of 15 patients in long term
remissions of 11 to 17 years. It was reasoned therefore
that the detection of this translocation was not of
prognostic significance, confirmed by Lambrechts et al
(1992) who studied 11 patients in complete clinical
remission and detected the persistence of tumour cells in
5 up to 47 months after the cessation of treatment.
However 3 patients with clinically evident disease in the
lymph nodes showed no evidence of lymphoma cells in the
BM hence the focal nature of the disease can hinder MRD
analysis. Recently, a report of normal PB cells bearing
t(14;18) markers has been made (Limpens et al 1992) which
has implications for the sensitive detection of such
events in low grade NHL in remission.
Tumour persistence therefore is common in low grade
lymphoma but the finding of Gribben et al (1991) that
reinfused tumour can contribute to relapse has
implications for PB derived stem cells if contamination
is lower than an equivalent BM harvest.
5.1.2 Leukaemia
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Several groups have reported semi-quantitative approaches
to the monitoring of disease persistence in B- and T-
lineage ALL by analysis of CDRIII, TcR6- and gamma-chain
loci. All techniques discussed below are capable of
detecting disease at the level of 10"^ to 10-^.
Yamada et al (1990) used CDRIII PCR to investigate a
group of 8 children with B-lineage ALL. Of the 6 who
remained in remission during the time of the study, PCR
positivity persisted for up to 25 months from
presentation. An increase in tumour load was detected in
one patient 3 months prior to bone marrow relapse. The
final patient relapsed in the central nervous system,
which was not predicted by following tumour contamination
in BM samples.
Five cases of B-lineage ALL were analysed by Maclntyre et
al (1990) using both TcR Y and 6 analysis. Four
patients remained in remission of whom 3, sampled at 1,
34 and 38 months respectively, were PCR negative whereas
one patient tested positive at one month but negative in
a subsequent 26 month BM sample. The final patient showed
residual disease at 12 months and relapsed soon
afterwards. The results for the 2 loci agreed with one
exception, where a high tumour load detected by TcRY
amplification was not detected by TcR6 due to clonal
evolution.
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Yokota et al (1991a) studied 27 B- and T-lineage ALL
patients, of these 8 tested within the first 6 months
were PCR positive by V62-D63 analysis. Samples from 11
patients were investigated at 6 to 41 months from the
start of treatment, 6 showed persisting positivity.
Samples from 11 patients were amplified post therapy and
found to be negative with the exception of one who
remained positive some 3.5 years after the end of
therapy. Two patients in this series relapsed and PCR
positivity was detected 4 months prior to morphological
detection in each case.
Nizet et al (1991) reported the common finding of PCR
positivity up to 6 months in 16 patients investigated by
CDRIII PCR. The incidence of PCR positivity was lower in
the 7-15 month period and only 2 patients showed residual
disease when sampled after the end of therapy. Two
patients showed an increasing tumour load 2 to 3 months
prior to relapse.
Five patients with T-ALL were followed by TcR6
amplification by Neale et al (1991), of whom one showed
an increase in disease 3 months before relapse. Of the
remaining 4, who entered long term remission, no
persistent disease was detected.
Biondi et al (1992) analysed 20 BM samples from 17 B- or
T- lineage ALL patients by V61-J61 or V62-D63 analysis.
Ten patients entered long term complete clinical
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remission (of duration 52 to 72 months at the time of
publication), 9 of whom tested PCR negative in samples
collected between 8 and 30 months though one patient was
PCR positive at 17 months but negative by 27. Five
patients relapsed before the completion of therapy and of
these 3 were consistently PCR positive whilst one showed
increasing disease though in the fifth case disease could
not be detected in a BM sample taken 16 months before
relapse. In 2 patients who suffered a relapse after
treatment had ceased, disease could not be detected in BM
samples collected 2 and 6 months previously.
These studies reported few samples collected at various
stages making definitive judgements regarding tumour
progression and prognostic significance difficult,
although trends are apparent. Early PCR positivity is a
common finding and this can persist into the second year
of therapy without heralding a relapse. PCR positivity
beyond this time may indicate an eventual relapse as
patients in long term remission are generally PCR
negative. An increasing tumour burden 2-4 months prior to
relapse has been described in several studies.
Longitudinal analysis rather than the study of a single
time point were more informative, although early
prediction of relapse was generally not possible.
Other groups have investigated individual key stages in
the assessment of risk. Morphological detection of tumour
at the end of induction identifies a high risk group
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(Miller 1974) and this was extended by Wassermann et al
(1992b) who used CDRIII PCR to study 44 children with B-
lineage ALL. By day 28, all BM samples studied were in
morphological remission but PCR analysis revealed a range
of degrees of residual tumour which were semi-quantified
by the method of Yamada et al (1989). A 1 to 4 log
reduction in disease was reported and no relapses during
the course of therapy was reported in the group with the
lowest amount of persisting tumour, though late relapses
still occurred. Conversely those with only a 1 log
reduction relapsed early in treatment in many cases.
However this study could not identify all patients with a
higher risk of disease recurrence.
5.1.3 Clonal evolution
A necessary condition for the investigation of tumour
natural histories is the availability of stable disease
specific markers. Cytogenetic markers have been shown to
be consistent from presentation to relapse, hence their
study was inferred to provide an accurate means for the
assessment of residual disease. However, the
heterogeneous nature of translocations outwith the
Philadelphia chromosome in CML and the t(14;18) in low
grade precludes their routine use in the analysis in many
haematological neoplasms. Analysis of the t(14;18) lesion
has shown this to be consistent from presentation to
relapse (Raffeld et al 1987) although the accumulation
of subclones with differing breakpoint sequences has been
described (Price et al 1991a).
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Immune receptor gene rearrangements are associated with
most T and B-lineage disease and sufficiently clone
specific to provide a marker for analysis. However as
gene rearrangements are a continuing process in malignant
lymphocytes (Bunin et al 1990), markers may alter as
disease progresses. The behaviour of neoplastic cells
throughout therapy is dynamic, hence the existence of
variant subclones at presentation may result in the
appearance of different major clones at relapse.
Beishuizen et al (1991) reported that 40% of patients
with B-lineage ALL had oligoclonal IgH rearrangements at
presentation as demonstrated by Southern blotting.
Further to this many patients demonstrated an altered
banding pattern at relapse although only 2 patients with
completely unrelated rearrangements at relapse were
reported. This study did not take into account partial D-
J recombination events that can only be detected by
Southern analysis but was used as evidence that CDRIII
PCR would not be informative in many cases and that TcR6
rearrangements would provide a more stable marker of
disease (Beishuizen et al 1992). Potter et al (1992) and
Wassermann et al (1992a) used sequence analysis to
investigate the role of V-V replacement events, which
result in the substitution of a VH segment with one more
5 ' , accounting for the majority of change at the IgH
locus. As these events influence the V-D region, the
design of D-J region specific oligonucleotide probes
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would allow the detection of V-V replacement events.
Potter et al reported that using PCR a complete clonal
change was seen in only 2 of 32 children with B-lineage
ALL. Independent rearrangements of partial DJ
recombinations to V segments in subclones will also
maintain the DNJ junction whilst generating clones with
variant VND sequences.
The stability of the TcR loci has not been as widely
documented and it was assumed to provide a more stable
marker due to the lower incidence of oligoclonality at
presentation. Maclntyre et al (1990) examined 12 6-chain
and 14 Y -chain alleles from 9 patients and found that
only one of each changed at relapse. Beishuizen et al
(1992) studied 20 cases and reported that by Southern
analysis 30% of patients with TcR5 markers showed an
altered pattern at relapse.
5.1.4 Aims
I set out to monitor residual disease in a group of
patients with leukaemia, lymphoma, and myeloma using a
semi-quantitative method to evaluate the prognostic value
of PCR analysis. Determination of tumour contamination in
PBSCH was compared to that of BMH to test whether these
would provide a source of progenitor cells for autologous
transplantation with lower tumour infiltration. The
effect of clonal evolution in determining MRD was studied




A total of 21 patients with PCR markers were available
for further analysis. Eleven ALL patients were studied
(10 B-lineage and 1 T-lineage) of which 8 were male and 3
female with a mean age of 15 years (range 3 to 29 years).
Five patients with low grade NHL (2 male, 3 female),
mean age 46 years (range 44 to 48 years) and 3 patients
with high grade NHL (2 male, 1 female), mean age 56 years
(range 55 to 57 years) were studied. One patient each
with HD (male, 52 years) and myeloma (male, 56 years) was
available for analysis.
Fourteen patients underwent PBSC harvesting (5 B-lineage
ALL, 4 low grade NHL, 3 high grade NHL, 1 HD and 1
myeloma).
5.3 MATERIALS
These were as previously described.
5.4 METHODS
These were as previously described with the following
additions.
5.4.1 Video densitometry
Videodensitometry was used to provide an estimate of
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tumour load in patients undergoing therapy (Billadeau et
al 1991). Amplified DNA was hybridised against an
internal bcl-2 probe (t(14;18) analysis) or a clone
specific probe (for IgH CDRIII or TcR6) as previously
detailed. Following a 2 to 4hr exposure, autoradiographs
were analysed by video densitometry and OD values
calculated. Log-^Q values were calculated from the OD
readings obtained from serial tenfold dilutions of tumour
DNA in normal mononuclear cell DNA and plotted as a
standard calibration graph of log^Q(OD) against dilution
factor. Log*LQ calculations of OD readings from samples
obtained during therapy were used to extrapolate an
approximate value of tumour load. A standard dilution
series derived from SU DH L6 DNA was used to calibrate
tumour load in samples from patients with a t(14;18) but
individual patient dilutions were used to calibrate the
clone specific reactions. Dilutions and serial samples
were amplified and hybridised to probes at the same time
to ensure consistency.
All reactions were performed in duplicate to minimise
variation between reactions and were found to concur to
within one log value in each case. Negative controls
consisting of normal pooled blood mononuclear cell DNA
and no template DNA were run for every series of
amplifications.
Graphs were plotted of median tumour load calculated from
duplicate reactions using the Microsoft Graph package.
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5.4.2 Control PCR
Control primers which amplified a 260bp segment of the
V62 gene were employed to test DNA quality. Reactions
contained lx PCR buffer, 200mM each dNTP, 1. 5mM MgC^^ 1U
Tag polymerase and 30pmol each of a 5 * V62 leader region
primer (51- GTCATGTCAGCCATTGAGTT -3') and a 3' V62 primer
(5'- TCTCTCTCTGATGGTGCAAG- 3'). Cycles were as detailed
in Table 3.3.
5.4.3 PBSC mobilisation and harvesting
PBSC mobilisation was usually mediated by standard
chemotherapy consisting of the UKALL XA in ALL, CHOP for
NHL and ChlVPP for HD (Craig et al 1992) . G-CSF was
administered to mobilise stem cells in one case of
myeloma. Harvests were collected on a Fenwal CS3000 or
Cobe Spectrum cell harvester during recovery phase of the
PB count. A total of 62 PBSCH were collected.
5.5 RESULTS
Samples were collected during therapy on 21 patients with
leukaemia, lymphoma and myeloma. The persistence of
residual disease was correlated with clinical status to
evaluate PCR analysis in predicting clinical outcome.
Estimation of tumour contamination in PBSC was also
undertaken and compared to that in BM sampled
concurrently to determine the extent of persisting tumour
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in autologous harvests.
5.5.1 Residual disease on treatment
Clinical manifestation of disease is correlated with PCR
status for patients with ALL in Table 5.1 and for
lymphoma and myeloma in Table 5.2. Semi-quantitative
densitometrie analysis was used to plot tumour
progression a group of 4 patients (3 ALL, 1 low grade NHL
with multiple samples (Figure 5.1 A-D).
Clone specific probes from 10 patients with TcR V62-D63
rearrangements were used to analyse remission PB and BM
for up to 2 years following induction therapy for B-
lineage ALL. Of the 7 patients achieving remission, 3
became PCR negative (CW at 14d, RK at 5mo and MC at
16mo). At 23 months all 3 remained PCR negative and in
complete remission. The remaining 4 who entered remission
showed persistant PCR positivity, of these one died after
one month from causes other than disease and the
remaining 3 ultimately relapsed (DP at 23m, DT at 2m and
GG at 43m). Reinduction and stem cell transplantation did
not result in loss of PCR positivity, all 3 patients
subsequently died. PCR positivity persisted in all 3
patient who did not enter remission, with the exception
of patient BM, who was transiently PCR negative at day 7
(Figure 5.2). Graphical analysis of tumour progression in
3 ALL is shown in Figure 5.1 A-C.
Analysis of the t(14;18) mbr translocation or CDRIII
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Patient Clinical Status
WL remission/+1mo died from
other causes
DP remission/ +23mo relapsed/
died
DT
BM remission not achieved/ +3mo
died
GG
RK remains in remission at 24mo
CW remains in remission at +23mo
MC remains in remission at +23mo
CA remission not achieved/ +10mo
MUD transplant/ remission/
+18mo relapsed
EC remission not achieved/ +lmo
died
T-ALL
DL remission/ died post BMT
PCR Status Probe
+ve during remission 10~5
+ve during remission/ PBSC nd
+ve/ +BMH +ve
+2Id BM and B -ve/ +28d 10"4
+ve
+ve up to +5mo/ remains -ve 10~5
at +24mo
+14d BM -ve/ remains -ve at nd
23mo
+ve up to 16mo/ remains -ve nd
at +23mo




remission/ +2mo relapsed/ +ve during remission/ PBSC 10"4
+6mo PBSCT/ remission/+7mo +ve/ +ve following PBSCT
relapsed/+8mo died




+ve during remission/ BMH nd
+ve/ +ve following BMT
Table 5.1 Summary of clinical and PCR data from 10
patients with B-lineage ALL and one T-ALL. Amplified
samples were hybridised against the relevant clone
specific probe. Clinical remission was determined by
morphologic and immunophenotypic criteria. The final
column indicates clone specific probe sensitivity.
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Patient Clinical Status PCR Status Probe
low grade NHL
SP remission/ +17mo PBSCT/ PBSC -ve/ BM +ve in 10~5
remission achieved/ +6mo remission/ BM remained -ve
relapsed 3mo+ BMT
LW partial remission/ +19mo PBSC+ve 10"^
relapsed
AM remission/ +47mo relapsed/ BM -ve in remission/ PBSC 10~4
+57mo partial remission / +ve in partial remission
+59mo BMT/ +60mo died
CL remission achieved post BMT 3mo+BMTBM-ve 10"^
high grade NHL
MM remission not achieved/ died PBSC +ve/ BM + nd
+21mo
SM partial remission/ +10mo PBSC -ve/ BM +ve during nd
BMT/remission/ relapsed partial remission
+16mo
RB remission/ relapsed +35mo +4mo PBSC +ve/ +6mo BM 10"4
-ve
myeloma
JM remission not achieved PBSC -ve nd
HD
JH remission/ relapsed +7mo/ PBSC -ve/ BM +ve during nd
+15mo PBSCT/remission 1st remission
Table 5.2 Summary of clinical and PCR data from 7
patients with B-lineage lymphoma and 1 each of myeloma
and HD. Samples were analysed by either t(14;18)
amplification or by hybridisation against the relevant
clone specific probe. Clinical remission was determined

























fVv day rel pre pst pst rel
21 \ M M Ml M2 M
sample
Figure 5.1 Graphical representation of densitometric
analysis of sensitivity titrations and disease
progression in 3 patients with ALL. The locus studied is
indicated after the patients initials. The green line
indicates the limit of morphological detection (5%) and
the blue line the limit of PCR detection (0.001-0.0001%).
In Figure C, the red line depicts clone A (presentation
probe) and the yellow line clone B (relapse probe). Rel
indicates a relapse specimen, rem remission, pre pre-
transplant and pst post-transplant. M indicates a BM
sample and mo indicates month.
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Figure 5.1 continued. Graphical representation of
densitometric analysis of sensitivity titrations and
disease progression in a patient with low grade NHL. The
locus studied is indicated after the patients initials.
The green line indicates the limit of morphological
detection and the blue line the limit of PCR detection.
Rel indicates a relapse specimen, rem remission, pre pre-
transplant and pst post-transplant. M indicates a BM
sample.
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Figure 5.2 Autoradiograph showing V62-D63 amplification
products from patient BM hybridised against a clone
specific probe. Tenfold serial dilutions of presentation
DNA are shown in the top row, lane 1 contains undiluted
tumour DNA. Sensitivity is at the 10 level (lane 5).
The lower row contains presentation PB, day 7 PB and BM,
day 21 PB relapse BM and normal PBL.
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clone specific probes were used to analyse 10 patients
with lymphoma and myeloma. Full remission was achieved in
5 patients with lymphoma, 3 showing corresponding PCR
negativity (RB, AM and CL) though 2 went on to relapse
(RB +33mo and AM +47mo). Of the 2 patients PCR positive
in remission, one (SP) became negative after a PBSC
transplant (Figure 5.3, densitometric analysis is shown
in Figure 5.ID) whilst the other relapsed (JH). Four
patients who did not enter full remission remained PCR
positive, except the patient with myeloma who had a PCR
negative PBSCH.
In patients with lymphoma, dissemination to the BM or PB
is not always detectable by morphological means at
presentation which has implications for the study of
remission BM. Contamination of PB and BM at presentation
was consistently detected in either in PB or BM in 7
patients with lymphoma (4 low grade NHL, 3 high grade
NHL) .
Control PCR reactions were performed on PCR negative
samples to exclude the possibility that these were
refractory to amplification (Figure 5.4). All samples
tested gave a consistent amplification pattern with the
exception of the day 7 BM from patient BM.
5.5.2 Tumour contamination in PBSC
A total of 62 PBSCH were collected on 23 occasions from
14 patients and in 8 cases BM samples were collected
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Pres. Rem PreT. Post T. Control
LN PB PB BMPBSC BMH PBSC BM +1m +3m PB No
• • I •
Figure 5.3 Autoradiograph showing t(14;18) mbr
amplification products from patient SP hybridised against
an internal bcl-2 probe. Pres indicates presentation and
rem remission. Pre and Post T. refer to pre- and post-
transplant samples. LN denotes lymph node. +lm and +3m









Figure 5.4 Control PCR products resolved by 4% agarose
gel electrophoresis and stained in ethidium bromide. Lane
1 contains a 0X174 size marker. Lanes 2 to 8 contain the
following samples: BM day 7 BM; RK +23mo BM; SP PBSCH; SP
3mo + PBSCT BM; SM PBSC; CW +6mo BM and CL 3mo BMT BM.
Lanes 9 and 10 contain normal PB DNA and lanes 11 and 12
no DNA controls.
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within 3 weeks of the harvest. When Southern analysis
with an IgHJ probe was performed on this group of
patients (Craig 1991), residual tumour was not detected
in any PBSCH and in only one remission BM, indicating
that any residual disease present must be at a level of
less than 5% (Table 5.3).
The enhanced sensitivity provided by PCR analysis,
facilitated the detection of residual disease in 34
harvests from 8 patients including all 5 ALL, 2 low and
one high grade NHL. Harvests from 4 ALL collected after
successive courses of therapy showed persisting PCR
positivity. PCR negative harvests were collected from 6
patients, 2 high grade NHL, 2 low grade NHL, one HD and
one myeloma. Figure 5.5 illustrates contamination in both
BM and PBSCH collected from a patient with ALL and
Figures 5.3 and 5.6 show 2 patients with lymphoma (one
high grade and one low high grade respectively) with BM
involvement but PCR negative PBSCH. Eight patients had BM
sampled within 3 weeks of PBSCH (6 concurrently) 3 of
which had residual tumour in BM but not in PBSCH (2 low
grade NHL and one high grade NHL). Densitometric analysis
of two patients with ALL indicated tumour contamination
in the BM was at a level 10 to 100 fold higher than that
in the the PBSCH. One ALL, however, had detectable
disease in the PBSCH whereas none was detected in a BM
sample taken 2 weeks previously. This sample amplified
poorly (day 7 BM, patient BM). The results of Southern
and PCR analysis are summarised in Table 5.3 with an
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Southern analysis PCR analysis
Disease Marker BM PBSC Marker BM PBS<
ALL
GG JH G G TcR8 "+• +
WL JH nd G TcRS 10-2-10"3 10"3.
BM JH nd G TcR5 - 10"1
DP JH G G TcRS + +
DT nd nd TcRS 10"1 10"2.
high grade NHL
RB JH R G JH 10"3-10"4 -
SM JH nd nd JH nd -
MM JH G G JH nd +
low grade NHL
SP JH G G t(14;18) 10-2-10"3 -
LW JH nd G t( 14; 18) nd 10-2
AM JH nd G JH + -
EP nd nd t(14;18) nd +
myeloma
JM nd nd JH nd -
HD
JH nd nd JH nd _
Table 5.3 Comparison of Southern blot and PCR analysis of
tumour contamination in PBSCH and BM sampled within 3













Figure 5.5 Autoradiograph showing V62-D63 amplification
products from patient WL hybridised against a clone
specific probe. Lanes 1 and 2 contain presentation PB and
BM DNA, lanes 3 and 4 remission PB and BM DNA and lanes 5
to 7 PBSCH samples. Lanes 8 and 9 contain control PB and
no DNA respectively.
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Pres. PBSCH Rem Control
LN BM 1 2 BM PB NoDNA
Figure 5.6 Autoradiograph showing CDRIII amplification
products from patient SM hybridised against a clone
specific probe. Lane 1 contains presentation lymph node
DNA and lane 2 presentation BM. Lanes 3 and 4 contain
PBSCH samples and lane 5 a remission BM. Lane 6 contains
normal PB and lane 7 no DNA.
205
indication of disease load wherever quantitation was
performed.
5.2.3 Clonal evolution
The potential impact of change in clone specific markers
was investigated in a group of patients followed to first
or second relapse. V62-D63 rearrangements were amplified
from 5 B-lineage ALL patients on whom presentation and
relapse material was available (including 2 followed to
second relapse). One patient (20%) showed a different
V62-D63 sequence at first relapse, though this sequence
persisted at second relapse. Of the remaining group, all
demonstrated consistent junctional sequences, including a
second patient followed to second relapse. Material
obtained at presentation and relapse was available on 5
patients with low grade NHL, none of whom showed changes
in t(14;18) banding pattern at relapse.
A group of 12 patients with B-lineage disorders were
analysed from presentation to relapse to investigate
evolution at the CDRIII locus. Overall, an alteration in
banding pattern was seen in 4 (33%). Sequence analysis in
two cases showed the emergence of unrelated sequences
which were not due to further V-DJ recombination or V-V
replacement events (Table 5.4). In a further 2 cases
bands were lost at relapse, one patient initially showed
2 bands, with one present at relapse, the other showed
one band at presentation.












































Table 5.4 Alterations of CDRIII and TcR6 sequences from
presentation to relapse. Results of sequence analysis of
V62-D63 and IgH CDR III rearrangements from a patient DT
with ALL at presentation and first and second relapse are
shown. CDR III sequences from a low grade NHL patient AM
with from presentation to relapse are also shown.
Homology with D segments is indicated with underlining
and P nucleotides are shown in bold type.
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was only seen in one instance, with change at one locus
in 3 cases (Table 5.5).
Changes in specific markers can result in false negative
disease assessment but also permit the study of the
growth kinetics of distinct sub-clones. Disease
progression in a patient with a high risk associated
t(4;ll) translocation is illustrated in Figure 5.7. A
probe sensitive at the 10"^ level derived from a V62-D63
sequence at presentation was hybridised against a series
of samples collected throughout the course of treatment
(Figure 5.7A). Marrow at day 21 was highly contaminated
although the patient had entered remission by
morphological criteria. However, the clone predominant at
presentation could not be detected in the first relapse
or subsequently. Sequence analysis of the amplification
product obtained at relapse confirmed that the V62-D63
sequence had altered. A second probe specific to the
relapse sequence hybridised strongly to the relapse
sample, but a signal was also obtained in the original
presenting BM hence both clones were initially present
(Figure 5.7B). Following PBSC transplantation, the
patient again achieved clinical remission, but PCR
positivity persisted, even with the stimulation of
natural killer cells by IL-2. The clone identified at
first relapse was identified at a subsequent second
relapse although no trace of the initial clone could be
detected suggesting selection for a chemoresistant clone


























Table 5.5 Summary of patients with 2 markers analysed
presentation to first relapse. A - symbol indicates that
this locus was not studied.
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Pre Post Post
Pres. Rem. Rel. Rem. Trans. Trans. IL-2 Rel. Control
PB BM S1 BM S2 BM S3 BM BM BM BM BM




Pres. Rem. Rel. Rem. Trans. Trans. IL-2 Rel. Control
PB BM S1 BM S2 BM S3 BM BM BM BM BM
• • • I I •
I • • M |
Figure 5.7 Autoradiograph showing V62-D63 amplification
products from patient DT hybridised against a clone
specific probe. A series of samples collected throughout
therapy hybridised against the presentation probe are
shown in A and the same samples against the relapse probe
in B. Pres. indicates presentation, rem remission and rel
relapse. SI to S3 indicates PBSCH 1 to 3. Normal BM was
used as acontrol in this instance.
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presentation. Densitometric data for the two probes is
shown in Figure 5.1C. Amplification and sequencing of the
IgH CDRIII region also showed an altered pattern at first
relapse which remained consistent at second relapse. PAGE
analysis of presentation, first relapse and second
relapse for both loci is shown in Figure 5.8 and sequence
data summarised in Table 5.4.
In summary, analysis of molecular markers can
successfully detect tumour contamination in samples
previously considered to be in remission. In ALL
persisting high level or increasing PCR positivity may
indicate relapse whereas those patients in long term
remission are generally PCR negative. The focal nature of
lymphoma renders relapse prediction more difficult. Blood
is generally a poorer indicator of systemic tumour load
than marrow although PB derived stem cells did have
detectable tumour contamination. Clonal evolution was
found to affect 20% and 33% of patients respectively when
the TcR6 and CDRIII loci were studied whereas none of the
5 low grade patients showed an altered t(14;18) mbr band.
5.6 DISCUSSION
PCR analysis of tumour specific loci facilitates the
study of disease at levels not previously attainable and
has redefined the concept of residual disease. The
biological significance of sub-microscopic tumour in








Figure 5.8 PAGE analysis of presentation and relapse PCR
products from patient DT stained with ethidium bromide.
Lane 1 contains a 0X174 size marker and lanes 2 to 5
contain presentation, 1st relapse, second relapse and a
normal DNA control respectively amplified with the CDRIII
primers and lanes 6 to 9 the same samples amplified with
the V62-D63 primers
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variety of techniques, however definitive conclusions
cannot be drawn due to the relatively small numbers of
patients studied and heterogeneity of sample collection
and differences in treatment protocols.
In this study I have attempted to correlate clinical
observations with PCR status in order to evaluate the
possible prognostic significance of MRD detection in
patients with leukaemia and lymphoma. Further to this
tumour infiltration in PBSCH was investigated as it has
been suggested that these provide a less contaminated
source of progenitor cells than autologous BM harvests
reducing the load of reinfused tumour cells which may
contribute to relapse.
Trends were apparent when longitudinal analysis was
performed in patients with ALL. PCR positivity in the
first year of treatment was a common finding hence not
predictive of eventual relapse although quantitation of
samples collected from 4 patients after induction showed
varying degrees of residual tumour. Rapid relapse was
observed in 2 patient with a disease load greater than
10 J whereas the remaining 2 showed persisting tumour at
a level of less than 10"^ and subsequently entered long
term remission. Wasserman et al (1992b) studied a larger
group and suggested that the level of disease detected
following induction could identify patients at risk of
early relapse, however patients likely to relapse further
out could not be identified. Positivity persisted into
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the second year of therapy in 3 cases although relapse
occurred only in 2 therefore persisting tumour at this
time does not necessarily herald relapse, confirmed by
Yamada et al (1990) who reported the persistence of
positivity up to 25 months in patients in remission. One
patient who achieved a partial remission had a negative
result at day 7, followed by a positive result at day 21
and went on to relapse after 3 months. This seemingly
anomalous finding was explained by a DNA sample partially
refractory to amplification. The 3 patients who achieved
long term remission became PCR negative between 14 days
and 16 months hence PCR negativity is associated with a
better prognosis. Relapses were always preceded by PCR
positive samples in this study. Yokota et al (1991)
reported a fall in the incidence of PCR positivity with
time and they and others (Macintyre et al 1990, Nizet et
al 1991 , Neale et al 1991 and Biondi et al 1992) found
that patients in long term remission were generally PCR
negative. Another common report was an increase in tumour
burden in patients prior to relapse, though relapse could
only be predicted less than 6 months in beforehand. Only
one T-ALL was available for analysis, who showed
persisting disease at the time of a BMH and subsequently
died post-transplant.
Increasing PCR positivity appears to be an important
indicator of relapse, hence quantitative analysis may
provide more accurate disease assessment. Various methods
have been described including limiting dilutions (Yokota
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et al 1990), the phage colony titre assay (Yamada et al
1989), densitometric analysis (Billadeau et al 1991) and
simple comparison to standard dilution series (Potter et
al 1992) to determine tumour specific TcR6 and CDRIII
template concentrations. The basic problems with
quantitation stem from the logarithmic nature of PCR,
varying amplification efficiencies due to variation in
conditions such as enzyme activity and the requirement
for representative dilutions. For these reasons all such
methods assume accuracy to within one log, therefore a
simple estimation of tumour load by comparison to
individual patient dilution curves should provide a
meaningful estimate of tumour load. The method used in
this study was less exhaustive than the densitometric
method described by Billadeau et al (1991) as an absolute
figure for tumour contamination was not calculated,
rather a useful means to represent tumour progression.
. .... —
Dilutions appear to provide linear titres in the sub 10
range, the level at which residual disease may be of
clinical relevance hence provide accurate values for
tumour load in this range. More exhaustive techniques,
such as the phage colony titre assay which compares the
tumour contamination detected by CDRIII specific probes
to a cell line bearing an IgH rearrangement diluted in
normal cells, does not take into account the differential
amplification of individual patient sequences hence will
not necessarily provide a more accurate indication of
tumour load than the method described in this study.
However the phage titre technique permits the sequence
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analysis of clones testing positive, a useful check
against non-specific hybridisation of CDRIII probes.
Fewer sample points were collected in patients outwith
the ALL group. The persistence of PCR positivity into
clinical remission was seen in 2 of 5 patients. Of the 3
patients with no detectable disease 2 went on to relapse,
in one case only 3 months after a PCR negative sample. In
this series therefore relapse prediction wasn't possible.
Full remission was not achieved in 4 patients and PCR
positivity persisted in all these patients with one
exception. A PCR negative PBSCH was collected from the
patient with myeloma even when BM involvement was
clinically evident. Billadeau et al (1992) studied PB
involvement in untreated patients with myeloma and found
levels of disease unrelated to that observed in BM which
may explain this finding. It would appear that MRD
analysis is of most value in ALL, due to the nature of
samples available. Lymph nodes cannot be routinely
biopsied and PB or BM sampling do not appear to provide
an indication of systemic tumour load. As low grade NHL
is characterised by slowly growing cells, the persistence
of disease does not indicate a poor prognosis (Price et
al 1991b), nor does the reduction of disease indicate
cure.
Disease progression in patients undergoing allogeneic
transplantation is modulated by donor T-cell activation
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which can result in a potentially lethal GVHD and
associated, though beneficial, GVL effect (Goldman et al
1988). Tumour persistence following allogeneic
transplantation has been studied in a large cohort of
patients with CML. Miyamura et al (1992) reported the
frequent detection of the bcr-abl transcript in patients
achieving sustained clinical remissions of durations of
up to 3 years at the time of publication. This did not
necessarily herald the onset of relapse although patients
who became PCR negative did not relapse. Cross et al
(1993) analysed 61 patients who underwent allogeneic
transplantation in first chronic phase for CML and
reported that patients generally remained PCR positive
for periods up to 9 months with positivity beyond this
time identifying a group at risk of relapse, although
this was not predictive on an individual patient basis.
All relapses were preceded by a positive result, but
relapses could occur only one year after a PCR negative
result. A correlation between chronic GVHD and PCR
negativity was not found and this was taken as evidence
of a separate graft mediated anti-leukaemia effect.
Quantitation of RNA based PCR is difficult but
competitive inhibition experiments may provide an idea of
tumour load and be of further prognostic value. A murine
model simulating high risk ALL undergoing transplantation
from a sibling donor has been developed (Drobyski,
Baxter-Lowe and Truitt 1993), in which male donor cells
were detected in a female recipient by Y specific PCR
This may facilitate the study of GVHD and GVL effects in
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vitro.
Tumour infused in an autologous graft may contribute to
relapse as well as endogenous disease surviving the
conditioning regime. In addition to this no donor T-cell
mediated GVL effect arises, leading to higher relapse
rates than that seen with allografting. Purging has been
performed in an attempt to reduce contaminating tumour
and PCR analysis allows the effectiveness of this
procedure to be monitored. Gribben et al (1991a) employed
immunologic purging of BMH in 114 low grade NHL with anti
CD10 and CD20 monoclonal antibodies. Amplification of the
t(14;18) translocation indicated that all harvests were
initially contaminated but purging resulted in a 3 to 6
log reduction in tumour load with 57 becoming PCR
negative. Post-transplant, the majority of relapses came
from the group receiving PCR positive harvests suggesting
that infused disease can contribute to relapse.
Retroviral tagging with a neomycin resistance gene has
been used to investigate the source of relapse in 2
patients undergoing autologous transplantation for AML
(Brenner et al 1993). Marked cells from the harvest were
detected in both cases at relapse which followed a period
of PCR negativity concomitant with remission state hence
it was apparent that disease introduced along with BMH
could contribute to relapse.
These findings suggest that methods minimising reinfused
tumour could improve the outcome of autografting and such
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an improvement may be provided by PBSC transplantation.
It was assumed that stem cells derived from the
peripheral circulation would provide a source of
autologous stem cells less contaminated by tumour (To et
al 1987) although there has been little experimental
evidence to confirm this. Bell et al (1990) used a
Southern blot technique to detect tumour in BM at a time
when PBSC were apparently tumour free. Yokota et al
(1991) observed that concurrently sampled PB from ALL
patients in remission was 10 to 100 fold less
contaminated with persisting disease than BMH however no
data exists on the detection of tumour contamination in
PBSC harvests by PCR techniques.
Of the 13 patients analysed, tumour was detected in PB
harvests from 8, hence these still harboured a
significant tumour load. Of the 5 in whom no tumour could
be detected, 3 showed contamination in a concurrently
sampled bone marrow. In 2 patients with contaminated BM
and PBSC, semi-quantitative analysis indicated that the
BM contained an approximate tenfold higher tumour burden.
This indicates that in 5 cases where both PBSC and BM
were analysed, PBSC would have provided a less
contaminated source of stem cells. In only one case did a
BM sample show lower disease contamination than a PBSCH.
The leukapheresis collection procedure enriches for the
mononuclear cell fraction which contains the neoplastic
lymphocytes, possibly increasing tumour load. Further to
this, approximately tenfold more cells are reinfused in a
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PBSC transplant as compared to a BM transplant, hence a
similar level of contaminating tumour cells may be
introduced with both techniques, although the increase in
accessory cells with PBSC enhances engraftment and may
modulate disease progression. Three patients underwent
PBSC transplants, of whom 2 received cells containing no
discernible disease. SP showed residual disease in all BM
sampled prior to transplantation whereas post-transplant
BM samples were PCR negative, hence a reduction in
circulating disease was achieved although the patient
relapsed six months post-transplant. Patient JH received
PCR negative stem cells before a subsequent relapse. In
the third instance patient DT received harvests
contaminated by 2 clones characterised by discrete TcR6
and CDRIII markers of which the clone identified at
second relapse was apparently chemoresistant. Only this
clone was evident at second relapse although a
significant amount of the chemosensitive presenting clone
was reinfused with the PBSCH. As the relapse occurred
shortly after transplantation, it suggests that
endogenous cells surviving myeloablative therapy brought
about relapse rather than reinfused tumour. This would
explain the presence of the second clone, if the graft
was responsible for relapse then both clones would have
been represented. It would appear in this patient that an
earlier cell with IgH and TcR genes in germline
configuration was producing daughter cells which had
different rearrangements as the clones observed at
relapse could not be explained by further recombination
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of the genes seen at presentation. The persistence of a
t(4;ll) during the course of disease confirms the common
origin of the clones. This simulates the "tagging" model
outlined by Brenner et al (1993), hence the study of
patients undergoing evolution may provide an alternative
to retroviral mediated marking. A leukaemic clone with
evidence for a progenitor with stem cell features was
also reported by Tycko et al (1992). They reported a
malignant clone with both CDRIII and TcR Y
rearrangements which maintained CDRIII sequences at
relapse, accompanied by a de novo V y sequence.
The response of a larger number of patients infused with
PBSC assayed by PCR are required before the role of
reinfused tumour can be determined. Enrichment for stem
cells, expressing markers such as CD34 may provide the
least contaminated source of autologous cells (Civin et 1
1990), although the removal of more mature accessory
cells may hinder engraftment. An anti leukaemic effect is
stimulated by the action of IL-2 on natural killer cells
(reviewed Hamblin 1988), though this is only effective
when disease bulk is significantly reduced. IL-2 was
administered to DT post PBSCH, but tumour detectable by
PCR may represent too high a level of residual disease
for successful immune modulation of tumour.
The differences in disease behaviour observed between
leukaemia and lymphoma highlights one of the problems
associated with MRD detection irrespective of the
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sensitivity of the technique employed, that is the focal
nature of disease. Leukaemic cells may not be
disseminated in the peripheral circulation, likewise
tumour may be localised in certain niches within the BM
which may not be sampled when marrow is collected
(Martens et al 1987). Such BM specimens can also be
contaminated with PB at the time of collection which
could potentially reduce the sensitivity of the assay by
10 to 100 fold. The focal nature of lymphoma is a greater
problem for the analysis of residual disease as routine
collection of lymph node biopsies is not practical and
disease may not be disseminated to the peripheral
circulation even when significant nodal infiltration can
be detected histologically (Lambrechts et al 1992). In 7
patients analysed at presentation, disseminated disease
was detected in each instance though this may not
necessarily provide an accurate indication of systemic
tumour load during therapy. Problems of residual disease
analysis in HD are increased by the relative rarity of
Reed-Sternberg cells within lymph nodes which may exist
in even lower levels PB or BM.
There is also a finite limit to the quantity of BM that
can be biopsied and amount of DNA that can be analysed.
Maximally 10pg of DNA can be amplified giving an optimal
sensitivity of 1 tumour cell in a background of 10®
normal cells and even with this level of detection 105
occult neoplastic cells can persist although
realistically, ljjg provides a better substrate for
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amplification. This in conjunction with the rapid
doubling time of a malignant clone could lead to relapse
soon after a PCR negative sample as has been obtained.
Sensitive detection of low level disease gives no
indication as to the clonogenic potential of the cell
population detected. Residual tumour contamination in CML
may originate in terminal cells transcribing bcr-abl
message which have become incapable of proliferation,
likewise leukaemic lymphoblasts may differentiate and
lose the ability to divide whilst maintaining TcR or
CDRIII marker sequences. Further to this PCR may amplify
DNA fragments released from cells lysed by chemotherapy,
hence sampling soon after therapy may overestimate
residual tumour.
Another major consideration is the stability of the
marker under analysis. It is crucial that the locus
chosen to follow disease progression remains stable if
prospective investigation of the significance of MRD is
to be meaningful. Beishuizen et al (1992) estimated the
evolution rate at the TcR6 chain locus by Southern blot
analysis to be 30%, and of 5 patients examined at relapse
in this study one showed change. This was a subtle
alteration which would not change the pattern observed on
Southern blot analysis, hence Beishuizen's figure may be
an underestimate. This patient showed a consistent
pattern at second relapse, hence the synthesis of a
single new probe allowed analysis of all intermediate
samples. This is not a problem for retrospective analysis
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however steps must be taken to minimise the effect of
clonal change if prospective studies are to be
undertaken. Of the 10 patients followed to second
relapse, 4 showed an alteration in CDRIII banding
pattern, although in only 2 was this pattern unrelated to
that seen at presentation. In contradiction to earlier
reports, the IgH CDRIII locus may provide a very stable
marker if care is taken in probe design. Potter et al
(1992) reported on a series of 30 patients from
presentation to relapse, the major source of clonal
change was found to be due to V-V replacement events. If
DNJ region probes were designed, only 6% of patients
would lose a detectable marker at relapse. The rates of
biallelism and oligoclonality at presentation are higher
at the IgH than TcR5 locus (39 and 6% respectively in our
series), hence a greater number of probes would have to
be synthesised if each IgH allele was to be followed. A
total of 87 CDRIII probes for 70 patients with leukaemia,
lymphoma and myeloma, an average of 1.24 probes per
patient would be required to follow each rearranged
allele, though this figure is an overestimate as DNJ
probes will detect related subclones in many cases.
Jonsson et al (1991) investigated the relative
sensitivities of probes derived from either allele in a
cell line with 2 rearrangements and found equivalent
sensitivities. Potter et al 1992 calculated that 1.5
probes per patient would be adequate to follow all
patients with B-lineage ALL. Of the patients studied by
CDRIII analysis in this study, only one (patient SM) was
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biallelic, though disease progression was only followed
with a probe specific to one rearranged allele.
The design of CDRIII DNJ probes is difficult if little
diversity is displayed at this junction. If 2 loci are
studied, a probe derived from the most diverse sequence,
either CDRIII or TcR6 would be best selected. In this
study 10 of 25 patients with B-lineage ALL (40%) shared
IgH and V62-D63 rearrangements. V62-D63 positive ALL
patients represent a selected subgroup, however a larger
group could be investigated if 2 or more loci are
studied. In one patient (DT) with B-lineage ALL, both the
V62-D63 and IgH rearrangements were amplified and
sequenced but as both sequences changed from presentation
to relapse, probe design considerations would have been
ineffective due to the effect of complete clonal change.
If all patients with B-lineage ALL were followed by both
TcR6 and CDRIII analysis, a total of 38 probes in 25
patients would be required, an average of 1.8 per
patient. The t(14;18) translocation in low grade NHL
provides an extremely stable and tumour specific marker
though analysis of CDRIII rearrangements does facilitate
the study of a larger group of patients.
PCR analysis of multiple loci is an exhaustive process
but the use of multiplex PCR to screen a variety of
markers simultaneously may both complement cytogenetic
analysis and identify patients amenable to MRD
investigation. Izraeli et al 1993 co-amplified 4 loci
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covering each of 2 variants of t(l;19) and t(9;22)
rearrangements in precursor B-ALL simplifying the process
of analysing a large number of patients for relatively
infrequent markers. This allowed the detection of these
lesions in 11% of 121 patients, the structure of which
could then be analysed by both single strand conformation
polymorphism (SSCP) (Kovar et al 1991) and sequence
analysis.
The sensitivity of PCR analysis may be improved by the
enrichment of biopsied marrow for B-lymphocytes. Bregni
et al (1989) reported a tenfold enhancement in the
sensitivity of Southern analysis when myeloid cells were
removed by incubating with monoclonal antibodies.
Treatment of BM with B-cell specific markers such as CD10
or CD20 may also provide such an increase in sensitivity
when extracted DNA is analysed by PCR, which will further
characterise the disease state in ALL and may enhance the
prognostic significance of MRD analysis in lymphoma.
The recent development of in situ PCR (Nuovo et al 1991)
allows the detection of leukaemia specific signals in
intact cells, enabling amplification of morphological
slide preparations. Sensitivity is limited by the number
of cells which can be analysed, but the technology would
be applicable to the analysis of cultured cells or sorted
cell populations. This would involve amplification of
rearranged loci with at least one CDRIII or TcR6 junction
specific primer to provide specificity. Amplification
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products are then hybridised to an internal digoxygenin
labelled oligonucleotide probe followed by
chemiluminescent detection. This would be of particular
interest in determining the nature of lymphoid blasts
observed by light microscopy and may allow clearer
definition of remission state or in the analysis of lymph
node biopsies.
An alternative to immune gene PCR could be provided by
"vectorette" PCR (Arnold & Hodgson 1991) which enables
discrete amplification with single primer specificity via
the use of synthetic linkers. This involves the digestion
of genomic DNA and ligation of vectorette linkers to
create libraries which are then screened by PCR. Many
translocations have not been sequenced or have
heterogeneous breakpoints and require an RNA template for
amplification due to the variation in size of the
breakpoint region. This gives no size discrimination of
products between patients hence carry-over is a potential
problem. Translocations in which one side of the
breakpoint is known are amenable to vectorette PCR such
as the t(9;22) bcr translocation in CML and ALL (Mills et
al 1992). Primers specific to the vectorette and to exon
b3 of the M-bcr were used to amplify and sequence the
junctional sequence from 3 patients with CML. This
allowed the design of patient specific PCR primers
allowing DNA based PCR. In addition to removing the need
for RNA this also reduces the problem of carry over and
eases quantification. Such an approach would facilitate
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the amplification and sequencing of translocations
involving TcR or IgH loci from other haematological
disorders providing stable targets for MRD analysis which
do not have to be differentiated from polyclonal
sequences as with immune gene markers.
The prognostic value of PCR analysis can only be improved
on by the implementation of prospective coordinated
multi-centre trials. Two such trials are currently
underway, the first involves the study of residual
disease in T and B lineage ALL in children being treated
on the Berlin Frankfurt Munster (BFM) treatment protocol
in Germany, Holland and Italy (Potter et al 1993 in
press). In marrow sampled at 3 month intervals over a 5
year period, MRD will be assessed by analysis of TcR6,
TcRgamma and Tal-1. A second trial, involving children
with ALL on the UKALL X/XI treatment protocol is
currently underway in Britain to investigate disease
persisting at the end of therapy and possible prognostic
significance (Steward et al 1993). In this trial,
duplicate samples will studied by TcR6, TcRy , t(9;22)
and IgH CDRI and III analysis different participating
centres providing corroboration of results and checks
against false positivity.
In conclusion, it is apparent that the implementation of
sensitive techniques has refined the definition of MRD.
Such techniques have been of particular interest in the
study of leukaemia, whereby marrow sampling can provide
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an indication of systemic disease. The results of several
studies show that the incidence of PCR positivity falls
with the increase in remission duration and relapse is
generally preceded by a PCR positive sample. PCR analysis
appears to be less informative in the study of lymphoma
due to the localisation of disease within the lymph
nodes. PCR analysis has shown that harvests collected
from PB are not necessarily free from tumour but they do
appear to represent a less contaminated source of
progenitor cells, which purging studies suggest may
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Summary. T cell receptor <5 chain (TCR<5) gene rearrange¬
ments were studied by Southern blot analysis in 36 patients
with common acute lymphoblastic leukaemia, including 14
adults and 22 children. The majority of patients (68%) had
either a rearrangement or deletion of one or more TCR<5
genes. The most frequent rearrangement involved a partial
recombination of V<52 to D<53 (55%). D32-D33 rearrange¬
ments were present in five patients (14%). To investigate the
TCR<5 rearrangement as a tumour marker in minimal
residual disease studies, presentation samples from 18
patients were amplified by PCR and directly sequenced.
Although the size of the V<52-D<53 junction varied by only 40
bp. sequence analysis showed extensive diversity. This was
derived from four factors: deletion of the 5' end of D<53 gene
(15/18) and 3' end of Vi>2 gene (16/IS): the presence of Do2
sequences (6/18l: insertion ofN nucleotides (15/18): associ¬
ation of P nucleotides with intact V<52 and D33 genes (5/18).
N nucleotides were the major feature, contributing to 75% of
the junction. D31 sequences were not involved. Twenty base
oligonucleotide probes, constructed from the junctional
sequences, were capable of detecting residual tumour cells at
the lO-4 sensitivity level. Cross hybridization studies con¬
firmed the probes to be clone specific. Longitudinal studies on
patients undergoing treatment were capable of detecting
tumour in remission samples.
A major clinical problem in the treatment of patients with
leukaemia is the presence of residual neoplastic cells follow¬
ing induction remission therapy. Improved evaluation of
minimal residual disease would assist in monitoring an
individual patient's response to therapy and provide an early
indication of impending relapse. Analysis of recombination
events associated with immune receptor genes in B- and T-
lineage disorders is of use in monitoring clonal populations of
neoplastic cells. Immunoglobulin heavy chain (IgH) gene
and T-cell receptor (TCR) gene rearrangements were pre¬
viously assayed by the classical methods ofSouthern blotting
and gene probing but these were limited by poor sensitivity.
More recently, the application of techniques based on
enzymatic amplification of immune receptor genes by poly¬
merase chain reaction (PCR) has identified minimal residual
populations of tumour cells. One such PCR based strategy
involves the rearrangement of the TCRd chain gene. Two
heterodimer forms of TCR are described, termed x/1 and yd
Correspondence: Dr R. S. Anthony. Department of Haematologv.
Royal Infirmary. [.auriston Place. Edinburgh EH 3 9YW.
(Allison et al. 1982: Brenneretal. 1986). Lymphocytes which
express y5 are present as a minor population (1-10%) in the
peripheral blood (Lanier & Weiss. 1986). Although TCR
molecules are expressed by T-lymphocvtes. rearrangements
of TCR genes appear not to be lineage restricted, most
notably. TCRd rearrangements have been reported in 70%
(Hara et al. 1988) and TCR/? rearrangements in 30% of B-cell
precursor acute lymphoblastic leukaemia (ALL) (Hara et al.
19S9).
Diverse mature TCRJ chains result from the rearrange¬
ment of variable (V). diversity (D) and joining (J) gene
segments during the early stages of T-cell differentiation. The
number of functional V. D and J segments is limited in TCR3
genes (six. three and three respectively I. however the
junctional diversity is determined by the presence of D gene
segments, deletion of germline nucleotides and randomly
inserted N nucleotides (Hata etal. 1 988: Loh etal. 19S7).The
limited germline diversity encoded at the TCR3 locus (Taki-
hara et al. 19S9) in conjunction with extensive junctional
diversity results in lymphocyte clones which provide a useful
target for PCR analysis. The restricted V32iDlD<>3 configu-
648
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PCR primers - V82 5' - GAG TCA TGT CAG CCATTG AG - 3'
D83 5' - AGG GAAATG GCA CTTTTG CC - 3'
sequencing primer V82 5' - GCA CCA TCA GAG AGA GAT GA - 3'
Fig 1. Genomic organization of the partial TCR VP 2- Do 3 rearrangement showing the locations and sequences of primers for PCR amplification of
V62-D(53 and of the sequencing primer.
ration, frequently associated with common ALL (cALL)
(Biondi etal. 1990). can be exploited to generate oligonucleo¬
tide probes specific for individual clones and used to monitor
minimal residual disease (Yokota et al. 1991b). Sequence
analysis of these junctions can be performed to investigate
the mechanisms involved in recombination and also has
implications in the study of T-cell ontogeny (Yokota et al,
1991a).
We aimed to study a group of adults and children with
cALL for the presence ofTCR Vi52-D(53 gene rearrangements
both by Southern blot analysis and by PCR amplification. In
18 of these patients we further analysed the V<52-Dd3
rearrangement by direct sequence analysis of the PCR
reaction product and from the sequence data we were able to
construct clone specific probes for use in assessing minimal
residual disease.
METHODS
Cell samples. Bone marrow or peripheral blood samples
were obtained at presentation from 36 patients with cALL
(MIC criteria. First MIC Cooperative Study Group. 1986).
These included 14 adults with median age 3 3 years and
range 16-60 years, and 22 children, median age 6 years and
range 2-14 years. Normal peripheral blood mononuclear
cells were separated by Ficoll density gradient centrifugation.
High molecular weight DNA was prepared by phenol/
chloroform extraction following lysis and proteinase K
digestion as described (Sambrook et al, 1989). 7 pg of
genomic DNA was digested to completion with restriction
endonucleases Hindill or Bgill. electrophoresed through
0-8% agarose and transferred to nylon membranes. Mem¬
branes were hybridized at 65°C in 7% sodium dodecyl
sulphate (SDS). 0-25 m NaH.POi with a j<5, probe (j<5S16
probe; Boehm el al. 1988). The probe was radio labelled by
multipriming (Feinberg & Vogelstein, 1983) to a specific
activity greater than 5 x 10" cpm/pg DNA. Membranes were
exposed to X-rav film after stringent washing.
PCR analysis. PCR analysis was essentially performed as
described by Saiki et al (1988). Each 100 pi reaction mixture
contained 10 mxiTrislpH 8-3). 50 itlm KC1. 2 m.\t MgCL. 200
psi each dNTP. 1 L" Taq polymerase tAdvanced Biotechnolo¬
gies. U.K.) and 30 pmol of each primer (Fig 1) (Y'okota et al,
1991b). Other 100 ng ofDNA from presentation samples of 1
fig of DNA from post-treatment samples was included per
reaction. The PCR reaction mixture was incubated for 35
cycles at 94°C for 90s. 55°C for 60s and 72°C for 90 s. In the
final cycle, the extension time was increased to 7 min at 72°C.
Products were analysed by 5% polyacrylamide gel electro¬
phoresis and visualized with ethidium bromide staining.
Sample cross-contamination was avoided by processing and
storing DNA in a separate location from PCR analysis and by
using aerosol hps and fresh solutions for each patient.
Direct sequencing analysis. The PCR reaction products from
presentation or relapse samples were purified using glass milk
(Geneclean. Stratech Scientific. U.K.) and sequenced using
the modified method of Winship (1989) together with
Sequenase (USB. Cambridge Bioscience. U.K.). The annealing
reaction contained 10% dimethyl suiphoxide (DMSO). > 50
pmol of sequencing primer (Fig 1). 5 p\ template DNA. 40 mxt
Tris (pH 7-5). 20 m.vt MgCL and 50 m.vt NaCI in a total
volume of 10 pi. The reaction mixture was boiled for 3 min.
snap frozen at — 70°C. To this was added 0-5 pst each of
dCTP. dTTP and dGTP. 1 p\ 3,;S dATP (111 TBq'mmol).
0-02 5 M DTT and 2 U Sequenase in a total volume of 4 pi. The
termination reactions (50°C for 3 min) were performed using
the manufacturer's mixes with the addition of 10% D.MSO
and the products resolved in a denaturing 6% polyacrylamide
sequencing gel.
Clone specific probes. Probes. 20 nucleotides in length, were
selected from the 'clone specific' Y-.N-D junctions as demon¬
strated by sequence analysis, synthesized commercially and
purified by gel filtration (Oswell DNA Services. Edinburgh).
These were end labelled by a standard T4 polynucleotide
kinase technique with y'-P dATP (222 TBq mmoli iSam-
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Fig 2. Southern blot analysis of Bglll digested DNA hybridized with
the )<5S16 probe. Normal peripheral blood DNA served as a control
(lane 1). Lane 2 shows a patient with a deletion of Jdl on one
chromosome and a V<52-D<53 rearrangement on the other. Lane 3
shows a patient with a biallelic rearrangement. V(52-D<53 and D(52-
D<53. Hindlll digested bacteriophage lambda DNA was used as a
molecular weight marker.
brook et al. 1980). 2 ftl of alkali denatured PCR reaction
product were slot blotted onto nylon membranes, prehybri-
dized at 65°C for 1 h and hybridized at 65°C for 1 h with the
appropriate clone specific probe. Filters were washed (2x10
min. RT) with 2 x SSC followed by a 30 min wash at 55°C
with 01 x SSC containing 0-1% SDS. Filters were exposed to
X-ray film for 2 h.
RESULTS
Southern blotting
In 22 patients (10 adults, 12 children) sufficient material was
available from presentation marrow to permit Southern blot
analysis of TCRd gene rearrangements using the J<5i probe.
Rearrangements or deletions were found in 15 patients
(68%). In two patients, both alleles were rearranged and in
four cases one allele was deleted. V<52-D<53 rearrangements
were detected in 12 patients (55%) and D<52-D<53 rearrange¬
ments in five patients including two with a biallelic re¬
arrangement involving V<52-D<53 (Fig 2).
PCR and direct sequence analysis
For PCR analysis, presentation samples from all 36 patients
were amplified using the Vi52 and D<53 primers (Fig I). The
products obtained from the PCR reaction were analysed by
4% agarose gel electrophoresis (Fig 3). The size of the product
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Fig 3. Polyacrylamide gel electrophoresis (5%) of PCR products from
five patients (lanes 2-6) and a pooled normal peripheral blood
control (lane 1) visualized by ethidium bromide staining. Haelll
digested 0X174 DNA served as a molecular weight marker. Band size
of the PCR product varied from 340 to 380 bp.
the junctional V<52-Dc53 region of approximately 40 bp. PCR
analysis demonstrated 19 patients (53%) with a VS2-D61
gene rearrangement. All those patients who had a Vc52-D<53
rearrangement as detected by Southern blotting were posi¬
tive when analysed by PCR and in addition seven of 14
patients not analysed by Southern blotting were PCR posi¬
tive. PCR products from 18 patients (seven adults. 11
children) were sequenced directly using an internal sequenc¬
ing primer (Fig 1) to reveal the \'«52(D)D<53 junctional
rearrangement. Table 1 shows the junctional sequences
aligned with the published germline configuration for V<52,
D<51. D<52 and D<53 (Lohetaf. 1989:Takiharaetof. 1989). An
extensive degree of variation can be seen in the junctional
region brought about by deletion of Vd2 and D<53 sequences,
inclusion of D<52 sequences. P nucleotides and varying
amounts ofN-nucleotide insertion. The size of the junctional
regions ranged from 0 up to 1 3 bp with an average of 7 bp.
Junctional sequences were considered to be derived from D<51
or D<52 genes if at least three consecutive nucleotides could be
aligned with germline sequences. There was no evidence for
the presence of D<51 derived nucleotides whereas D<52
sequences were present in six junctions. Regions of randomly
inserted N-nucleotides were seen in 1 5 patients with an
average length of 5-5 nucleotides. In addition, these inser¬
tions were found to be GC rich (79% GC content). The
amount of nucleotide deletion in the germlinc sequences of
VS2 and D<53 varied from none to complete deletion of the
D<53 gene in three patients. The average deletion of nucleo¬
tides from V<52 was 3-7 (range 0-151 and from D33 and
adjacent sequences was 6 0 Irange 0-24). Intact gene
segments were present in four patients with both intact V<32
and D33 present in one patient. I'-region nucleotides, defined
as forming a palindromic sequence with adjacent nucleotides
ofan untrimmed gene segment, were present in five patients.
PCR Analysis ofTCRS Gene Rearrangements in ALL 651
Table I. Sequence analysis of TCR V<52-D<53 junctions amplified from presentation bone marrow in 11 children and seven adults with CALL.
Germline sequences of V52. D<51. D<52 and 061 are shown. The presence of D<52 sequences in the junction is denoted by broken underlining and P-
nucleotides by bold italics. Other sequences in the junction are N-nucieotides.
GERMLINE V52 D51 D52 D53
CTGTGCCTGTGACACC GAAATAGT CCTTCCTAC ACTGGGGGATACG CACAGTGCTACAAA
CHILD CALL
RK CTGTGCCTGTGAC GTGTCTCCGTC GGGATACG
EC CTGTGCCTGTGACAC
CA CTGTGCCTGTGAC CGA GGGATACG
CW CTGTGCCTGTGACACC GGGGGG TGGGGGATACG
HM CTGTGCCTGTGACAC GGGG CTGGGGGATACG
MC CTGTGCCTGTGACAC GGCCTT TACG
JM CTGTGCCTGTGA GACCCAC GGGGATACG
SM CTGTGCCTGTGACAC TCCCCTGGGGG TGGGGGATACG
LR CTGTGCCTGTG CCCCCCGGA
MK CTGTGCCTGTG GTCTGT ACTGGGGGATACG













WL CTGTGCCTGTG CCACAG GGGGGATACG CACAGTGCTACAAA
DP CTGTGCCTGTGACAC GCA GGATACG CACAGTGCTACAAA
GG CTGTGCCTGTGAC CCGACCCCCATGG TGGGGGATACG CACAGTGCTACAAA
BM C CGTCGCCGG GTGCTACAAA
DT CTGTGCCTGTGACAC TCCCCATTGT ACTGGGGGATACG CACAGTGCTACAAA
TM CTGTGCCT CCCTTCGGAC CG CACAGTGCTACAAA







Fig 4. Hybridization of clone specific probes front live patients to
amplified DNA samples from presentation bone marrow and of
pooled normal peripheral blood control (PBL). Replicate slot blots
were hybridized with each individual clone specific probe with probe
A being derived from patient 5. etc.
Clone specific probes
From the sequence data office patients (DP. WL. BM. DT and
GG). 20 bp oligonucleotide probes from across the junctional
region were synthesized by standard methods. These were
radio labelled and used to test both the specificity and
sensitivity characteristics of the probes. The specificity was
determined by amplifying presentation samples from these
patients and from a pool of normal peripheral blood lympho¬
cytes obtained from healthy individuals. Each of the clone
specific probes was hybridized to five other cALL patients and
to the normal pool. The results are shown in Fig 3. None of
the clone specific probes hybridized to the normal pooled DNA
or to any other individual cALL patient who had demon¬
strated a clonal rearrangement of TCR<5. Therefore 20 bp
probes are of sufficient length to be specific for their derived
clone. The sensitivity of the clone specific probes was
determined by mixing experiments. DNA from patients was
mixed in serial 10-fold dilutions with DNA from pooled
normal lymphocytes. PCR amplified and hybridized with the
patient specific probe. The resolution ability of the clone
specific probe was approximately one tumour cell in 104
normal cells (Fig 4). Clone specific probes from 10 patients
were used to analyse remission blood and marrow samples
V.
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Table II. Clinical and PCR status during treatment in 10 patients with cAIX. Clone specific probes for analysing remission samples were derived
from sequenced PCR products from presentation bone marrow (pres BM) or marrow obtained at relapse trel B.\ll. Clinical remission was
determined by morphologic and immunophenotypic criteria.
Probe
Patient source Clinical status PCR status
MX Pres BM Remission/+ 1 month died from other causes + vc during remission
DP Pres B.M Remission/+ 23 months relapsed + ve during remission/PBSCH -ve BMH +ve
DT Pres B.M Remission/ 4- 2 months relapsed/+ 6 months PBSCT/ + ve during remission/PBSCH — ve — ve following PBSCT
remission+ 7 months relapsed/ + 8 months died
BM Pres B.M Remission not achieved/ + 3 months died + 21 d BM and B — ve/ + 2S d - ve
CC Pres B.M Remission/+ 4 months B.MT/+ 14 months relapsed/ + ve during rcmission/BMH - ve rve following BMT
remission/+ 33 months relapsed/remission/
+ 40 months relapsed/+ 43 months died
RK Pres BM Remains in remission at +24 months + ve up to +5 months/remains — ve at + 24 months
CW Rcl BM Remains in remission at +23 months + 14 d BM — ve/remains — ve at 2 3 months
MC Pres BM Remains in remission at +23 months + ve up to +16 months/remains — ve at +23 months
CA Rel B.M Remission not achieved/+ 10 months, matched + ve during remission following BMT
unrelated donor transplant/remission/
+ 18 months relapsed
EC Rel B.M Remission not achieved/+ 1 month died Remained +ve
eral blood stem cell (PBSC) transplant or matched unrelated
donor transplant had no effect on PCR. status. In addition,
tumour was detected in bone marrow harvested during
remission and PBSC harvests collected in recovery' phase.
DISCUSSION
To investigate TCR<5 gene rearrangements as a potential
tumour marker which may be analysed by PCR amplifica¬
tion. we screened a group of 22 CALL patients by Southern
blot analysis. A V<52-D<53 recombination was present in the
majority (12/15. 80%) of our patients with a TCRi) re¬
arrangement. Yokota el al (1991b) studied 201 children as
part of a large multicentre trial in Germany and found TCRd
rearrangements in 162 (81%) of which \T)2-D03 was the
most frequent recombination in 57% of these patients. In a
recent study on 32 children with cAIX. Vd2-D<53 was also
the most frequent recombination occurring in 78% of 18
patients with a rearrangement at the TCRc) locus (Yano ft al.
1991). The overall incidence of V<52-D<)3 rearrangements in
our group of patients was 55%. In the two other studies on
consecutively sampled patients the reported overall incidence
of V<52-D<53 recombination was 92/201 (46%) (Yokota el al.
1991b) and 14/18 (44%) (Yano ft al. 1991). From these
results on a combined total of 255 patients. Vt)2-D<53
rearrangements are a useful clonal marker, present in
approximately one half of patients with cALL.
On the basis of these results we next investigated the
frequency of V<52-D(5 3 rearrangements in 36 patients by PCR
analysis. This confirmed the Southern blot analysis with 5 5%
of patients having a clonal PCR marker. We reasoned to
directly sequence the PCR products from the putative
V<52(D|D(53 recombination to provide the following: lil
further characterize this rearrangement including I) segment
involvement, (ii) to confirm the diversity of the junction
which varied in size by only 40 bp. (iiii to construct clone
for up to 2 years following induction treatment at diagnosis
or relapse (Table II and Fig 5). In three of eight patients who
attained remission, the PCR status became negative at
varying times following treatment (CW, 14 d: RK. 5 months:
MC 16 months). At 23 months all three patients were in
complete remission and remained consistently PCR negative.
The majority of patients analysed were PCR positive during
periods of remission which lasted from 2 to 23 months.
Intensive therapy including bone marrow transplant, periph-
10° 10"1 10-2 10"3 1CB* 10-5
BM PB BM PB BM PBL
Pres. Post Rx Rel.
Fig 5. Slot blot analysis of serial dilutions of tumour DNA in norma!
PBL DN'A and of samples collected throughout therapy from patient
BM. Bone marrow (B.M) and peripheral blood (PB) samples taken
following AIJ. type chemotherapy showed no evidence of tumour.
However, a second peripheral blood sample taken within 1 week of
the first blood and marrow samples demonstrated a clonal V<52-Dt>3
rearrangement. The patient went on to clinically relapse as was
evident bv a bone marrow sample (B.M Bel) taken 6 weeks later.
PCR
specific probes from the sequence data for minimal residual
disease studies and thus remove the need for nested PCR
techniques as described in other studies (Yokota et al. 1991b).
Our sequence data confirms the extensive diversity of the
incomplete TCR V<52-D<53 rearrangement. This is generated
by several factors including insertion of D<52 gene segments
and N-region nucleotides, the presence of P-region nucleo¬
tides and variable deletions of the 3' end of V<>2 and 5' end of
D<53 genes. D<52 gene derived nucleotides were present in 33%
ofour sequenced patients with D<51 sequences absent. Overall
these nucleotides contributed 1S% of the junctional region.
N-nucleotides contributed substantially to the junction,
forming on average 75% of nucleotides involved. They were
predominantly GC rich (79%) due to the action of the
enzyme, terminal deoxynucleotidyltransferase (TdT) which
adds template independent nucleotides to the terminals of
combining gene segments and has a substrate preference for
GC or CG base pairs (Desiderio et al. 1984). A third type of
junctional feature, termed P-nucleotides. was first described
by Lafaille et al (1989) as a model for V-D-J recombination
based on the frequent observations of mononucleotides or
dinucleotides in palindromic sequence with intact joining
gene segments and are therefore germline encoded. These
were associated with five of nine intact V52. D<52 or D<53
genes. Exonuclease activity results in 'nibbling' or deletion of
the terminals of the recombining gene segments. This was a
major feature of the rearrangements which were sequenced.
In some patients deletion was extensive, involving 15
nucleotides from V<52 in one patient and in three patients the
complete D<53 gene segment. In only three and two cases
respectively were the D<53 and V<52 gene segments intact.
In a recent study Yokota et al (1991 a) published sequence
data on V<52-D<)3 rearrangements in nine children with
CALL. When compared to our sequence data several differ¬
ences are evident. Firstly. Yokota et al (1991a) found no
convincing evidence for the presence of D<51 or D<52 gene
segments in their junctions, whereas D<52 was present in one
third of our patients. Secondly, they reported an extremely
high incidence of intact 5' ends of D<53 (8/9. 89%) and
although this is not a characteristic feature of cALL. they
suggested it may preferentially occur in this type of leukae¬
mia. However, we report only three of 18 patients (1 7%) with
intact 5' D<53 ends. In addition there was a higher frequency
of P-nucleotides associated with the intact D<53 ends (67% v
29%). Using direct sequence analysis of PCR products from a
normal lymphoid population, the incidence of intact I)d3
ends was reported as 50% (Loh et al. 1989; Takihara et al.
1989: Yokota et al. 1991a). There was no obvious explana¬
tion for the low incidence of intact 5' D<53 boundaries in our
patient group. Patients were selected consecutively at presen¬
tation and classified by standard phenotypic methods. How¬
ever. the varied deletion of the D<53 end contributed to the
extensive diversity in the V<52-1)0 3 junction which we report
in our patient group.
From the sequence data we designed clone specific probes
of 20 nucleotides in length using, where possible, the
variation encoded by inserted sequences and deletions at the
V<52-D<53 junction. We have referred to these as clone specific
probes to differentiate from the term clonospecilic probes
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which are generated directly from nested PCR amplification
of the V<52-D<53 junction and which are approximately 300
bp in length (Yokota et al. 1991b). In hybridization experi¬
ments. clone specific probes did not cross-react with amplified
tumour from other patients or with normal pooled bone
marrow. The sensitivity of the clone specific probes directed
against the partial V<52-D<53 rearrangement was 10"4. This
reduced sensitivity was predicted (van Dongen et al. 1992)
with 10"' being the theoretical detection limit for PCR
amplification using 10 ;<g template DNA. The detection limit
is in part determined by the size of the junctional region,
which in ourpatients averaged 6-8 3 nucleotides. In complete
V<51 —J<51 rearrangements, with junctional inserts up to 3 7
nucleotides in length, highly specific clone specific probes can
be designed capable of detecting leukaemic cells down to a
frequency ofl in 106 (van Dongen et al. 1992). The presence
of other non-random sequences in the V<52-D<53 recombina¬
tion including D<52 and P-nucleotides and the GC rich nature
of the randomly inserted N-nucleotides may contribute to a
reduction in the potential detection limits of these probes for
minimal residual disease analysis. Clone specific probes
derived from V<52-D<53 were able to detect residual tumour in
blood and marrow obtained during clinical remission. Serial
analyses of remission samples showed residual tumour may
either persist for periods of up to 2 years before the onset of
relapse or may become undetectable by PCR indicating
possible eradication of tumour following therapy. In the
latter, loss of PCR detectable disease occurred at varying
times after treatment and these patients continued to be in
remission at 2 years. These two patterns, loss of detectable
tumour and persistence of disease, were reported in ALL by
other groups using different PCR clonal markers (IgH CDRIII.
Yamada et al. 1990: TCR V<5-J<5. Neale etal. 1991: TCR V<52-
D<)3, Yokota et al. 1 99 lb). Based on these reports with similar
sensitivities, there was considerable variation in the persist¬
ence of tumour during remission. From our results there was
loss of tumour in one patient within 14 d of treatment
whereas other groups have reported the persistence of
tumour in remission at 3 years (Campana et al. 1990b). This
may indicate that complete elimination of residual disease is
not an essential prerequisite for long-term survival, although
in our group the continued presence of tumour up to 2 years
resulted in relapse. The small numbers studied in these
reports and the variation in tumour response makes it
difficult to interpret PCR analysis of remission samples as
having a predictive value for long-term survival. However.
Neale et al( 1991) have suggested those patients who are PCR
negative within 16 months of diagnosis may have a better
prognosis. The continued presence of residual tumour may
have an effect on stem cell transplantation where bone
marrow and PBSC are harvested during remission. Both
PBSC and bone marrow harvests were contaminated with
tumour and although high-dose therapy and stem cell
transplantation induced remission it did not result in eradica¬
tion of PCR detectable tumour. Whether this indicated
chemoresistant tumour or the inability of high-dose therapy
to reduce tumour levels below the threshold of PCR analysis
was not clear. Double-colour immunofluorescence is capable
of detecting cells expressing leukaemic phenotypes at an
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equivalent sensitivity to that of PCR based techniques
(Campana et al. 1990a). Although standard antibody re¬
agents are used in a simpler experimental technique and
more applicable to routine analysis, immunological analysis
of minimal residual disease is limited to 3 5% of pre-B ALL
patients and can also generate false negative results in 20% of
patients who relapse (Bregni et al. 1989). Combined immu¬
nological and PCR analysis was recommended (Campana et
al. 1990b) and features such as clonal instability (Potter et al.
1992) and oligoclonality (Tycko et al, 1992) may be
effectively monitored using PCR analysis based on two or
more different techniques (TCR<5, TCRy or IgH CDRIII).
Our technique for generating clone specific probes to VS2-
D<53 gene rearrangements differs from that described by
Yokota et al (1991 b) who used the amplified junction product
as a clonospecific probe. We elected to directly sequence the
V<52-D<53 junction from amplified presentation sample and
synthesize 20b oligonucleotide using the sequence data. This
allowed for a standard stringent wash to be used following
hybridization, whereas PCR derived clonospecific probes
required a high stringent final wash (0-05 xSCC at 68°C).
This was presumably because these probes contained
sequences from minor populations of normal cells present in
the amplified tumour sample. Synthetic oligonucleotide
probesderived from sequence data in T-ALL (Neale et al. 1991)
were also reported to have a greater specificity in detecting
leukaemic clones than techniques based on using probes
derived from the PCR product (Hansen-Hagge et al 1989).
Although PCR techniques to monitor minimal residual
disease are becoming more easily adapted for routine labora¬
tory analysis, there remain several limitations to the tech¬
nique. Firstly changes in clonality or subclonal formation
during treatment may lead to false-negative results. Changes
in TCR gene rearrangements have not been widely reported;
however, this problem is associated with IgH gene analysis
where subclonal formation is reported to occur in 1 5-30% of
precursor B-ALL (van Dongen & Wolvers-Tettero, 1991).
Secondly, the restricted size of the junctional region in the
incomplete TCR<5 gene rearrangement influences the sensiti¬
vity of the clone specific probes making it more difficult to
quantify tumour contamination in remission samples. Lastly,
the clinical significance of extremely low levels of tumour
cells during remission has not been completely evaluated. At
present. PCR data on longitudinal studies of patients with
ALL during treatment is limited; however, the ability to study
greater numbers of patients using TCR V<52-D<53 as a clonal
marker will make these long-term objectives more feasible.
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Clonal Selection in Acute Lymphoblastic Leukaemia Demonstrated by Polymerase
Chain Reaction Analysis of Immunoglobulin Heavy Chain and T-Cell Receptor 8
Chain Rearrangements
Kenneth Langlands, Jenny I.O. Craig, Robert S. Anthony, and Alastair C. Parker
Department of Haematology, Royal Infirmary, Edinburgh, UK
Immunoglobulin heavy chain (IgH) and T-cell receptor (TcR) genes
can be monitored as markers of clonality by polymerase chain
reaction (PCR) analysis in acute lymphoblastic leukaemia (ALL).
We report the short clinical course of a 16-year-old patient with
ALL and a t(4;11) who relapsed early following treatment and
subsequently received reinduction chemotherapy followed by
peripheral blood stem cell transplantation with interleukin 2
therapy. Despite this, the patient relapsed and died 8 months after
presentation. The leukaemic cells were analysed by PCR and
showed rearrangements of TcR V52-D53 and IgH CDRIII genes.
Direct sequence analysis of the TcR5 and IgH PCR products
revealed two leukaemic clones at diagnosis with one present at
minimal levels. After initial therapy the major clone was no longer
detected even in subsequent relapse samples but the originally
minimal clone persisted and increased despite further treatment,
indicating drug resistance.
INTRODUCTION
Relapse of disease in patients with haematological
malignancies following chemotherapy or stem cell trans¬
plantation may result from neoplastic cells persisting
throughout treatment or from reinfusion of tumour
contaminating stored stem cells. This has previously
been detected by cytogenetics, immunophenotyping,
and Southern blotting with immunoglobulin heavy
chain (IgH) and T-cell receptor (TcR) probes. These
approaches can detect clonal populations of cells only
when they exceed approximately 2-5% of the sample
under study (1) .The advent of polymerase chain reac¬
tion (PCR) analysis has enabled the investigation of
residual disease at a sensitivity of one cell in a back¬
ground of 10s normal cells (2). Both IgH and TcR5
genes can be amplified in a proportion of patients with
acute lymphoblastic leukemia (ALL). Using primers
complementary to TcR V52 and D53 genes, the inter¬
mediate junctional regions can be amplified, and used
as clone-specific probes (3). Similarly, using primers
homologous to consensus VH and JH gene segments,
oligonucleotide probes to the intervening third comple¬
mentarity-determining region (CDRIII) of IgH can be
designed (4).
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PCR-based antigen receptor gene analysis may have
limited application in patients who present with multiple
gene rearrangements (oligoclonality) or who acquire new
rearrangements at relapse (clonal evolution). This risks
a false negative assessment of residual disease. The IgH
rearrangement may be a particularly unstable tumour
marker. Forty-five percent of patients with B-cell
ALL were found to have an oligoclonal or biclonal IgH
rearrangement at presentation (5) and clonal evolution
was a frequent event in 50% of these patients (6). In a
recent case report of childhood ALL, a complete clonal
change was evident during the initial treatment period
within 10 months of presentation (7). TcRS rearrange¬
ments are thought to be a more stable marker, although
the presence of biallelic TcR V52-D53 rearrangements (8)
may make it more difficult to design tumour specific
probes.
We present a case of a patient with a t(4; 11) ALL in
whom IgH and TcR rearrangements were detectable by
PCR. The TcR§ rearrangements were exploited to
generate tumour-specific probes to two clones present
at diagnosis. Monitoring of sequential samples taken
throughout the patient's clinical course demonstrated
that one clone was chemoresistant and led to relapse.
Despite reinfusion of the chemosensitive clone at the
time of peripheral blood stem cell (PBSC) transplanta¬
tion it could not be detected in any further marrow
samples up to the patient's death.
CASE REPORT
A 16-year-old male presented with symptoms of
anaemia, hepatosplenomegaly and fundal haemor¬
rhages. Peripheral blood showed haemoglobin 63 g/1,
the white cell count was 151 x 109/1 with 98% blast
cells, and platelets at 42 x 109/1. Bone marrow aspirate
confirmed early pre-B-cell ALL. The blasts demons¬
trated terminal deoxytransferase (TdT), class II and
CD19 positivity, but were negative for CD10, CD20, and
surface immunoglobulin. Cytogenetic analysis revealed
a t(4; 11) translocation.
Induction treatment was according to the UKALL XA
schedule. The day 21 bone marrow aspirate showed
morphological remission and no evidence of ALL by
immunophenotyping or cytogenetic analysis. Peripheral
blood stem cell harvesting (PBSCH) was performed
using a Cobe Spectra as his white count was recovering
and the cells were cryopreserved. After UKALL XA
intensification chemotherapy, remission appeared to be
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maintained. Further PBSCH were cryopreserved.
Cranial irradiation and maintenance therapy were
commenced.
Two months later the patient experienced general
malaise, and bone marrow relapse was confirmed by
morphology, immunophenotyping, and cytogenetic
studies. Morphological and immunophenotypic remis¬
sion was achieved with mitozantrone 20mg/m2 for 2
days and cytosine arabinoside 3 g/m2 for 5 days, with
further PBSCH obtained on recovery. Cytogenetic
studies however showed the presence of a t(4; 11) in 10%
of the cells, one-third of which also had 7q— and
monosomy 18.
As no HLA identical sibling was available, peripheral
blood stem cell transplantation (PBSCT) with inter-
leukin 2 (IL-2) to increase graft versus leukaemia
was undertaken after cyclophosphamide and total
body irradiation conditioning. Morphological, immuno¬
phenotypic, and cytogenetic remission was achieved.
One subsequent course of IL-2 was administered but 7
weeks after PBSCT, the patient relapsed morpho¬
logically and died only 8 months after presentation.
MATERIALS AND METHODS
DNA Extraction
Peripheral blood (PB) and bone marrow (BM) mononuclear
cells were separated over Ficoll-Hypaque (density 1.077 g/1,
Pharmacia, Uppsala, Sweden), lysed, digested with proteinase
K and high molecular weight DNA extracted with phenol/
chloroform (9).
PCR Amplification
TcR V52-D63 junctions were amplified using primers detailed
in Table 1 (3). For the IgH CDRIII junction, consensus primers
for the variable (V) and joining (J) domains were used (Table
1)(10). The 19 base pair (bp) J amplimer was homologous to
a core region shared by all six J region segments. PCR
amplification was performed under standard conditions (2)
with 1 U Taq polymerase (Applied Biotechnologies, London,
UK) per 100 pi reaction and either 2 mM (TcR) or 1 mM MgCl2
(CDRIII). Amplification consisted of 94°C for 90 s , 56°C for
60 s and 72°C for 90 s for 35 cycles with an extension step of
7 min in the final cycle. One microgram of post-therapy DNA
or 0.1 jig of presentation DNA was amplified in duplicate. Pro¬
ducts were analysed by 6% polyacrylamide gel electrophoresis
(PAGE) stained with ethidium bromide.
Table 1. Sequences of Primers.
Locus Primer pmol
IgH
PCR and sequencing primers (10)
VH 5' - acacggcc\tg\ctgtattactgt - 3' 25
JH 5' - acctgaggagacggtgacc - 3' 25
TcR V82-D83
PCR primers (3)
V82 5' - gagtcatgtcagccattgag - 3' 30
D83 5' - agggaaatggcacttttgcc - 3 ' 30
Sequencing primer
V82 5' - gcaccatcagagagagatga - 3' 50
Direct Sequence Analysis
TcR<5 and CDRIII PCR products were resolved in 4°7o NuSieve
GTG agarose (FMC Bioproducts, Denmark) and the relevant
band purified using glass beads (Geneclean, Stratech Scien¬
tific, UK). A modified (11) dideoxy-termination sequencing
method (12) was used on the double-stranded PCR products.
Detection of Leukaemia
From the sequence data, specific anti-junctional oligonucleo¬
tides were selected against the junction of the TcR VS2-D53
rearrangement and obtained commercially (Oswell DNA
services, Edinburgh, UK). DNA samples to be probed were
amplified as described above, 2 pi of PCR product was
alkaline-denatured (13), slot-blotted onto nylon membranes
(GeneScreen Plus, Du Pont, UK) and prehybridised in 7%
sodium dodecyl sulphate (SDS), 0.5 m NaH2P04 pH 7.5, and
1% bovine serum albumin at 62°C for 1 h. Oligonucleotide
probes were end labelled with 32P-dATP (6000 Ci/mmol)
using T4 polynucleotide kinase and 1.0 x 106 cpm/ml
hybridisation fluid added. After a further 1 h incubation at
62°C membranes were rinsed in 2 x standard sodium citrate
(SSC) and washed at 55°C in 0.1 xSSC with 0.1°7o SDS.
Autoradiographs were exposed at — 70°C for 2-4 h.
RESULTS
PCR and Direct Sequence Analysis
Amplification of presentation BM demonstrated an IgH
band of approximately 110 bp and a TcR<5 band of
12345 6789
Figure 1. Polyacrylamide gel electrophoresis (6%) of PCR
amplification products. Lanes 2-5 contain IgH CDRIII products and
lanes 6-9 contain TcR V52-D83 products. DNA from presentation
BM is shown in lanes 2 and 6, first and second relapse BM samples
are shown in lanes 3 and 7 and in lanes 4 and 8, respectively.
Lanes 5 and 9 contain products from pooled normal peripheral
blood DNA as negative controls. Lane 1 contains a HinU digested
0X174 molecular weight marker. A single IgH band at presentation
was shown to contain a biclonal IgH rearrangement on sequence
analysis which at both relapses was evident as two distinct bands.
The size of the relapsed TcR products also differed from
presentation.
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CAAGA GATGTTGAGGGTTATTGTAGTAGTACCAGCTGCTAT AACTGGTT [ J5 ]
(DLR4)
CGAGA GAGATCTACGTATTACGATATTTTGACTGGTTAT AACTGGTT [J5]
(DXP4)
1st/2nd Relapse
CAAGA GCATGATATTGTAGTAGTAC.CAGCTGCCCGGGCCGATATTTTGACTGGTTATTA TACTACTAC [J6 ]
(DLR4 DXPI)
CAAGA GGAGGTGTATGCATTTAT TACTACTAC [ J6 ]
(DLRI)
Inserted D segments are denoted by underlining and P-nucleotides are shown in bold. CDRIII D segments were classified according to Ichihara (21). In TcR6 rearrange¬
ments, D62 was involved at presentation and D81 at relapse. A biallelic rearrangement was found for IgH CDRIII genes at presentation and relapse.
350 bp (Figure 1). Analysis of BM DNA at first relapse
revealed two IgH bands of approximately 110 bp and
140 bp,along with a TcR5 band of 340 bp. Band sizes at
second relapse were identical to those at first relapse. No
discrete PCR products were visible in normal control
DNA.
TcR5 and IgH PCR products from presentation and
relapse BM were sequenced and the results summarised
in Table 2. Two distinct clones were identified from
TcRS sequences. Sequences derived from D<52 and
P-nucleotides associated with an intact D<53 gene were
present in clone A, whereas in clone B there was deletion
of V62 and D<53 gene segments, and D51 sequences were
inserted. Two distinct biallelic IgH rearrangements were
seen by sequence analysis of presentation and relapse
BM. The rearrangements involved different J segments
(presentation J5, relapse J6), different D segments, and
variable N-nucleotide insertion.
Detection of Leukaemia
Clone-specific probes (probe A and B) were designed
to the V52-D63 junction from the sequence of clones
A and B and used to examine amplified DNA from
serial samples collected through the patient's treatment
(Figure 2). Both probes could detect tumour at a level of
one leukaemic cell in 104 to 105 normal cells. When
hybridised to PB and BM at presentation and the day
21 BM, considered to be in morphological and immu-
nophenotypic remission, probe A demonstrated the
presence of tumour (Figure 2a). The PBSCH performed
after induction and intensification were also positive
(SI, S2). However, the BM at relapse and all subsequent
samples were negative. Probe B was hybridised against
the same samples (Figure 2b). The presentation samples,
day 21 BM and PBSCH following induction and inten¬
sification were faintly positive. PBSCH obtained after
induction, intensification, and reinduction therapy had
minimal contamination with clone B tumour. The
relapse BM and post IL-2 treatment BM were all PCR
positive for clone B.
DISCUSSION
This case illustrates the typical short clinical course of a
young man with a t(4:11) ALL. This leukaemia typically
presents with high risk features and although remissions
are achieved, these are usually of short duration (14-16).
Despite conventional and experimental treatment includ¬
ing PBSCT and IL-2 therapy, our patient relapsed early
and died from resistant disease. Although entering
remission on morphological, immunophenotypic, and
cytogenetic analyses, it was apparent on molecular
studies that the leukaemia exhibited two clones at
presentation, one of which was sensitive to chemo¬
therapy. The second clone, which although present in
low amounts at diagnosis, became predominant at
relapse and persisted despite reinduction chemotherapy,
PBSCT, and IL-2 therapy.
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Figure 2. Autoradiograph of replicate slot blots of patient's sequential TcR<5 amplification products hybridised with clone-specific probes
A and B. Clone A was present in presentation (Pres.) peripheral blood (PB), bone marrow (BM), PBSCH after induction (S1) and intensifica¬
tion (S2), and in the apparent remission bone marrow aspirate taken on day 21 (BM). Clone B was apparent in all of the above samples
and additionally in the first relapse (Rel.) bone marrow, PBSCH taken after reinduction (Rem. S3), and bone marrows taken pre- and post-
PBSC transplant and IL-2. The final relapsed bone marrow was heavily contaminated when probed for clone B. Negative control consisted
of pooled normal bone marrows (Control BM).
The clinical relevance of PCR-detected contamination
in reinfused PBSCH or bone marrow is still unknown.
Despite receiving a PBSCT with harvests containing
clone A, this was not detected at subsequent relapse and
therefore, in our patient, this source of tumour was not
clinically important.
This case is one of a proportion of ALLs amenable to
PCR analysis using two tumour markers. Approx¬
imately 80% of patients with B-lineage ALL can be
studied with CDRIII primers (4), although the use of
family-specific VH primers can increase this percentage
(17). Biondi (18) reported a 50% incidence of V62-D53
partial recombinations in patients with common ALL.
However this case also highlights some of the problems
associated with PCR-based systems using IgH and TcR
genes as clonal markers for tumour detection. An impor¬
tant feature of PCR analysis is that the leukaemic cells
form the majority clonal population. This can be iden¬
tified as discrete bands on polyacrylamide gel elec¬
trophoresis which, to generate clone-specific probes, are
either sequenced (4) or the bands extracted and used as
a probe (3). However problems may occur where there
is a biclonal or oligoclonal rearrangement with each
clone present in differing proportions, as was demon¬
strated in this case. PAGE alone indicated a monoclonal
rearrangement at presentation, which after induction
and intensification therapy was replaced by a second
neoplastic clone at relapse. Sequence analysis permitted
detailed examination of the rearrangements and syn¬
thesis of two oligonucleotide probes which on subse¬
quent reprobing of all samples revealed the presence of
a biclonal rearrangement at presentation. The complete
loss of one clone and persistence of a second during
therapy suggests that the second clone was chemoresis-
tant, and selected for by treatment. Clonal evolution or
VH gene replacement, which has been reported in 30%
of childhood ALL patients (19), was, therefore, not a
feature of this patient's tumour. In a recent case report
of early pre-B-cell ALL, a biclonal IgH gene rearrange¬
ment was stable during the course of the disease which
included an initial remission of 5 years (20). In contrast,
a single TCR7 gene rearrangement at diagnosis was
replaced completely with an unrelated biclonal gene
rearrangement at relapse.
In conclusion, the presence of a biclonal or oligoclonal
IgH or TcR rearrangement at presentation reduces the
effectiveness of monitoring residual disease by clone-
specific probes as they cannot predict which subclone
will be responsible for relapse. However, clone-specific
probes are useful in monitoring the response of indiv-
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idual subclones to chemotherapy and other forms of
treatment such as IL-2 therapy and may be useful in
combined studies monitoring tumour chemoresistance.
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